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ABSTRACT 
Economic Burden of Low-value Healthcare on Patients with Localized Prostate Cancer: 
Statistical & Machine Learning Approaches 
Ryan M. Fiano, MPH 
Adults with incident localized prostate cancer represent a large, medically complex population at risk for low-
value care. Evidence-based guidelines recommend conservative management (CM) for localized prostate 
cancer patients with multimorbidity and limited life expectancy, however, 2 in 3 still choose treatment. This 
dissertation pursued three Aims to address research gaps related to healthcare practices associated with 
significant morbidity and economic burden on older men with incident localized prostate cancer: 1) examine 
the leading predictors of low-value healthcare practice of prostate cancer treatment for low-risk prostate 
cancer; 2) assess the role of patient‐reported experience with care on high-value prostate cancer management; 
and 3) estimate the association of high-value care on non-cancer related healthcare expenditures using 
machine learning and statistical approaches. In this study, 2 in 3 adults received low-value prostate cancer 
treatment. Multimorbidity and care fragmentation were among the leading predictors of low-value prostate 
cancer treatment and contrary to expectations, life expectancy was a weak predictor of treatment receipt. Social 
determinants of health were highly ranked predictors of treatment. Higher “timeliness of care” patient reported 
experience scores were associated with high-value CM use. Other forms of low-value care before incident 
prostate cancer diagnosis were associated with higher non-cancer related healthcare expenditures while high-
value CM was associated with lower costs. In summary, this dissertation highlights the negative effect of 
multimorbidity and care fragmentation on overtreatment, high-value care, and cost outcomes. Perceptions of 
timely care with healthcare providers and systems have significant impact on high-value CM use among older 
men with localized prostate cancer. This dissertation reports strong independent predictive associations of 
incremental low-value healthcare use before incident prostate cancer diagnosis to have significant increases on 
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1.1 Background and Significance 
Epidemiology of localized prostate cancer 
Prostate cancer is the most frequently diagnosed malignancy and the 2nd leading cause of cancer death 
among men in the United States.(1) In the last several decades, prostate cancer-specific mortality has 
decreased significantly and future estimates project robust survivorship growth from 3.3 to 4.5 million by 
2026.(2) Wide-spread use of prostate-specific antigen testing has increased detection of malignant and 
indolent cancer thus presenting evidence-based management challenges to address prostate cancer specific 
mortality of higher-, and avoid overtreatment of lower-, risk disease.(3)     
Localized, low-risk prostate cancer 
American Joint Commission on Cancer (AJCC) establishes a standard staging system using Tumor, 
Node, Metastasis (TNM) classifications for incident prostate cancer diagnoses; primary tumor (T), regional 
lymph node involvement (N), and distant metastasis (M) are assessed.(4) Localized prostate cancer, or cancer 
that is confined to the prostate, is classified as clinical stage T1 to T2a.(4) Risk stratification, broadly, includes 
clinical staging, Prostate Specific Antigen testing, and Gleason Score with 3 main risk groups: low-, 
intermediate-, and high- risk prostate cancer.(5) Low-risk prostate cancer is defined as T1 to T2a, Gleason 6, 
PSA <10ng/mL, intermediate risk defined as T2b-T2c or Gleason 7 or higher or PSA 10-20 ng/mL, and high 
risk defined as T3a or Gleason 8 or higher or PSA > 20 ng/mL.(6) 
Treatment selection for localized prostate cancer 
Older men with indolent localized prostate cancer and/or limited life expectancy are vulnerable to 
adverse effects of overtreatment.(7,8) Overtreatment of localized prostate cancer is associated with negative 
health outcomes such as sexual, urinary, and rectal dysfunction including impotence, incontinence, and bowel 
irritation.(9–11) To avoid overtreatment morbidities, non-curative conservative management (CM) strategies 
have been established as an evidence-based option for adults with localized, low-risk cancer and/or limited life 
expectancy.(6,12) Clinical practice guidelines have recommended CM approaches for a decade.(13) More 




less than 5 years of life expectancy without discussing CM is considered an indicator of sub-optimal healthcare 
quality.(12,14) Thus, the premise of CM is to avoid overtreatment-related adverse effects as localized 
malignancies pose little risk of prostate cancer-specific mortality. 
The Burden of Low-value Healthcare 
For decades, wasteful healthcare spending in the United States has not improved the cost, quality, and 
outcomes in comparison to other developed countries. Efforts to identify and address waste, as outlined in the 
Institute of Medicines (IOM) seminal work Crossing the Quality Chasm, have promoted a national effort to 
develop healthcare quality measurements to promote patient centered care; timely, well-coordinated care to 
inform healthcare decisions that reflect the patient’s values.(15) To build on the IOM seminal work, The 
National Quality Task Force has redefined effective and patient-centered care as “appropriate, person-centered 
care”, thereby recognizing the adverse effects associated with inappropriate healthcare and affirming the need 
to understand chronic conditions management within the context of overall well-being.(16)    
Low-value care, defined as inappropriate healthcare lacking a net clinical benefit to the patient, 
contributes to avoidable morbidities and excessive healthcare costs.(17) Low-value care is prevalent among 
elderly patients affecting 1 in 4 Medicare beneficiaries(18) and accounts for $75.7 - $101.2 billion in annual 
healthcare costs.(19,20) Use of low-value healthcare services among medically complex patients can lead to 
cascades of unnecessary down-stream care, cumulating costs as high as 10 times the original low-value 
healthcare service.(21)  
To combat and eliminate low-value care, initiatives supported by the American Board of Internal 
Medicine Foundation have established the Choosing Wisely campaign to work with other professional societies 
to develop lists of low-value screenings, tests, and procedures.(22) Since the establishment of Choosing Wisely 
in 2012 study of low-value care has increased substantially. The National Quality Forum outlined opportunities 
for increasing requirements to “educate and engage” specific patient populations to reduce low-value care, 
while increasing patient-centered, high-value care.(16) However, few studies are oncology focused, with many 
examining the overuse of screening (i.e., breast and prostate cancer screening) versus more harmful impacts 
associated with overtreatment(23). Significant research gaps exist in the understanding how low-value care 





Patients with incident localized prostate cancer represent a large, medically complex population at risk 
of low-value care in the form of overtreatment. Older patients with localized prostate cancer have high rates of 
multimorbidity, defined as more than 2 chronic conditions, and often experience an increase in care 
fragmentation at diagnosis.(24) Care fragmentation is known to present barriers to shared decision making 
and evidence-based recommendations among adults with multimorbidity,(25,26) therefore adults with 
multimorbidity may be at increased risk for receiving overtreatment, low-value care, and/or increased down-
stream survivorship costs.  
Shared decision making facilitates patient choice amid the risks and benefits of treatment and non-
treatment options. Incident prostate cancer patients are challenged by multimorbidity and care fragmentation 
that influence perception of the healthcare system, potentially pushing them to choose an immediate cure(27) 
versus managing an additional chronic condition in a fragmented system. Fear of treatment regret, anxiety, 
and misunderstanding the risks and benefits of curative treatment within the context of cancer risk grouping 
and life expectancy are likely influenced by a patient's perception of care.(27)  
The use of patient-reported experience measures can amplify the patient’s perspective of the continuity 
of care among primary care and specialty clinicians. Patient reported experiences of care include domains such 
as physician communication, timely care, and perceptions of getting needed care and are increasingly used as 
quality measures by health plans, medical groups, and physician practices.(28) Positive patient‐reported 
experience scores are associated with adherence to medical advice, improved clinical outcomes, and lower 
utilization of unnecessary health‐care services.(15,29) Identifying specific measures of patient‐reported 
experiences that facilitate CM use among patients with incident localized prostate cancer and multimorbidity is 
needed to promote evidence‐based cancer care.(30) For example, in colorectal cancer populations, patient‐
reported experiences with perceived timely care are associated with evidenced‐based follow‐up.(31) 
Understanding the relationship between patient‐reported experiences of care on CM use can inform patient‐
centered care approaches by identifying gaps in timely care from the patient’s perspective to improve adoption 
of CM use thereby reducing the adverse effects of overtreatment among older patients with multimorbidity and 




Economic burden of localized prostate cancer 
Many studies have examined comparative costs between different prostate cancer treatment modalities 
including CM.(32) CM use is known to reduce short-term treatment-related costs, however, long term costs 
associated with overtreatment or low-value care is not known. Use of low-value services prior to incident 
prostate cancer may be associated with increased costs throughout survivorship regardless of curative 
treatment or CM modalities. 
1.2 Innovation 
 Using recent literature reviews(27,33–37) and healthcare initiative recommendations(16,22), the 
research presented in this dissertation addresses significant research gaps as related to healthcare practices 
that provide limited clinical benefit, potentially harmful effects, and a significant economic burden on older 
men with incident localized prostate cancer. Specifically, we used novel machine learning techniques with 
nationally representative samples of older men with localized prostate cancer to answer research questions 
with both clinical and population relevance. We used interpretative model-agnostic approaches to understand 
the complex machine learning outputs with a focus on understanding predictors of localized prostate cancer 
treatment. We also used traditional statistical approaches to understand the impact of patient-reported 
outcomes on CM use and non-treatment related costs associated with the use or low-value care prior to 
incident localized prostate cancer diagnosis. We identified misalignment between prostate cancer specific, 
validated measures of life expectancy and use of guideline recommended care among localized prostate cancer 
patients. We also identified the predictive qualities of care fragmentation and use of low-value care on non-
cancer related healthcare expenditures during survivorship. The innovation of this work addresses the strategic 
objectives, research recommendations, and general research gaps as we identify novel factors, such as care 
fragmentation, low-value care use, and patient-reported outcomes, on high- and low-value treatment and costs 
outcomes among older adults with localized prostate cancer.  
To highlight healthcare practices that provide limited clinical benefit, potentially harmful effects, and a 





1.3 Specific Aims 
Aim 1: Use machine learning (ML) to identify leading predictors of cancer treatment within 12 months of 
diagnosis among older men with localized, low-risk prostate cancer. 
● Quasi-hypothesis H1: Leading predictors of low-risk prostate cancer treatment will be age, 
multimorbidity, care fragmentation, and life expectancy. 
Aim 2: Examine the associations of patient‐reported experiences with providers and healthcare systems and 
multimorbidity on high-value care (CM use) among older men with localized prostate cancer. 
● H2: Older men with multimorbidity and higher patient experience scores will be more likely to use CM 
compared to those without multimorbidity and lower patient experience scores, after adjusting for 
patient-, clinician-, and practice ecosystem factors. 
Aim 3: Identify leading predictors and estimate the association of high- and low-value care use on non-cancer 
related healthcare expenditures among older men with localized prostate cancer.  
● Quasi-hypothesis H3.1: Leading predictors of non-cancer related healthcare expenditures will be age, 
life expectancy, low- and high- value care. 
● Quasi-hypothesis H3.2: Independent of treatment or conservative management use, adults using low-
value care, versus no low-value care, will have higher non-treatment related healthcare costs 12-24 
months after a localized prostate cancer diagnosis. 
1.4 Approach 
Conceptual Framework 
  Management of preexisting multimorbidity, care fragmentation, and the shared decision making 
process associated with choosing treatment or conservative management for incident prostate cancer requires 
the use of limited resources (i.e., time to manage chronic conditions and availability of health‐care 
professionals and resources). Therefore, in this dissertation we used a competing demands model to 
conceptualize factors known to affect localized prostate cancer treatment selection within clinician, patient, 
and practice ecosystem domains.(33,38,39) 
Data Sources 




data files. SEER-Medicare data includes data on all incident prostate cancer cases occurring in 18 regions 
throughout the United States. Incident prostate cancer, prostate cancer specific clinical information (i.e., 
Gleason Score and Prostate-specific antigen values), and cancer staging information were derived from the 
SEER database. Medicare claims were derived from inpatient, outpatient, and other files linked to SEER.  
For aim 2 we used a separate SEER with Medicare Consumer Assessment of Healthcare Providers & 
Systems (MCAHPS®) survey linkages. MCAHPS, administered by the CMS, use standardized and validated 
questionnaires to collect information on patient‐reported experiences with health‐care providers.(40) 
MCAHPS collection methodologies use a weighted probability sampling procedure covering all the 50 US 
states, DC, and Puerto Rico, which are then linked to SEER patients.(40,41) 
Area Health Resource File (AHRF) files were linked via MEDPAR FIPS state and county codes and used 
to calculate urologist densities.(42) Census files were linked to calculate county-level median income and 
college education. 
 We used both statistical and machine learning approaches in this dissertation. All model adjustments 
were made with factors known to influence treatment or conservative management selection. We used 
frequency and percentages (i.e., Chi-square tests and t-tests) to identify significant group differences by 
categorical variables and standard deviations for continuous variables. Generalized linear models (GLM) with 
log-link and gamma distribution were used to estimate key independent variable associations with healthcare 
cost. In aim 2, multivariable logistic regression was used to estimate the effect of patient-reported experience 
measures of care and healthcare providers on conservative management use. 
 ML methods can determine the most effective and parsimonious model/algorithm through 
classification of a binary target (i.e., yes or no dependent variable) via iterative learning. We used the XGBoost 
classifier, a decision-tree ensemble machine learning algorithm, to predict prostate cancer treatment or CM use 
among patients with low-risk prostate cancer diagnosis.(43)  
 Traditional statistical approaches use the entire data set and goodness of fit statistics for model 
specification.(44) Machine learning techniques utilize a training and test data set to estimate the predictive 
accuracy of a model. In ML models, original datasets were split (70%/30%) into training and test data. Next, 




training data via hyperparameter tuning using stratified 10-fold cross validation. Hyperparameters can adjust 
regularization through iterative tuning runs. Stratified cross validation describes the process of splitting the 
training data into identical “folds” that can be used as versions of “unseen” data during testing. Once the 
XGBoost algorithm is optimized on training data for accuracy, it is “tested” on the original 30% split. We 
assessed predictive performance on the test set using precision, recall, accuracy, and Precision-Recall Receiver 
Operating Curve scores for machine learning models in aim 1. In aim 3, XGBoost regressors we used to assess 
prediction of log-healthcare costs and performance was assessed using R2 and negative mean squared error. 
Shapley Additive exPlanations 
 To improve machine learning model interpretability, Shapley Additive exPlanations (SHAP) were used 
to visually summarize the contributions and associations of the features to the target variable. SHAP values 
represent the magnitude of effect from each feature on the model output by conditional expectation when the 
feature is “hidden”. Attributed changes induced on the model output are then averaged overall possible feature 
orderings in the data set (i.e. coalition) to provide the SHAP value.(45) Feature importance can be calculated 
by sorting absolute average SHAP values whereas summary plots sort average SHAP outputs with positive and 
negative variations on the x-axis. Partial dependence plots (PDP) average SHAP values for a feature by a 
feature’s unit value (for example, average age SHAP values by the feature age in years). Unlike traditional PDP, 
SHAP PDP shows dispersion around feature units reflecting the impact of all the other features in the model. 
Lastly, PDP interactions display the attribution effect of two features simultaneously. For aim 1 and 3, model 












2 Prediction of Low-value Cancer Care among Older Men with Low-Risk Prostate Cancer: A 
Machine Learning Approach   
2.1 Abstract 
Background: Older men with incident prostate cancer are vulnerable to low-value prostate cancer treatment. 
Despite evidence-based support for conservative management (i.e., non-treatment), approximately 2 in 3 
Medicare beneficiaries receive treatment for low-risk prostate cancer. Adults with multimorbidity who 
experience care fragmentation are vulnerable to departures from evidence-based medicine. A comprehensive 
analysis of clinical and non-clinical factors, such as life expectancy and care fragmentation, that may drive low-
value prostate cancer treatment is lacking. 
Objective: Use machine learning (ML) to identify leading predictors of cancer treatment within 12 months of 
diagnosis among older men with low-risk prostate cancer. Novel predictors included validated prostate-cancer 
specific life expectancy and care fragmentation. 
Methods: In this retrospective cohort study we linked Surveillance, Epidemiology, and End Results cancer 
Registry (SEER), Medicare Claims, Census, and Area Health Resource files and included older men with 
incident low-risk prostate cancer from 2009 to 2014 (n=13,870). We used claims data to identify treatment 
(Yes/No) in the first 12 months after diagnosis. We used the XGboost algorithm and SHapley Additive 
exPlanations (SHAP) to rank feature importance in treatment prediction.  
Results: In our study cohort (n=13,870), 66.9% of older adults received cancer treatment. Age, 
multimorbidity, care fragmentation, social support, and social determinants were leading predictors of cancer 
treatment (Accuracy=0.70, Precision=0.71, Recall=.92, Precision-Recall Area Under the Curve = 0.78). 
Relationships of college education, income, and care fragmentation on low-value cancer treatment were 
nonlinear and complex. Life expectancy was a weak predictor of prostate cancer treatment.  
Conclusion: Our results suggest that non-clinical factors such as social determinants, care fragmentation, 
and social support are the most important predictors of treatment among older men diagnosed with low-risk 
prostate cancer. Despite a critical role in evidence-based treatment recommendations, life expectancy had 






Localized prostate cancer diagnoses are often indolent, representing a large potential source of low-
value cancer care. Older men with low-risk prostate cancer and limited life expectancy risk significant urinary, 
erectile, and rectal morbidities without the benefit of significant improvement in prostate cancer specific 
mortality outcomes.(7,8,10) High-level evidence discourages treatment (3) of individuals with low-risk prostate 
cancer with less than 10 years of life expectancy or higher-risk disease with a life expectancy of 5 years or 
less.(6) Despite evidence-based support for CM in recent years, treatment for low-risk prostate cancer is highly 
prevalent, for example, among Medicare beneficiaries as a majority (58%) still receive treatment as compared 
to integrated healthcare network cohorts (20%).(46)  
Decision to treat low-risk prostate cancer with radiation, surgery, cryotherapy, chemotherapy, or 
hormone therapy requires life expectancy estimation within the context of prostate cancer specific mortality 
and death from competing risks. Evidence-based guidelines recommend conservative management for low-risk 
prostate cancer and life expectancy of 10 or fewer years.(6) Examining the impact of life expectancy as a 
predictor is critical in assessing low-value treatment of low-risk prostate cancer, however, many methods used 
in population studies vary considerably and many lack validity in prostate cancer populations.(34)  
Multimorbidity is another factor that may influence treatment of low-risk cancer. Over 60% of older 
adults with incident prostate have multimorbidity defined 2 or more chronic conditions.(47),(48) Prior studies 
with SEER-Medicare data have shown that older men with 3 or more chronic conditions were significantly 
more likely to get treated for localized prostate cancer in adjusted multivariable models.(49)  
Adults with multimorbidity who experience care fragmentation are vulnerable to departures from 
evidence-based medicine and poorer health outcomes.(26) Approximately 50% of adults with multimorbidity 
already see 3 or more specialists (50) and increased care fragmentation is associated with diagnosis of incident 
prostate cancer.(24) Medically complex adults experiencing care fragmentation prior to diagnosis are likely to 
encounter additional barriers to shared-decision making process critical for understanding the risks and 
benefits of treatment. Shared decision-making engagement fosters trusting relationships that facilitate 
communication of evidence-based recommendations and is associated with reductions in both cancer and non-




Supervised ML models are increasingly used to predict healthcare outcomes, quality, and cost 
outcomes.(52) However, many studies investigating low-value prostate cancer care use only conventional 
statistical approaches. A comprehensive analysis of clinical and non-clinical factors, namely, valid life 
expectancy measures, multimorbidity, and care fragmentation, that drive low-value cancer treatment among 
adults with incident low-risk prostate cancer is lacking. Supervised ML can be used to identify the leading 
predictors and non-linear relationships among medically complex adults with higher probability of 
overtreatment. 
Therefore, the objective of this study was to identify leading predictors of low-value cancer care among 
older men with low-risk prostate cancer using machine learning methods (ML). We used supervised ML 
models to identify leading predictors of low-value prostate cancer care by using nationally representative 




In this retrospective cohort study, the date of incident low-risk prostate cancer diagnosis was used as an 
index date and 12 months before diagnosis was used as the baseline period. We defined the treatment for low-
risk prostate cancer (radiation, surgery, chemo- and hormone- therapies) during a period of 12 months after 
diagnosis based on validated methods for claims data.(53) 
Study population  
Older adults (age ≥ 66 years) diagnosed with low-risk prostate cancer during the study period (2009-
2014) were included in the study population. Cancer diagnosis was identified using International Classification 
of Diseases for Oncology (ICD-9). Low-risk prostate cancer was defined as American Joint Committee on 
Cancer stage T2a or less, Gleason Score ≤ 6, and a PSA test ≤ 10 ng/mL.(6)    
Data sources 
This study used the Surveillance, Epidemiology, and End Results (SEER)-Medicare linked data files. 
SEER-Medicare data includes data on all incident prostate cancer cases occurring in 18 regions throughout the 




Prostate-specific antigen values), and cancer staging information were derived from the SEER database. 
Patient Medicare claims were derived from inpatient, outpatient, and other files linked to SEER.  
Area Health Resource File (AHRF) files were linked via MEDPAR FIPS state and county codes and were 
used to calculate urologist densities.(42) Census files were linked to calculate county-level median income and 
college education (percentage with college degree). 
Study inclusion/exclusion criteria 
Adults with low-risk prostate cancer were included in the study if alive and continuously enrolled in 
Medicare Parts A and B throughout the baseline and follow-up periods (Appendix Supplemental Figure 7.7). 
Adults with missing cancer stage, PSA values, Gleason Scores, and/or those diagnosed with prostate cancer at 
autopsy were excluded. 
Target variable: Prostate cancer treatment (yes/no) 
Prostate cancer treatment was estimated within the first 12 months after diagnosis using a previously 
validated, claims-based algorithm and included radiation, surgery, and chemo-, cyro-, and/or hormone- 
therapy.(53) 
Key features 
Life expectancy  
Prostate cancer comorbidity index (PCCI) is a weighted comorbidity index validated in prostate cancer 
patient populations to predict life expectancy.(54) Medical colleges, patient advocacy groups and evidence-
based recommend informed decision-making in using conservative management or treatment for men with 
low-risk prostate cancer and a life expectancy of greater than 10 years.(6) We calculated PCCI during the 
baseline period to create predictive models based on validated life expectancy (10 year or greater life 
expectancy; PCCI<8) to reflect evidence-based recommendations.(6,54) Categorical variables at clinically 
meaningful cut-offs are presented in Table 2.1 and were also included in sensitivity analyses for interpretative 
purposes. 
Multimorbidity 
The multimorbidity framework developed by the United States Department of Health and Human 




arthritis, asthma, coronary artery disease, congestive heart failure, chronic kidney disease, chronic obstructive 
pulmonary disease, cardiac arrhythmias, acute myocardial infarction, dementia, diabetes, depression, 
hepatitis, hyperlipidemia, hypertension, human immunodeficiency virus, osteoporosis, substance abuse, 
schizophrenia, stroke, and anemia.(55) We defined multimorbidity presence of 3 or more chronic conditions. 
Care fragmentation 
We used a modified version of the Bice-Boxerman continuity of care index to calculate care 
fragmentation during the 12 month baseline period.(56,57) The continuity of care index represents the 
concentration of visits per patient among health care providers based on visit number, proportion of 
encounters to each provider, and total number of visits. The BBI has been used to compare care fragmentation 
among cancer survivors and is highly correlated with other measures of care fragmentation.(58) We used 
physician specialty codes representing primary care, oncology, and various specialist visit encounters; where n 
is the total number of visits, nk is the total number of visits associated with a physician specialty, and k the total 
number of physician specialty codes.(59) For example, multiple encounters with a single provider would result 
in a score of zero, however, multiple encounters among several health care providers would result in a score 
approaching 100. We included primary care, oncology, and many other specialty codes.  
Other features 
 Patient factors included age, race, marital status, county-level median income and education (college 
graduation percent). Practice ecosystem included urologist/radiation oncologist density, diagnosis year, SEER 
region and Rural groups (Metro, Urban, Rural). All features were calculated in the 12 months before cancer 
diagnosis.  
Propensity to seek care was also measured by two domains: the number of low-value care services as 
well as high-value care. Low-value healthcare services were operationalized using a claims-based algorithm 
representing Choosing Wisely campaign recommendations via procedure, diagnosis, hospitalization, and 
Berenson-Eggers Type of Service (BETOS) codes using previously published methods.(60–62) We estimated 
the feature importance of individual low-value care procedures and summed those with an importance score 
greater than zero. We operationalized preventative services based on the National Commission on Prevention 




screenings, influenza vaccinations, and primary care well visits. We used Healthcare Common Procedure 
Coding System (HCPCS) codes to identify preventative care. 
 All predictors were measured during the 12 month baseline period before incident low-risk prostate 
cancer diagnosis. 
Statistical Analysis 
 Chi-square tests and t-tests were used to identify significant group differences in prostate cancer treat 
or CM use by categorical variables. All statistical tests were 2-sided with a 5% Type I error rate and completed 
in SAS (SAS Institute Inc., Cary, NC, USA. Version 9.4, using Windows 10). 
Machine learning 
 ML methods can determine the most effective and parsimonious model/algorithm through 
classification of a binary target (i.e., yes or no dependent variable) via iterative learning. We used the XGBoost 
classifier, a decision-tree ensemble machine learning algorithm, to predict prostate cancer treatment or CM use 
among patients with low-risk prostate cancer diagnosis.(43)  
 First, our original dataset was split (70%/30%) into training and test data. Next, predicted labels and 
probabilities were optimized on the training data via hyperparameter tuning using repeated stratified 10-fold 
cross validation. We used hyperparameter tuning on the training data to optimize performance and avoid over-
fitting. Hyperparameter tuning parameters codes are available in Appendix Table 7.1.  
Final model predictions were evaluated using the original “hold-out” test data. We assessed predictive 
performance on the test set using precision, recall, accuracy, and Precision-Recall Receiver Operating Curve 
scores. Machine learning analyses were conducted using Python 3.7 with open-source scikit-learn 0.21.3 
wrapper interface for XGBoost classifier. 
Machine learning interpretation 
 In the ML model, Shapley Additive exPlanations (SHAP) were used to visually summarize the 
contributions and associations of the features to the target variable. SHAP values represent the magnitude of 
effect from each feature on the model output by conditional expectation when the feature is “hidden”. 
Attributed changes induced on the model output are then averaged overall possible feature orderings in the 




absolute average SHAP values whereas summary plots sort average SHAP outputs with positive and negative 
variations on the x-axis. Partial dependence plots (PDP) average SHAP values for a feature by a feature’s unit 
value (for example, average age SHAP values by the feature age in years). Unlike traditional PDP, SHAP PDP 
shows dispersion around feature units reflecting the impact of all the other features in the model. Lastly, PDP 
interactions display the attribution effect of two features simultaneously. All model SHAP outputs are log-odds 
and are ranked in decending order.     
TreeSHAP was used to generate SHAP values, feature importance, partial dependence plots, and PDP 
interactions with Python 3.7 and the SHAP package (0.29.2). 
2.4 Results 
Descriptive cohort statistics  
 The study cohort was predominantly non-Hispanic, white (83.3%), marital status of married (69.1%) 
with a median age of 72.0 (Mdn=71.1, SD=4.46).     
Overall, marital status of married, younger men in the age group 66-74 years, higher income, higher 
education level, lower physician quartiles, and adults residing in Northeastern SEER regions more frequently 
received treatment for low-risk prostate cancer (Table 2.1). In recent years, (2013 and 2014) mean age was 
lower among adults using treatment (M=71.3, SD=4.05) versus no treatment (M=71.7, SD=4.29; p<0.001). Life 
expectancy did not significantly differ between adults using treatment versus no treatment, however, 
multimorbidity was significantly more frequent among treatment groups (Table 2.1). Preventative care, flu 
vaccinations, and primary care visits were significantly more frequent among treatment groups.  
Highest ranking predictors 
Marital status of married, men in the age group 66-74 years, care fragmentation, median income, and 
college education were the top 5 predictive features of low-risk prostate cancer treatment (Figure 2.1). Men 
who were married, aged 66-74 years, and experienced care fragmentation were more likely, and those with 
higher median income and college education were less likely to receive treatment (Figure 2.1). Northeast SEER 
region, diagnostic year 2010, multimorbidity, and west SEER region, more recent diagnostic year (2014 and 
2013), were associated with higher and lower SHAP values (log-odds) of treatment prediction, respectively 




Figure 2.3 shows the complex individual variation among the top 4 predictive features. Overall, SHAP 
log-odds decreased with higher median income, however, substatntial individual-level variation in log-odds by 
distinct median income values was observed (Figure 2.3 (d)). 
Lowest ranking predictors 
Life expectancy of 10 or more years (PCCI) and non-cancer low-value care use ranked 22nd and 27th, 
respectively in feature importance out of 29 total features (Figure 2.1). SHAP partial density plots illustrate 
variation among adults with life expectancies less than 10 years with SHAP log-odds of treatment (Figure 2.4). 
Hispanic, black, and white race were 23rd, 24th, and 25th ranked predictors, respectively (Appendix 7.1)    
2.5 Discussion   
In this first study using ML to predict treatment among older men with low-risk prostate cancer, we 
observed that 2 in 3 adults with low-risk prostate cancer received treatment. Other recent SEER-Medicare data 
studies also report high (57.9%)(63), while integrated care network studies report low (21%), rates of low-risk 
prostate cancer treatment among older men (65+ years). High rates of low-value treatment are concerning as 
many men are likely to experience avoidable, negative health related quality of life and higher healthcare costs. 
For example, in the Prostate Cancer Intervention vs Observation Trial (PIVOT), a survival benefit to treatment 
versus conservative management was not significant after 10 years of follow-up. Treatment of low-risk prostate 
cancer confers significant risk of avoidable morbidities(10) and imposes a heavy economic burden of 1.2 billion 
dollars in annual cost(64). We speculate that treatment for low-risk prostate cancer may be high as older men 
experience adverse mental health effects associated with notification of higher PSA levels, pending biopsy 
results, and a prostate cancer diagnosis.(27) However, we observed that diagnosis year was a leading predictor 
of treatment, with adults diagnosed in later years (i.e. 2013 and 2014) less likely to receive treatment for low-
risk prostate cancer. Our findings revealing diagnostic year as a highly ranked predictive feature are consistent 
with published studies that show treatment of Medicare FFS adults with low-risk prostate cancer have 
decreased substantially in the last decade from 86% to 58%(63).  
Care fragmentation was among the leading predictors of treatment for low-risk prostate cancer in this 
study. Adults experiencing care fragmentation and incident prostate cancer may be inclined to “take care of it” 




adjusted machine learning models, care fragmentation prior to incident prostate cancer diagnosis was the 3rd 
highest in SHAP feature importance, suggesting a strong associative prediction of low-value prostate cancer 
treatment. We also observed that older men with multimorbidity were more likely to receive treatment, 
consistent with findings of our recently published study indicating that multimorbidity was significantly and 
positively associated with likelihood of treatment among older men with localized prostate cancer.(49) 
Multimorbidity adds to the complexity to prostate cancer management decisions given that limited physician 
and patient resources often compete for management. Specialty healthcare (i.e., urologists and oncologists) 
need after an incident prostate cancer diagnosis among older men with multimorbidity is known to increase 
care fragmentation.(24)  However, although multimorbidity was associated with higher odds of treatment use 
in the current study, interactions with care fragmentation were not informative. 
Surprisingly, life expectancy was not associated with treatment receipt in this study. Evidence-based 
guidelines are based on risk group stratification (i.e., PSA, Gleason Score) and life expectancy. Although clinical 
assessment of life expectancy is a critical element to informed decision making for older adults with low-risk 
prostate cancer, our study findings suggest that treatment selection might not sufficiently take into 
consideration life expectancy.(6) We speculate that greater variation in low-value care use between 
organizations, versus between physicians, may reflect practice patterns associated with physician affiliation 
and organization management (i.e., compensation, practice guidelines).(66) Findings of other published 
studies using alternative methods of life expectancy estimation have been inconsistent, with investigations 
showing both positive (67) and negative relationships (68) between comorbidity burden and CM use in 
Medicare FFS populations.(49) Taken together, clinical and population differences in comorbidity life 
expectancy definitions are likely to account for these mixed findings. We speculate that discrepancies may be 
explained by the use of common use of comorbidity indexes that imprecisely measure life expectancy in 
prostate cancer populations and likely account for mixed findings.(34,69) 
A noteworthy finding of the current study is the apparent role of social determinants (i.e., education 
and income) in predicting treatment of low-risk prostate cancer. The relationships were complex among 
individuals living in counties with varying levels of income and education. Socio-demographic factors, such as 




and many other (27) investigations. Social determinants of health have also been used to accurately predict 
inpatient and emergency room utilization, demonstrating how social determinants can improve predictive 
ability of ML models.(70) We found race to be a low-ranking predictor of treatment among low-risk prostate 
cancer. Unequal access to care in racial minorities may result in poor management and/or overtreatment of 
low-risk prostate cancer as rates of low-risk prostate cancer treatment among racial groups vary between 
integrated and fee-for-service cohorts.(71,72) However, we found race to be a low-ranking predictor of 
treatment among low-risk prostate cancer in this study. 
To our knowledge, this study is the first application of machine learning to estimate predictors of 
prostate cancer treatment among adults with low-risk prostate cancer. Unlike traditional statistical 
approaches, robust resampling and cross-validation techniques can be used to “train” machine learning 
algorithms to accurately predict healthcare utilization. More recently, model agnostic interpretations, such as 
SHAP used in this study, enable feature importance ranking and visualizations of individual-level contributions 
of patient, clinician, and practice ecosystem factors on target variables. Trade-offs between high performance 
and interpretability of complex “black-box” algorithms can be mitigated with SHAP feature importance ranking 
and data visualization. Our approach identified the top predictors of low-value treatment of low-risk prostate 
cancer and complex non-linear associations among features of high importance. Our results inform clinicians, 
payers, and policies makers regarding the predictive associations of features articulated in guideline 
recommendations, namely the lack of predictive importance of life expectancy, and the importance of social 
determinants, multimorbidity, and care fragmentation.  
2.6 Strengths and limitations 
Our study has several notable strengths. We used novel machine learning and model agnostic 
interpretations (SHAP) to predict and understand treatment use among older men with low-risk prostate 
cancer. We included validated measures of prostate cancer-specific life expectancy to identify older men with 
low-risk prostate cancer that could benefit from conservative management. Commonly used proxy measures of 
comorbidity burden are limited in estimating death risk from prostate cancer. We distinguished between 
comorbidity and life expectancy while previous studies have used comorbidity burden as a surrogate of life 




many older men could benefit from policies and/or interventions designed to reduce low-value prostate cancer 
treatment.  
Our study must be interpreted within the context of several limitations. Foremost, the study is a claims-
based, retrospective analysis; therefore, we cannot establish causality and our results are subject to 
unobservable variable bias and selection bias of paid Medicare claims. To minimize the proportion of missed 
claims we limited analyses to continously enrolled in Medicare (A&B, without HMO) throughout the study 
period. Second, our analysis may not be generaliable to commerical insurance beneficiaries as we only 
observed Medicare FFS beneficiairies. Third, social determinants of health (i.e., income, education) were not 
available at the individual level therefore county level measures were used. We were unable to estimate patient 
preference with SEER-Medicare data, and were thus unable to account for adults with longer life expectancies 
who prefer curative treatment as conservative management or active surveillance are evidence-based treatment 
options.  
2.7 Conclusions  
   Using interpretable machine learning approaches provided evidence for several strong, modifiable 
predictors of low-value treatment of low-risk prostate cancer, including care fragmentation and social 
determinants of health. Healthcare policies could reduce low-value treatment by addressing fragmentation of 
care and management of multimorbidity. “Health in all policies” (73) that address upstream features such as 
income and education should be considered to reduce low-value prostate cancer care associated with 
significant adverse health related quality of life and cost burdens. Despite a decade’s worth of evidence-based 
recommendations of observation for adults with low-risk prostate cancer and a life expectancy of more than 10 
years, we observed life expectancy to be a low-ranked predictor of treatment. Physician- and patient- focused 
education may be needed to utilize more precise life expectancy estimates in shared decision making of 







Table 2.1 Patient Characteristics by Treatment Use among Fee-for-Service Medicare 
Beneficiaries with Incident Low-risk Prostate Cancer (Linked SEER Cancer Registry and 
Medicare claims files, 2009-2014 (n= 13,870) 
  CM  Treatment Χ
2 p-value 
  n=4596 33.1 9274 66.9   
Multimorbidity      66.697 <0.001 
 0-2 MM 2157 37.0 3678 63.0   
 >2 MM 2439 30.4 5596 69.6   
Life expectancy      5.091 0.078 
 10+ years 3555 33.5 7057 66.5   
 5-10 years 714 31.1 1580 68.9   
 <5 LE 327 33.9 637 66.1   
Age group      113.674 <0.001 
 66-74 3287 30.8 7384 69.2   
 75 and above 1309 40.9 1890 59.1   
Race       18.128 <0.001 
 White 3796 32.8 7762 67.2   
 Black 497 35.4 908 64.6   
 Hispanic 48 22.6 164 77.4   
 Others 231 36.7 398 63.3   
 Unknown 24 36.4 42 63.6   
Marital status      209.023 <0.001 
 Unmarried 318 35.5 577 64.5   
 Married 2843 29.7 6742 70.3   
 Sep/div/wid 545 37.6 903 62.4   
 Unknown 890 45.8 1052 54.2   
Income quartile      17.902 <0.001 
 $2,512-43,709 997 30.4 2286 69.6   
 $43,711-57,34 1058 32.6 2185 67.4   
 $57,350-76,87 1142 34.6 2156 65.4   
 
$76,888-
250,0 1283 34.4 2442 65.6   
Education 
quartile      8.371 0.039 
 0.00-24.0 1192 33.5 2370 66.5   
 24-29.0 1066 31.6 2306 68.4   
 29.0-34.1 1088 32.4 2269 67.6   
 34.1-100 1135 34.8 2130 65.2   
Rural group      3.470 0.325 
 Metro 3925 33.4 7824 66.6   
 Urban 587 32.0 1248 68.0   
 Rural ** ** ** **   
 Unknown ** ** ** **   
Based on 13870 older (age ≥ 66 years) Fee-for-Service Medicare beneficiaries, with continuous enrollment in Medicare Part A & Part B, diagnosed with incident low-risk 
prostate cancer (Gleason 6, PSA <10, Stage ≤T2a) between 2009 and 2014. 
Age group included 66-74 and 75 and over categories. SEER= Surveillance, Epidemiology, and End Results cancer Registry. 






Continued Table 2.1 Patient Characteristics by Treatment Use among Fee-for-Service 
Medicare Beneficiaries with Incident Low-risk Prostate Cancer using Linked SEER Cancer 
Registry, 2009-2014 (n=13,870) 
Metro group      5.253 0.072 
 Metro county 3940 33.5 7827 66.5   
 Non-metro county 648 31.1 1436 68.9   
SEER Region      106.457 <0.001 
 Northeast 838 27.8 2171 72.2   
 South 1171 30.5 2666 69.5   
 North Central 433 32.6 896 67.4   
 West 2154 37.8 3541 62.2   
Radiation 
oncology quartile      14.578 0.002 
 0-0.44 1128 31.2 2485 68.8   
 0.44-0.99 1207 32.3 2527 67.7   
 0.99-1.47 1085 35.2 1997 64.8   
 1.48-22.0 1168 34.1 2254 65.9   
Urologist quartile      17.438 <0.001 
 0-1.25 1117 30.4 2562 69.6   
 1.25-2.38 1255 34.2 2411 65.8   
 2.38-3.22 1039 34.3 1990 65.7   
 3.23-28.4 1177 33.9 2300 66.1   
Preventative A1c 
screening      2.238 0.135 
 Yes 650 34.6 1226 65.4   
 No 3946 32.9 8048 67.1   
Preventative Flu 
vaccination      57.509 <0.001 
 Yes 2113 30.1 4898 69.9   
 No 2483 36.2 4376 63.8   
Preventative lipid 
screening      0.002 0.967 
 Yes 1283 33.1 2592 66.9   
 No 3313 33.1 6682 66.9   
Primary care 
physician visit      44.881 <0.001 
 Yes 3618 30.6 8205 69.4   
 No 628 38.9 988 61.1   
Based on 13870 older (age ≥ 66 years) Fee-for-Service Medicare beneficiaries, with continuous enrollment in Medicare Part A & Part B, 
diagnosed with incident low-risk prostate cancer (Gleason 6, PSA <10, Stage ≤T2a) between 2009 and 2014. 
Age group included 66-74 and 75 and over categories.  
SEER= Surveillance, Epidemiology, and End Results cancer Registry. 






Figure 2.1 Feature Importance of Treatment Prediction using SHAP values among Fee-for-Service Medicare 
Beneficiaries with Incident Low-risk Prostate Cancer using SEER Cancer Registry, 2009-2014 (n=13870) 
 
Top 15 mean SHAP values in descending order of log-odds. Based on 13870 older (age ≥ 66 years) Fee-for-
Service Medicare beneficiaries, with continuous enrollment in Medicare Part A & Part B, diagnosed with 
incident low-risk prostate cancer (Gleason 6, PSA <10, Stage ≤T2a) between 2009 and 2014. 
Age group included 66-74 and 75 and over categories. 
Care fragmentation = Bice-Boxerman continuity of care index to calculate care fragmentation during the 12 
month baseline period (See Methods).  











Figure 2.2 Positive and Negative Feature Relationships of Treatment Prediction among Fee-for-Service 
Medicare Beneficiaries with Incident Low-risk Prostate Cancer using SEER Cancer Registry, 2009-2014 
(n=13870) 
 
Mean SHAP values in descending order of log-odds. Based on 13870 older (age ≥ 66 years) Fee-for-Service 
Medicare beneficiaries, with continuous enrollment in Medicare Part A & Part B, diagnosed with incident low-
risk prostate cancer (Gleason 6, PSA <10, Stage ≤T2a) between 2009 and 2014. 
Age group 66-74 vs. adults over age 74 
Multimorbidity group = 3 or more chronic conditions. 
Care fragmentation = Bice-Boxerman continuity of care index to calculate care fragmentation during the 12 
month baseline period (See Methods).   










Figure 2.3 SHAP Partial Dependence Plot of Top 4 Predictive Features of Treatment among Fee-for-Service 


















SHAP Partial Dependence plots (PDP) of log-odds SHAP values by (A.) Marital status “Married”, (B.) Age 
group 66-74, (C) Care fragmentation, and (D) Median Income. Based on 13870 older (age ≥ 66 years) Fee-for-
Service Medicare beneficiaries, with continuous enrollment in Medicare Part A & Part B, diagnosed with 
incident low-risk prostate cancer (Gleason 6, PSA <10, Stage ≤T2a) between 2009 and 2014. 
Age group 66-74 vs. adults over age 74 
Care fragmentation = Bice-Boxerman continuity of care index to calculate care fragmentation during the 12 
month baseline period (See Methods). 
Median income = County-level median income from Area Health Resource File linkage. 
SHAP = Shapley Additive ePlanations.   










Figure 2.4 SHAP Partial Density Plot of Life Expectancy and Multimorbidity Predictive Features on 
Treatment among Fee-for-Service Medicare Beneficiaries with Incident Low-risk Prostate Cancer using SEER 









SHAP Partial Dependence plots (PDP) of log-odds SHAP values by (A.) PCCI “Life expectancy over 10 years”, 
(B.) “Multimorbidity”. Based on 13870 older (age ≥ 66 years) Fee-for-Service Medicare beneficiaries, with 
continuous enrollment in Medicare Part A & Part B, diagnosed with incident low-risk prostate cancer (Gleason 
6, PSA <10, Stage ≤T2a) between 2009 and 2014. 
PCCI = Prostate Cancer Comorbidity Index. 
Multimorbidity defined as 1 = two or fewer non-cancer chronic conditions, 2 = three or more non-cancer 
chronic conditions.   
SHAP = Shapley Additive ePlanations.   


















3 Associations of Multimorbidity and Patient-reported Experiences of Care with Conservative 
Management among Elderly Patients with Localized Prostate Cancer  
3.1 Abstract 
Background: Many elderly localized prostate cancer patients could benefit from conservative management 
(CM). This retrospective cohort study examined associations of patient-reported access to care and 
multimorbidity on CM use patterns among Medicare Fee-for-Service (FFS) beneficiaries with localized prostate 
cancer.  
Methods: We used linked Surveillance, Epidemiology and End Results cancer Registry, Medicare Claims, and 
the Medicare Consumer Assessment of Healthcare Providers and Systems survey files. We identified FFS 
Medicare Beneficiaries (Age ≥ 66; continuous enrollment in Parts A & B) with incident localized prostate 
cancer from 2003–2013 and a completed MCAHPS surveys within 12-months of diagnosis (n=496). We used 
multivariable models to examine MCAHPS measures (getting needed care, timeliness of care, and doctor 
communication) and multimorbidity on CM use. 
Results: Localized prostate cancer patients with multimorbidity were less likely to use CM (adjusted odds 
ratio (AOR)=0.42 (0.27- 0.66), P<0.001); those with higher scores on timeliness of care (AOR=1.21 (1.09, 
1.35), P< 0.001), higher education attainment (3.21=AOR (1.50,6.89), P=0.003), and impaired mental health 
status (4.32=AOR (1.86, 10.1) P<0.001) were more likely to use CM.  
Conclusion(s):  Timeliness of care was significantly and positively associated, and multimorbidity, 
significantly and inversely associated with CM use. Addressing specific modifiable barriers to timely care along 
the cancer continuum for elderly localized prostate cancer patients with limited life expectancy, and the 
reasons for lower CM use among those with multimorbidity, could reduce the adverse effects of overtreatment 
on health outcomes and costs.  
Text pages: 17, Tables: 4, and 2 Figures 





3.2 Introduction  
Conservative management (CM) has emerged as a common disease management approach for older 
adults with localized prostate cancer.(63) CM use is supported by high-level evidence for localized prostate 
cancer patients with low or favorable intermediate risk disease or higher risk disease with limited life 
expectancy.(6) CM includes protocols for low or intermediate risk prostate cancer, such as follow-up biopsies 
and PSA testing, or “watchful waiting” for patients with less than 5 years of life expectancy. Use of CM among 
patients with low‐risk prostate cancer or limited life expectancy improves health‐related quality of life (ie, 
urinary, bowel, and/or erectile dysfunction) and could reduce excessive annual health‐care costs of 
overtreatment by $1.2 billion.(10,64) 
CM decisions are complex as 60% of older adults (age > 65 years) with localized prostate cancer have 
pre-existing multimorbidity.(47,48) Multimorbidity affects life expectancy(47) and more than 50% of patients 
with multimorbidity seek care from three or more healthcare specialists.(50) Patients with multimorbidity and 
cancer may be vulnerable to poor quality of cancer care and have prompted greater attention in measuring, 
monitoring, and incentivizing patient‐centered care.(15) Measures of patient‐centered care, such as patient‐
reported experiences with care include domains of physician communication, timely care, and perceptions of 
getting needed care, are increasingly used as quality measures by health plans, medical groups, and physician 
practices. Positive patient‐reported experience scores are associated with adherence to medical advice, 
improved clinical outcomes, and lower utilization of unnecessary health‐care services(29,74) such as 
overtreatment of low‐risk localized prostate cancer. 
Patient‐reported experiences may differ by multimorbidity status, which may further complicate or 
facilitate treatment choices for low‐risk prostate cancer.(75) Identifying specific measures of patient‐reported 
experiences that facilitate CM use among patients with incident localized prostate cancer and multimorbidity is 
needed to promote evidence‐based cancer care.(30) For example, in colorectal cancer populations, patient‐
reported experiences with perceived timely care are associated with evidenced‐based follow‐
up.(31) Understanding the relationship between patient‐reported experiences of care on CM use can inform 
patient‐centered care approaches to improve adoption of CM use, thereby reducing the adverse effects of 




Despite the importance of patient‐reported experiences, CM studies primarily focus on disease 
characteristics, clinical, and sociodemographic factors.(27,38,39,63) To date, no studies have investigated the 
impact of patient‐reported experiences on CM use among medically complex patients with localized prostate 
cancer. Therefore, the primary objective of this study is to examine the associations of multimorbidity and 
patient‐reported experiences on CM use among Fee‐for‐Service (FFS) Medicare beneficiaries with localized 
prostate cancer using Consumer Assessment of Healthcare Providers and Systems (MCAHPS®) patient 
surveys and Medicare claims linkages. 
3.3 Methods 
The study cohort included men diagnosed with localized prostate cancer defined as American Joint 
Committee on Cancer stage T2a or less,(6) aged 66 or older, with continuous enrollment in FFS Medicare Parts 
A and B throughout the study period (Figure 3.1). 
Date of incident localized prostate cancer diagnosis was used as an index date and 12 months before 
diagnosis was used as the baseline period. During the baseline period, we identified multimorbidity using 
Medicare claims and calculated life expectancy estimates. 
We also defined the “CM measurement” period as 12 months after diagnosis. During this period, we 
identified CM based on validated methods for claims data.(53) 
As MCAHPS surveys can be administered at varying points during the post diagnosis period, we 
followed individuals for an additional period of 12 months. Thus, our follow‐up period consisted of 24 months 
after incident localized prostate cancer diagnosis. 
To account for varying months from diagnosis to survey administration, we included time from 
diagnosis to survey as one of the independent variables in the models. However, as this variable was not 
significant and did not affect our main results, we did not include time from diagnosis to survey administration 
variable in the final model. As a sensitivity analysis, we also estimated CM use during 24 months after 
diagnosis (Appendix 7.3). 
Data sources 
The Surveillance, Epidemiology and End Results (SEER) cancer registry contains tumor and 




Medicare eligibility from the SEER data (Figure 3.1). We extracted fee-for-service Medicare claims from 
Medicare Provider Analysis and Review (MEDPAR), Carrier Claims, Outpatient Claims, Home Health Agency, 
and Durable Medical Equipment files.  
Medicare Consumer Assessment of Healthcare Providers & Systems (MCAHPS®) surveys, 
administered by the CMS, use standardized and validated questionnaires to collect information on patient‐
reported experiences with health‐care providers.(40) MCAHPS collection methodologies use a weighted 
probability sampling procedure covering all the 50 US states, DC, and Puerto Rico, which are then linked to 
SEER patients.(40,41) 
Area Health Resource File (AHRF) files were linked via MEDPAR FIPS state and county codes and were 
used to calculate radiation oncologist and urologist densities.(42) Census files were linked to calculate county‐
level median income quartiles. 
Dependent Variable  
 We operationalized CM use as the absence of curative treatment within 12 months after incident 
localized prostate cancer. Treatment was identified using International Classification of Diagnosis 9th edition 
(ICD9), ICD9 procedure codes, and Healthcare Common Procedure Coding System (HCPCS) codes from FFS 
Medicare claims (Appendix 7.4).(6,38,53) 
Key Independent Variables  
The multimorbidity framework developed by the United States Department of Health and Human 
Services for guiding programs, practice, and policy guided the selection of chronic conditions as follows: 
arthritis, asthma, coronary artery disease, congestive heart failure, chronic kidney disease, chronic obstructive 
pulmonary disease, cardiac arrhythmias, acute myocardial infarction, dementia, diabetes, depression, 
hepatitis, hyperlipidemia, hypertension, human immunodeficiency virus, osteoporosis, substance abuse, 
schizophrenia, stroke, anemia, and lower limb fracture.(55) The most common definition of multimorbidity is 
the concurrent presence of two or more conditions in the same individual.(76) We defined multimorbidity as 
the presence of three or more conditions in the same individuals as older men diagnosed with prostate cancer 




comorbid conditions, aged 61‐74 and 75 years or older, 10‐year other cause mortality is 40% and 71%, 
respectively.(77) 
Prostate cancer comorbidity index (PCCI), a weighted comorbidity index validated prostate cancer 
patient populations, was used to predict 5‐ and 10‐year life expectancy in prostate cancer patient 
populations.(77) PCCI was calculated during the baseline period to estimate 5‐ and 10‐year life expectancy. 
PCCI was categorized into three groups: 0–8 (>10‐year life expectancy); 9 to 13 (5‐ to 10‐year life expectance); 
and > 13 (<5‐year life expectancy). In all models, PCCI total 0‐8 was used as the reference group. 
Published research in prostate cancer patients often uses Charlson Comorbidity Index (CCI); therefore, 
we conducted a supplemental analysis using CCI. In these analyses, CCI scores were dichotomized with “0‐1” as 
the reference group.(78) 
We included three MCAHPS composite measures— “getting needed care,” “getting care quickly,” and 
“doctor communication”—which rates the ability to get needed appointments, timeliness of care when care is 
needed, and how well the physician communicated. Patients report experiences with health‐care access in the 
last 6 months. MCAHPS surveys have been extensively validated for measuring patient‐reported access to care 
and are commonly used for quality improvement as well as value‐based purchasing initiatives.(40) MCAHPS 
are based on a 0‐100 scale with 0 representing the lowest and 100 representing the highest score; we examined 
the effect of 10 unit changes in composite items on the dependent variable. 
Management of preexisting multimorbidity and shared prostate cancer treatment decision‐making 
requires the use of limited resources (ie, time to manage chronic conditions and availability of health‐care 
professionals and resources). Therefore, for other independent variables, the competing demands model was 
used to conceptualize factors known to affect localized prostate cancer treatment selection within clinician, 
patient, and practice ecosystem domains.(38,53,79) (Figure 3.2). 
Multivariable models were adjusted with independent variables: diagnosis year group (2003‐2009 and 
2010‐2013), low‐risk prostate cancer (operationalized as Gleason Score ≤ 6 and PSA test ≤ 10 ng/mL or 
Gleason Score>=7 or PSA> = 10 ng/mL), self‐reported general and mental health status, education‐level, zip‐
code income quartiles, and county‐level quartiles of urologists and radiation oncologists per 10,000 persons 




Our analyses include several case‐mix adjustment variables such as age, education, general health 
status, mental health status, income level, and race. Secondary analyses using additional recommended case‐
mix adjustment variables, such as dual‐eligible Medicaid respondents, “proxy” survey completion, and time 
from cancer diagnosis to survey completion, did not significantly improve model specification.(80) 
To assess the potential influence of missing data, we examined missing data patterns using covariate‐
dependent missingness methods.(81) Mean values were imputed to independent variables of interest. For 
categorical variables, including general and mental health status, missing data indicators were created and 
included as a separate category in the regression models. 
Chi‐square tests and t tests were used to identify significant group differences in CM use by categorical 
variables. Multivariable models were fit using separate unadjusted and adjusted logistic regressions to identify 
independent and interactive associations of multimorbidity and patient care experiences on CM use. 
All statistical tests were two‐sided with a 5% Type I error rate and were completed in STATA (StataCorp, 
College Station, TX). 
3.4 Results  
 The study cohort was predominantly non‐Hispanic, whites (84.5%). The median age at diagnosis was 
72.8 years and did not differ by year of diagnosis (2003‐2009:73.6 = M, 5.38; 2010‐2013:73.6 = M, SD = 5.14). 
Average composite scores for doctor communication, getting needed care, and getting care quickly were 91.0 
(SD = 12.2), 88.6 (SD = 15.6), and 70.8 (SD = 21.7), respectively. 
Overall, 33.5% used CM, defined as no curative treatment within 12 months of incident localized 
prostate cancer diagnosis. Use of CM was only marginally higher in men with low‐risk relative to those with 
higher‐risk disease (≤ cT2a and PSA>= 10 ng/mL or Gleason Score > 6) (38.7% vs 30.9%, respectively, P = .08) 
(Table 3.1). High‐school graduation, college education, low‐risk prostate cancer diagnosis, and mental health 
status were significantly more frequent among patients using CM (Table 3.1). CM use by localized prostate 
cancer patients with higher‐risk disease was 30.9%. Higher‐risk disease was significantly more common among 
age groups 75+ (75.9%) vs 66‐74 (62.4%) (P = .002) and significant differences by patients with multimorbidity 




  In our study cohort, 57.2% had multimorbidity. Patients 75 years or older were significantly more likely 
to have multimorbidity than those aged 66‐74 years (64.4% vs 53.4%). Blacks had a higher percentage of 
multimorbidity as compared to whites (76.1% vs 53.9%). Patients with multimorbidity using treatment (n = 
207) did not differ significantly by patient, clinician, or practice ecosystem factors except for mental health 
status of excellent/very good (74.6%) and good (77.5%) vs patients using CM (P = .031). Patients with 
multimorbidity and higher‐risk disease (n = 183) significantly more frequently used treatment if aged 66‐74 
(82.5%) (P = .011). Average composite scores for doctor communication, getting needed care, and getting care 
quickly did not differ by multimorbidity status. CM use was significantly lower in men with vs without 
multimorbidity (27.1% vs 72.9%, respectively, P < .001). 
Average getting care quickly composite scores (ie, timely care) were higher for those with CM use as 
compared to those without CM use (Table 3.2). CM use significantly differed by PCCI categories, with lower 
percentages among groups with less than 10 (27.0%) and 5 (27.0%) vs more than 10 (38.9%) years of life 
expectancy (Χ2 = 7.82, P = .020) (Table 3.2). 
PCCI life expectancy groups did not statistically differ by CM use. Higher‐risk patients reporting fair or 
poor mental health status (62.1%; P = .002) vs excellent mental health status, and college education (33%) or 
high‐school graduates (37.5%) vs no high‐school graduation (13.7%), significantly used CM more frequently. 
Getting care quickly composite scores were significantly higher among higher‐risk patients (n = 333) using CM 
(M = 75.8) vs curative treatment (M = 69.8), (t=−2.43, CI 95%= 69.3, 73.9, P = .016). 
   Multimorbidity was significantly and inversely related to CM use in unadjusted logistic regression 
analyses (odds ratios (OR) = 0.55; 95% CI = 0.35, 0.75). Adjustment for other factors, including timeliness of 
care, further strengthened this association (adjusted OR (AOR) = 0.42, CI 0.27‐ 0.66) (Table 3.3); additional 
models adjusting for other patient experience domains or CCI were not significant. Getting care quickly showed 
a significant, positive association with CM use in both the unadjusted analyses (OR = 1.15; 95% CI = 1.05, 1.27) 
and the fully adjusted models (AOR = 1.21; 95% CI = 1.09, 1.34). In models including PCCI life expectancy 
categories, less than 10‐ and 5‐year life expectancy were inversely associated with CM use (Appendix 7.2). 
  CM use was also significantly and positively associated with fair/poor mental health status, low‐risk 




3.3; Appendix 7.1 and 7.2). We found no evidence for a modifying effect of patient‐experience variables, 
multimorbidity, PCCI, or other independent variables on the observed associations. 
3.5 Discussion  
In this study, we assessed the independent associations of multimorbidity and patient‐reported 
experiences with care on CM use among older men with localized prostate cancer. Despite proven benefits of 
CM, one in three (33.5%) of all men with localized prostate cancer, and only two in five (41%) men over the age 
of 75 years, used CM. Our estimates of CM use among patients with localized prostate cancer are lower than 
those reported in recent investigations using SEER‐Medicare data (42.1% in 2015)(63) but higher than 
reported in an investigation of Michigan Medicare beneficiaries (22.3% in 2014).(53) We speculate that these 
differences could be due to variation in study population characteristics (ours included prostate cancer patients 
from many regions of the US) and geographic practice patterns.(82–84) 
Multimorbidity and life expectancy are critical components of patient counseling after a localized 
prostate cancer diagnosis as many older men do not live long enough to benefit from treatment. Patients with 
low or favorable intermediate‐risk disease or higher‐risk disease with limited life expectancy could avoid 
significant urinary, erectile, and rectal treatment morbidities without increasing the risk of prostate cancer‐
specific mortality with CM.(85,86) However, in our study, men with multimorbidity were significantly less 
likely to use CM compared to those without multimorbidity after controlling for age, low‐risk prostate cancer, 
and other sociodemographic variables. We speculate that men with multimorbidity and low‐risk cancer may 
not opt for treatment because they may have a preference for immediate cure (ie, “take care of it”)(87) and may 
not want to add one more condition that requires long‐term management. Furthermore, men with 
multimorbidity may fear nontreatment regret,(88) emotional distress,(89) and anxiety.(90) Strong 
multidisciplinary management strategies, including significant psychological support from primary care 
physicians and specialists (ie, urologist and/or medical and radiation oncologists), are needed to mitigate 
decisional conflict(91) and therefore facilitate CM use.(27) 
In adjusted models, including validated life expectancy measures for prostate cancer survivors, patients 
meeting evidence‐based criteria2 for CM were 58% less likely to use CM based on life expectancy alone (ie, less 




burden and CM use in Medicare FFS populations.(67,68,92) In a supplemental analysis in this study, CCI was 
not significantly associated with CM use. Taken together, these findings suggest that clinical and population 
differences in comorbidity definitions are likely to account for mixed findings in several previous 
investigations.(69) By defining multimorbidity using a list of conditions prioritized by policy makers in the 
US,(55) our study made a unique contribution to this field. However, as pointed out by a systematic review that 
current life expectancy prediction tools lack both practical and theoretical utility,(34) comorbidity measures 
that can be easily operationalized in a clinical setting are needed. Recently, age‐adjusted indexes, such as the 
PCCI used in our study, were developed to provide life expectancy estimates in patients with prostate 
cancer.(54) Certain types (cardiovascular disease) and combinations (cardiometabolic and respiratory)(65) of 
chronic conditions are associated with treatment regardless of patient, clinician, and health‐care ecosystem 
factors. Additional research is needed to understand the relationship between more precise estimates of life 
expectancy and multimorbidity on CM use in FFS Medicare populations. 
In our study, patient‐reported experiences, specifically timeliness of care, were positively associated 
with CM use. Patients with higher timeliness of care scores were significantly more likely to use CM after 
adjusting for demographic, clinical, socioeconomic, and health‐care system factors. Timely access to care for 
localized prostate cancer patients is not limited to initial diagnosis of prostate cancer, but the opportunity and 
ease by which a patient is able to utilize needed services along the continuum of care throughout 
survivorship.(93) Choices for elderly localized prostate cancer patients involve selecting curative and non-
curative treatments with trade‐offs in efficacy, potential adverse quality of life effects, and competing risk 
mortality. MCAHPS timeliness of care domains, such as perceived barriers to appointment scheduling, are 
fundamental to shared decision‐making among multiple health‐care providers that significantly influence 
localized prostate cancer treatment choice.(94–96) We speculate that patients with higher timely care ratings 
may choose CM because they may have a favorable perception of health‐care system capacity to provide 
services once a need is detected. 
Our study findings have important policy implications. Currently, no value‐based mechanisms exist to 
support the use of CM in Medicare FFS populations. Existing literature also suggest that CM use in FFS system 




incorporate risk‐adjusted CM use as a quality indicator along the cancer care continuum(97) to promote CM 
use among men with localized prostate cancer. Recently, the NCCN Quality and Outcomes committee 
identified significant gaps in evaluating high‐quality cancer care with patient experience measures and 
evidence‐based practice.(85) More research is needed to identify specific barriers to timely care and how 
validated patient‐reported experience measures can be used to support evidence‐based management of 
localized prostate cancer patients in oncology care models. 
 
We also observed that elements of social determinants, such as education, were associated with CM use. 
Although educational attainment may not be modifiable among older adults, initiatives such as “health in all 
policies” by World Health Organization and the Centers for Disease and Prevention Control “integrate and 
articulated health considerations” into community health policy.(73) These experts concluded that social, 
economic, and physical environments have a significant impact on the health of an individual and these effects 
should be considered in the development of all public policies and programs.  
3.6 Strengths and Limitations 
The SEER‐CAHPS data linkage is a robust and unique resource that provides an ideal opportunity to 
study patient‐centered care delivery of contemporary treatment patterns among patients with localized 
prostate cancer and multimorbidity. We build on previous findings by including validated estimations of life 
expectancy and definitions of multimorbidity to access the impact of comorbid conditions on patterns of 
contemporary treatment options for older localized prostate cancer patients. 
Our study results must be interpreted with important limitations. MCAHPS surveys request patient‐
reported experiences with care “in the last 6 months”.(40) Due to relatively small sample size, we included 
surveys completed within 6 months after localized prostate cancer diagnosis which may overlap with the 
baseline period. However, our results were robust to multivariable adjustments for time between cancer 
diagnosis and survey completion. Due to MCAHPS survey administration processes and collection, we cannot 
directly attribute MCAHPS composite ratings to physician specialty or the prostate cancer diagnosis; instead, 
our results are generalizable to the entire patient experience after diagnosis which may include multiple care 




adults, potentially limiting generalizability to ethnic minorities, rural, or other populations. Our study was 
restricted to Medicare FFS enrollees 65 years or older and may not be generalizable to younger adults or 
individuals on private insurance. Lastly, due to sample size limitations, we were unable to analyze the 
relationship of individual chronic conditions with CM use. 
3.7 Conclusions  
Our results highlight the effect of patient‐reported experiences, multimorbidity, and life expectancy on 
CM use among older men with localized prostate cancer. While factors such as multimorbidity and life 
expectancy are critical clinical components that may affect the choice of CM vs over treatment, our study 
highlights the role of nonclinical factors, specifically patient‐reported experiences with care on treatment of 
localized prostate cancer. Our findings support a “population health‐based” oncology care model in which both 
clinical and nonclinical factors, such as patient‐reported experiences, are integrated to promote CM use and 



















Table 3.1 Patient Characteristics by Conservative Management among Fee-for-Service Medicare Beneficiaries 
with Incident Localized Prostate Cancer using Linked SEER Cancer Registry with MCAHPS, 2002-2013 
(n=496) 
  CM No CM   
  
  
N % N  % Χ2 p-value 
ALL  166 33.5 330 66.5   
Age in Years       1.32 0.250 
  66-74 102 31.7 220 68.3    
  75+ 64 36.8 110 63.2    
Race         0.07 0.964 
  White 140 33.4 279 66.6    
  Black 15 32.6 31 67.4    
  Other 11 35.5 20 64.5    
Marital Status       0.2 0.905 
  Married 115 32.9 235 67.1    
  Unmarried 22 34.9 41 65.1    
  Unknown 29 34.9 54 65.1    
Income quartiles       0.54 0.909 
  First 38 33.3 76 66.7    
  Second 39 33.6 77 66.4    
  Third 38 31.1 84 68.9    
  Four 51 35.4 93 64.6    
Education        8.11 0.017 
  College or more 100 36.6 173 63.4    
  High School Grad. 42 35.9 75 64.1    
  No High School Grad. 13 18.8 56 81.2    
General health status       3.32 0.19 
  Excellent/Very Good 59 35.5 107 64.5    
  Good 54 28.6 135 71.4    
  Fair/Poor 47 37.6 78 62.4    
Mental health status       11.3 0.004 
  Excellent/Very Good 104 31.6 225 68.4    
  Good 34 30.1 79 69.9    
  Fair/Poor 22 57.9 16 42.1    
Bold values denote statistical significance at the P‐value < .05 level. 
Based on 496 older (age ≥ 66 years) Fee‐for‐Service Medicare beneficiaries, with continuous enrollment in 
Medicare Part A & Part B, diagnosed with incident localized prostate cancer between 2003 and 2013. 
Abbreviations: CM, Conservative management; MCAHPS, Medicare Claims and the Medicare Consumer 







Table 3.1 “continued” 
Urologist density       4.99 0.173 
  0 to 1.41 41 33.1 83 66.9    
  1.41 to 2.49 33 26.6 91 73.4    
  2.5 to 3.46 51 39.8 77 60.2    
  3.47 to 10.2 41 34.2 79 65.8    
Radiation oncologist density       5.43 0.143 
  0 to 0.44 37 29.8 87 70.2    
  0.45 to 1.07 41 33.1 83 66.9    
  1.07 to 1.49 52 41.6 73 58.4    
  1.51 to 5.35 36 29.3 87 70.7    
SEER region      
 5.09 0.166 
  Northeast 33 35.5 60 64.5 
 
  
  South 35 30.4 80 69.6 
 
  
  North-central 13 22.4 45 77.6 
 
  
  West 85 37 145 63.0 
 
  





  Metro 138 34.3 264 65.7 
 
  
  Non-Metro 28 29.8 66 70.2 
 
  
Diagnosis Year   
  
0.44 0.509 
  2002-2007 96 32.3 201 67.7 
 
  
  2008-2013 70 35.2 129 64.8 
 
  
Low-risk prostate cancer   
   
2.93 0.087 
  Yes 63 38.7 100 61.3 
 
  
  No 103 30.9 230 69.1 
 
  
Bold values denote statistical significance at the P‐value < .05 level. 
Based on 496 older (age ≥ 66 years) Fee‐for‐Service Medicare beneficiaries, with continuous enrollment in 
Medicare Part A & Part B, diagnosed with incident localized prostate cancer between 2003 and 2013. 
Abbreviations: CM, Conservative management; MCAHPS, Medicare Claims and the Medicare Consumer 












Table 3.2 Multimorbidity and Patient Experiences by Conservative Management among Fee-for-Service 
Medicare Beneficiaries with Incident Localized Prostate Cancer using Linked SEER Cancer Registry with 
MCAHPS, 2002-2013  
CM No CM 
  
 
N % N % Χ2 p-value  
166 33.5 330 66.5 
  
Multimorbidity 
    
12.1 <0.001 
Yes 77 27.1 207 72.9 
  
No 89 42.0 123 58.0 
  
PCCI 
    
7.82 0.020 
< 5 years life expectancy 20 27.0 54 73.0   
≥ 5 and < 10 years life expectancy 41 27.0 111 73.0  
 
≥10 years life expectancy 105 38.9 165 61.1 
  
 Mean SE Mean SE t-Value p-value 
Getting Needed Care 87.1 1.33 89.3 0.81 1.48 N.S. 
Getting Care Quickly 75.0 1.48 68.7 1.25 -3.06 0.002 



















Table 3.3 Unadjusted (UOR), Adjusted Odds Ratios (AOR) and 95% Confidence Intervals (CI) of 
Multimorbidity, Mental Health, Timeliness of Care, Low-risk Prostate Cancer, and Education on Likelihood of 
Conservative Management Use among Fee-for-Service Medicare Beneficiaries with Incident Localized 
Prostate Cancer using Linked SEER Cancer Registry with MCAHPS, 2002-2013 (N = 496). 
 UOR [95% CI] AOR [95% CI] 
Patient Experience:  Getting Care Quickly 
Multimorbidity  
 p-value   p-value 
 Yes 0.51 [0.35 - 0.75] 0.001 0.42 [0.27 - 0.66] <0.001 
 No (Ref.) 
   
   
Getting Care Quickly 1.15 [1.05 - 1.27] 0.003 1.21 [1.09 - 1.35] <0.001 
Low-risk prostate cancer       
 Yes 1.41 [0.95 - 2.08] 0.088 1.76 [1.14 - 2.72] 0.01 
 No (Ref.) 
   
   
Mental Health Status       
 Fair/Poor 2.97 [1.50 - 5.90] 0.002 4.32 [1.86 - 10.1] <0.001 
 Ex/VG/Good (Ref.) 
   
   
Education       
 College or more  2.49 [1.30 - 4.78] 0.006 3.21 [1.50 – 6.89] 0.003 
 High-school graduate 2.41 [1.18 - 4.92] 0.015 3.53 [1.59-7.83] 0.002 
 No high-school graduation (Ref.)       
Patient Experience:  Getting Need Care 
Multimorbidity       
 Yes   0.088 0.45 [0.30 - 0.70] <0.001 
 No (Ref.)       
Getting Needed Care - - N.S. - - N.S. 
Patient Experience:  Doctor Communication 
Multimorbidity       
 Yes   0.088 0.45 [0.29 -0.68] <0.001 
 No (Ref.)       
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4 Healthcare Expenditures Associated with Low-value Care among Older Men with Incident 
Localized Prostate Cancer: Statistical and Machine Learning Approaches 
4.1 Abstract 
Background: Older adults with incident localized prostate cancer represent a large, medically complex 
population at risk of low-value care in the form of overtreatment. Conservative management (CM), or non-
treatment of prostate cancer with little cancer specific mortality risk, can reduce the adverse effects of 
overtreatment. Other types of low-value care services are associated with high, compounding “downstream” 
costs and may be useful for predicting cancer survivorship costs. 
Research Objective: Use statistical and machine learning approaches to estimate the association of low-
value care use prior to incident prostate cancer diagnosis on average non cancer related total healthcare 
expenditures 12-24 months after diagnosis. Generalized linear models (GLM) with log-link and gamma 
distribution were used to estimate total healthcare cost. Predictive feature importances of healthcare costs and 
non-linear relationships were estimated using the XGBoost Machine Learning (ML) algorithm and SHapley 
Additive exPlanations (SHAP). 
Study Design:  Retrospective cohort study. 
Population Studied: We used linked Surveillance, Epidemiology, and End Results cancer Registry, Medicare 
Claims, Census, and Area Health Resource files identify Medicare Fee-for-Service beneficiaries with continuous 
enrollment in Parts A & B and incident localized prostate cancer from 2005 to 2014 (n=75671). We identified 
20 low-value care measures 12 months prior to localized prostate cancer diagnosis using SEER-Medicare 
registry and claims files. Conservative management was defined as no treatment 0-12 months after diagnosis. 
Non cancer related total healthcare expenditures were defined as all costs independent of cancer treatment 
modalities 12-24 months after diagnosis. 
Principal Findings: Overall, 25.2% used low-value care services in 12 months prior to cancer diagnosis. 
Screening for asymptomatic carotid artery stenosis, Magnetic Resonance Imaging (MRI) for low-back pain, 




use of any low-value care was lower among patients using CM (15.2%), with MRI for low-back pain, traction for 
low-back pain, and asymptomatic carotid artery stenosis more frequent among patients using treatment.  
In adjusted GLM models, every 1-unit increase in low-value care use was associated with an $858.82 increase 
in healthcare expenditures. Multimorbidity (physical condition count), care fragmentation, and conservative 
management use were the top 3 predictors of healthcare expenditures with the highest absolute mean SHAP 
values. 
Conclusions: We found incremental low-value healthcare use before incident prostate cancer diagnosis was 
significantly and positively associated with long-term non-cancer related costs. Using ML, both low-value care 























Low-value care, defined as unnecessary tests or treatment lacking a net clinical benefit to the patient, 
contribute to avoidable morbidities and excessive healthcare costs.(17) Low-value care is prevalent among 
elderly patients, affecting 1 in 4 Medicare beneficiaries(18) and accounting for $75.7 - $101.2 billion in annual 
healthcare costs.(19,20) Use of low-value healthcare services among medically complex patients can lead to 
cascades of unnecessary down-stream care, leading to costs as high as 10 times the original low-value 
healthcare service.(21)  
Adults with incident localized prostate cancer represent a large, medically complex population at risk of 
low-value care in the form of overtreatment. Older adults with localized prostate cancer have high rates of 
multimorbidity and often experience care fragmentation that present barriers to shared decision making and 
evidence-based recommendations.(25) These adults may be at risk for receiving low-value care, augmenting 
down-stream costs. Many studies have examined comparative costs between different prostate cancer 
treatment modalities including conservative management (CM) (32); however, long term costs associated with 
overtreatment or low-value care remain unknown.  
Recently, machine learning algorithms have been used to identify high-cost patients (98), including, for 
example,  high-cost breast cancer patients (99). However, the potential predictive effects of low-value care on 
non-cancer related total healthcare expenditures among medically complex localized prostate cancer survivors 
remains little explored. 
The primary objective of this paper is to examine whether low-value care is a leading predictor of long-
term (12-24 months after diagnosis) non-cancer related expenditures among older adults with incident 
localized prostate cancer using machine learning algorithms and model agnostic interpretations. We used 
traditional generalized linear models to examine the association of life expectancy, high- and low- value care 







This study used a retrospective longitudinal design with a 12-month baseline and a 24-month follow-up 
period. The baseline period comprised the 12-month period before date of localized prostate cancer diagnosis. 
The follow-up period included the 24-month after localized prostate cancer diagnosis. Healthcare expenditures 
were calculated during the second half of the follow-up period (12-24 months). 
Data sources 
This study used the Surveillance, Epidemiology, and End Results (SEER)-Medicare linked data files. 
SEER-Medicare data includes data on all incident prostate cancer cases occurring in 18 regions throughout the 
United States. Incident prostate cancer, prostate cancer specific clinical information (i.e., Gleason Score and 
Prostate-specific antigen values), and cancer staging information were derived from the SEER database. 
Medicare claims were derived from inpatient, outpatient, and other files linked to SEER.  
Area Health Resource File (AHRF) files were linked via MEDPAR FIPS state and county codes and were 
used to calculate radiation oncologist and urologist densities. Census files were linked to calculate county-level 
median income quartiles. 
Study population  
Patients (age ≥ 66 years) diagnosed with localized prostate cancer during the study period (2005-2014) 
were included in the study population. Cancer diagnosis was identified using International Classification of 
Diseases for Oncology (ICD-9). Localized prostate cancer was defined as cancer stage ≤T2a.   
Study inclusion/exclusion criteria:  
Patients with localized prostate cancer were included in the study if alive and continuously enrolled in 
Medicare Parts A and B throughout the baseline and follow-up periods. Patients with missing cancer stage, PSA 
values, Gleason Scores were excluded. Patients diagnosed with prostate cancer at autopsy were excluded 
(Appendix Figure 7.7). 
Dependent variable/target 
Total healthcare expenditures were calculated by summing inpatient (MEDPAR), outpatient (Outsaf, 
NCH), and “other” (durable medical equipment, and home health agency) claims. To compare non-cancer 




expenditures were estimated 12-24 months after localized prostate cancer diagnosis. Consumer price index 
(CPI) was used to adjust all expenditures to 2016 constant dollars. (100)  
Key Independent variables/features 
Low-value care 
Various professional societies identify medically unnecessary and/or potentially harmful procedures, 
tests, and treatments for Choosing Wisely in an international effort to reduce low-value care.(20,22) Low-value 
healthcare services were operationalized using a claims-based algorithm representing Choosing Wisely 
campaign recommendations. The Low-value care algorithm included procedure, diagnosis, hospitalization, and 
BETOS codes using previously published methods.(60–62)   
Other independent variables 
Conservative management  
Conservative management was estimated within the first 12 months of the 24-month follow-up period 
using a validated claims-based algorithm.(53) Patients without treatment claims were designated as using 
conservative management.  
Multimorbidity 
The multimorbidity framework developed by the United States Department of Health and Human 
Services for guiding programs, practice, and policy guided the selection of chronic conditions as follows: 
arthritis, asthma, coronary artery disease, congestive heart failure, chronic kidney disease, chronic obstructive 
pulmonary disease, cardiac arrhythmias, acute myocardial infarction, dementia, diabetes, depression, 
hepatitis, hyperlipidemia, hypertension, human immunodeficiency virus, osteoporosis, substance abuse, 
schizophrenia, stroke, anemia, lower limb fracture.(55) We used clinically meaningful cut points (77) of 
multimorbidity (i.e., >2 chronic conditions) in descriptive analyses and included total counts of mental and 
physical health conditions in ML models. 
Prostate cancer comorbidity index   
Prostate cancer comorbidity index (PCCI) is a weighted comorbidity index validated in prostate cancer 
patient populations to predict 5 and 10 year life expectancy.(54) PCCI was calculated during the baseline period 




to 13 (5-10-year life expectancy); and > 13 (< 5-year life expectancy). In GLM models, PCCI total representing 
>10 years of life expectancy was used as the reference group. In ML models, we included PCCI as a continuous 
variable. 
 Managing pre-existing conditions and an incident prostate cancer diagnosis requires the use of limited 
patient, clinician, and practice ecosystem resources; patients must balance the management of several chronic 
conditions and participate in shared-decision making to select prostate cancer management within a practice 
environment with variation in supply and demand of healthcare resources (i.e., supply of clinician specialists). 
Therefore, a competing demands framework and previous literature reviews were used to guide the selection of 
other independent variables known to affect low-value care and prostate cancer treatment selection within 
patient, clinician, and practice ecosystem domains.(20,27,32,101) 
Other independent variables included: diagnosis year group (2003-2009 and 2010-2013), low-risk 
prostate cancer (operationalized as Gleason Score ≤ 6 and PSA test ≤ 10 ng/mL), education (Less than high-
school graduation and college graduation per 10,000 persons over age 65), income, urologist, and radiation 
oncologist quartiles (per 10,000 persons over age 65).  
We used a modified version of the Bice-Boxerman continuity of care index to calculate care 
fragmentation.(56) The continuity of care index represents the concentration of visits per patient among health 
care providers based on visit number, proportion of encounters to each provider, and total number of visits. We 
used physician specialty codes representing primary care, oncology, and various specialist visit encounters; 
where n is the total number of visits, nk is the total number of visits associated with a physician specialty, and k 
the total number of physician specialty codes.(59) For example, multiple encounters with a single provider 
would result in a score of zero, however, multiple encounters among several health care providers would result 
in a score approaching 1. We included many specialties as patients with multimorbidity and/or limited life 
expectancy may require services from multiple specialists. Care fragmentation was measured during the 12 
month baseline period. 





 Chi-square tests and t-tests were used to identify significant group differences in low-value care and CM 
use by categorical variables. Generalized linear models (GLM) with log-link and gamma distribution were used 
to estimate total healthcare cost. GLM transforms the mean cost directly, reversing the transformation is 
possible without bias estimation of mean cost. Differences between cost associated with each independent 
variable of interest and the exponentiated intercept term were reported as the incremental average cost (i.e., 
mean) associated with independent variables of interest. GLMs were fit using separate unadjusted and adjusted 
regressions to identify independent and interactive associations of key independent variables and total 
healthcare expenditures. All statistical tests were 2-sided with a 5% Type I error rate and were completed in 
SAS (SAS Institute Inc., Cary, NC, USA. Version 9.4, using Windows 10). 
Machine learning 
 We used the XGBoost regression, a decision-tree ensemble machine learning algorithm, to determine 
the association of low-value care to healthcare expenditures.    
Model training was conducted on 70% of the original data with 10-fold cross validation based on the 
original data set. Hyperparameter adjustments were made during training interactions to address overfitting. 
Healthcare expenditures were log transformed to approximate a normal distribution. Prediction performance 
was assessed on unseen data by reserving a 30% stratified random sample of the original data (i.e., the test set). 
Model tuning and test prediction performance were assessed using Residual Mean Squared Error and R2. 
Hyperparameter tuning parameters codes are available in Supplemental Materials 1. 
SHAP is an additive feature attribution method that provides consistent, locally accurate, 
individualized feature attributions based on conditional expectation. SHAP is an improvement over other 
feature importance methods that utilize model performance metrics (i.e., gain/accuracy) subject to 
inconsistency bias. SHAP values can be sorted to illustrate feature importance and display cumulative effects of 
interactions. We used SHAP feature importance to describe the top 10 predictive features of non-cancer related 
total healthcare cost 12-24 months after incident prostate cancer diagnosis. SHAP summary and partial density 
plots for key variables were used to illustrate non-linear relationships between important features and non-




XGBoost hyperparameters can be adjusted to fine-tune regularization to control model complexity to 
optimize predictive performance.(43)  
 Machine learning analyses were conducted using Python 3.7 with open-source scikit-learn 0.21.3 
wrapper interface for XGBoost regressor. 
 TreeSHAP was used to generate SHAP and SHAP feature plots using Python 3.7 and the SHAP package 
(0.29.2).  
4.4 Results 
Study cohort description 
The study cohort was predominantly non-Hispanic white (81.3%) (Table 4.1). The median age at 
diagnosis was 73.5 years and did not differ by year of diagnosis (2003-2009: M=73.8, SD= 5.4; 2010-2013: M= 
73.2, SD=5.2). Overall 18.1% used CM, defined as no curative treatment within 12 months of incident localized 
prostate cancer diagnosis. 
Among older men with incident localized prostate cancer, 25.2% used LVC in the 12 months prior to 
cancer diagnosis. Screening for asymptomatic carotid artery stenosis, Magnetic Resonance Imaging (MRI) for 
low-back pain, and traction for low-back pain were the most frequently reported low-value care procedures. 
Low-value care use counts ranged from 1 to 6, with 13422, 4105, and 5649 patients using 1, 2, or 3 or more LVC 
services, respectively.      
Cohort characteristics and Low-value care  
Use of low-value care was significantly more common in older men aged 75 years or older, with 
multimorbidity, with less than 10 years of life expectancy, and who used preventative care (Table 4.1). Use of 
any low-value care was lower among patients using CM (15.2%), with MRI for low-back pain, traction for low-
back pain, and asymptomatic carotid artery stenosis more frequent among patients using treatment 
(Supplemental Table 4.2). 
Predictive feature importance of low valve care  
The predictive feature importance for low-value on healthcare expenditures ranked 7th (Figure 4.1). 
Absence of low-value care was inversely associated with healthcare expenditures, with a complex linear 




Statistical Associations of Low-value care to healthcare expenditures  
Average outpatient, inpatient, “other”, and non-treatment related total healthcare expenditures were all 
significantly higher in low-value care than in no low-value care use groups (Table 4.2). In adjusted models 
using GLM with log-link function, every 1-unit increase in low-value care use was associated with an $858.82 
increase in healthcare expenditures (Table 4.4).  
Other Leading predictors of healthcare expenditures  
 Multimorbidity (physical condition count), care fragmentation, and conservative management use were 
the top 3 predictors of healthcare expenditures with the highest absolute mean SHAP values (Figure 4.1). 
Partial density plots display linear and complex relationships with healthcare expenditures (Figure 4.2). Lower 
(0 to 1) and higher (>99) values of care fragmentation were inversely associated with healthcare expenditure 
prediction (Figure 4.2). Physical health condition counts displayed more variation lower (0-4) versus higher 
(>7) chronic condition counts (Figure 4.2). In contrast, CM use was inversely associated with healthcare 
expenditure prediction (Figure 4.1).   
Statistical Associations among other important features 
Patients with a life expectancy of greater than 10 years had lower average healthcare expenditures 
(M=$6941.96, SD=16028.12) versus 5-10 year (M=$12638.58±24002.64) and less than 5 year 
(M=$21284.75±34633.97) life expectancy groups (M=$8893.27 ±19802.73) (F=1618.68, p<0.001). Healthcare 
expenditures were also significantly lower among patients using CM (M=$7332.74 ± 18787.79) versus patients 
without CM use (M= $9237.09 ± 20003.22) (p<0.001).  
CM use was associated with a $932.05 decrease in non-treatment related total healthcare expenditures 
versus treatment for low risk prostate cancer (Table 4.4). Life expectancies less than 10 years were associated 
with significantly higher, and CM use, significantly lower, non-treatment related healthcare expenditures in 
adjusted GLM models (Table 4.3). 
4.5 Discussion  
 In this study, we used claims-based algorithms supported by expert consensus to identify low-value 
care use prior to incident prostate cancer diagnosis. We observed that 1 in 4 older men with incident prostate 




expenditures, defined as total non-cancer related healthcare expenditures 12- 24 months after incident prostate 
cancer diagnosis.  
Low-value care use prior to incident prostate cancer diagnosis was also associated with substantial increases in 
healthcare expenditures. On average, older patients using low-value care before an incident localized prostate 
cancer diagnosis were more likely to use treatment (versus CM) and to have higher healthcare expenditures. 
These associations remained robust after adjustment for prostate cancer-specific life expectancy estimates, 
low-risk prostate cancer, and practice ecosystem factors such as physician supply and care fragmentation, 
suggesting that low-value care was a significant driver of cost within 2 years of diagnosis.  
 Efforts to promote a high-value, patient-centered healthcare system has led to increased attention on 
excessive spending on low-value care, under-provision of high-value care, and policy approaches to controlling 
the rising cost of cancer care. Recently, the Centers for Medicare & Medicaid Services (CMS) developed an 
Oncology Care First Model that establishes performance based payment components based on prospective 
total cost of care targets among patients completing curative treatment. As portions of cancer care 
reimbursement are transitioned from fee-for-service (FFS) to capitation payments, identifying the most 
important features of cost prediction could help providers establish more effective policies and interventions 
for high cost patients. Up-stream, low-value care, such as PSA screening for men over age 70, are known to 
contribute to increased short- and long- term costs associated with subsequent biopsies, treatment, and/or 
additional PSA tests. We found that other non-cancer related low-value care procedures were predictive of 
downstream expenditures after incident prostate cancer diagnosis. Our results have important implications for 
predicting patient cost after incident care diagnosis, given that low-value care use prior to incident prostate 
cancer diagnosis is predictive of higher cost. 
 CM use, defined as no treatment within one year post diagnosis (102), was one of the highest ranking 
features in predicting healthcare expenditures using machine learning models. Previous studies report that CM 
use, including both Active Surveillance and Watchful Waiting, could reduce annual healthcare costs associated 
with avoidable localized prostate cancer treatment by an estimated 1.2 billion dollars.(64) Other studies have 




respectively.(32) We found that CM use was associated with a $1905 reduction in 12-24 month healthcare 
expenditures independent of treatment-related costs.  
High level evidence supports CM for localized prostate cancer among men with low-risk disease and/or 
limited life expectancy to reduce overtreatment morbidities and excessive healthcare expenditures. Regardless 
of initial treatment modality, incident prostate cancer patients encounter significant ephemeral anxiety that 
predisposes patients to treatment without prostate cancer specific mortality benefit.(94) Decisional conflict, 
adverse mental health effects, and survival expectations (103) associated with diagnosis are independent 
factors associated with treatment selection regardless of risk grouping or comorbidity burden.(27) Other 
studies report cascades of downstream care associated with avoidable treatment-related morbidities, 
competing demand for chronic condition management and preventative care, and compounding costs. (21) We 
speculate that an incident localized prostate cancer diagnosis among patients using low-value care services may 
affect other forms of overtreatment or use of unnecessary care leading to higher cancer survivorship costs.    
 Older adults with multimorbidity, living in an urban locality, and/or specialist dense regions are at risk 
for low-value care and down-stream cascades of high cumulative costs.(21)  Patients with incident prostate 
cancer and multimorbidity are likely to encounter additional care fragmentation, which may include 
consultation from medical, urological, radiation, and/or surgical oncologists. Care fragmentation during 
prostate cancer survivorship is associated with redundant use of healthcare services, PSA testing, and 
proportional increases in cost.(24) As in previous studies, we found care fragmentation and multimorbidity 
prior to incident prostate cancer diagnosis to highly ranked predictors of long term healthcare expenditures. 
 Current Oncology Care Model (OCM) do not address care complexities associated with multimorbidity, 
care fragmentation, or non-treatment approaches to localized prostate cancer survivorship. Although 
multidisciplinary approaches have been proposed as a management strategy for prostate cancer survivors, it 
remains unclear how primary care and oncology professionals can effectively coordinate care in a fragmented 
FFS environment. More research is needed to identify predictors of high cost consumption of care in order to 
inform population health management initiatives and allow policymakers to develop tailored interventions to 




4.6 Strengths and Limitations 
Despite calls to identify low-value care use in vulnerable populations, no studies have investigated how 
use of low-value care in men with incident localized prostate cancer is associated with longer term survivorship 
costs. We used previously validated algorithms to identify conservative management use, prostate cancer 
specific mortality index, care fragmentation, and multimorbidity estimates to understand the predictive 
importance of low-value care use on healthcare cost during survivorship. We also estimated non-treatment 
related total expenditures 12-24 months after diagnosis to identify long-term costs lacking characterization in 
the current literature. We applied statistical, machine learning, and novel machine learning interpretative 
approaches to estimate and predict the impact of low-value care use on healthcare expenditures.   
 Our results must be interpreted with important limitations. First, this observational study is a claims-
based, retrospective analysis, therefore, our results are subject to unobservable variable bias and selection bias 
of paid Medicare claims. To minimize the proportion of missed claims we included beneficiairies only 
continously enrolled in Medicare (A&B, without HMO) throughout the study period. Second, our analysis may 
not be generaliable to commerical insurance beneficiaries as we only observed Medicare FFS beneficiairies. 
Our estimates of low-value care use are likely underestimated as methods for identification of low value care in 
claims data are limited. Social determinants of health (i.e., income, education) were not available at the 
individual level therefore county level measures were used. We only included measures detectable within a one 
year period to match the length of the baseline period before diagnosis, likely leading to further 
underestimation of costs. Although NCCN guidelines recommend CM for patients with low-risk cancer and a 
life expectancy of less than 10 years, both curative therapies and Active Surveillance are evidenced-based 
choices for patients with a life expectancy of greater than 10 years.(6) Lastly, we did not account for follow-up 
costs such as PSA and/or biopsy procedures that are commonly part of routine medical practice for patients 
using Active Surveillance and/or treatment related monitoring.  
4.7 Conclusion 
 In this study, incremental use of low-value healthcare showed a significant positive association with 
long-term, non-treatment related costs after adjustments for multiple possible confounders. Use of evidence-




machine learning, we estimate both low-value care and CM use to be high-ranking features of cost prediction 
12-24 months after incident prostate cancer diagnosis. Targeting patients with low-value care use prior to 
cancer diagnosis using existing claims data could help to reduce low-value care related morbidities by 
































Table 4.1 Patient Characteristics by Low-value Care Use among Fee-for-Service Medicare Beneficiaries with 
Incident Localized Prostate Cancer using Linked SEER Cancer Registry, 2005-2014 (n=75671) 




N % N  % Χ2 p-value 
ALL  19,071 25.2 56,600 73.3 
  





  66-74 12075 24.4 37474 75.6 
  
  75+ 8135 31.1 17987 68.9 
  





  White 16701 27.1 44853 72.9 
  
  Black 2079 24.1 6533 75.9 
  
  Hispanic 352 27.5 927 72.5 
  
 Other 1025 25.4 3014 74.6   
Marital Status     52.97 <0.001 
  Married 1271 24.7 3881 75.3 
  
  Unmarried 13908 26.5 38585 73.5 
  
 Separated/Divorced/Widowed 2495 26.3 7002 73.7   
  Unknown 2536 29.7 5993 70.3 
  
Income quintiles     38.85 <0.001 
  First 3746 25.5 10938 74.5 
  
  Second 3841 26.0 10912 74.0 
  
  Third 3909 26.5 10860 73.5 
  
  Four 3992 27.1 10726 72.9 
  
 Fifth 4283 28.4 10785 71.6   





  First 4184 28.4 10545 71.6 
  
  Second 4062 27.4 10748 72.6 
  
  Third 3962 26.7 10890 73.3 
  
 Four 3872 26.1 10941 73.9   
 Fifth 3712 25.0 11146 75.0   
Urologist density quintiles      
 
49.73 <0.001 
  First 3809 25.3 11262 74.7 
  
  Second 4265 27.7 11114 72.3 
  
 Third 3889 26.9 10562 73.1   
 Four 4349 28.0 11206 72.0   
 Fifth 3880 25.7 11231 74.3   
Note: Based on 75671 older (age >66 years) Fee-for-Service Medicare beneficiaries, with continuous enrollment 
in Medicare part A & Part B, diagnosed with incident localized prostate cancer between 2005 and 2014. 






continued Table 4.1  
Radiation oncologist quintiles     202.91 <0.001 
 First 3773 24.5 11641 75.5   
 Second 4239 29.0 10365 71.0   
 Third 3739 25.2 11071 74.8   
 Four 4667 29.9 10960 70.1   





  0-2 Chronic conditions 4052 12.1 29314 87.9 
  
  >2 Chronic conditions 16158 38.2 26147 61.8 
  
Prostate Cancer Comorbidity Index     5992.61 <0.001 
 10 or more years life expectancy 11676 20.2 46207 79.8   
 5-10 years life expectancy 5290 42.6 7140 57.4   
 5 or less years life expectancy  3244 60.5 2114 39.5   
Conservative management     152.88 <0.001 
 Conservative management use 3070 22.5 10592 77.5   
 No conservative management use 17140 27.6 44869 72.4   
Preventative A1c test     497.32 <0.001 
 A1c test 3604 35.9 6442 64.1   
 No a1c test 16606 25.3 49019 74.7   
Preventative flu     644.46 <0.001 
 Influenza vaccination 9630 31.7 20756 68.3   
 No influenza vaccination 10580 23.4 34705 76.6   
Preventative lipid screen     146.13 <0.001 
 Lipid test 6270 30.2 14520 69.8   
 No lipid test 13940 25.4 40941 74.6   
Metro     60.93 <0.001 
 Metro county 17337 27.2 46301 72.8   
 Non-metro county 2855 23.9 9074 76.1   
SEER Region     115.28 <0.001 
 Northeast 4499 29.0 11020 71.0   
 South 5018 25.9 14345 74.1   
 North Central 2533 29.6 6030 70.4   
 West 8160 25.3 24066 74.7   
Year of diagnosis     166.45 <0.001 
 <2009 9651 29.1 23567 70.9   
 ≥2009 10559 24.9 31894 75.1   
Note: Based on 75671 older (age >66 years) Fee-for-Service Medicare beneficiaries, with continuous enrollment 
in Medicare part A & Part B, diagnosed with incident localized prostate cancer between 2005 and 2014. 






Table 4.2 Healthcare Expenditures by Low-value Care Use among Elderly Fee-for-Service Medicare 
Beneficiaries with Incident Localized Prostate Cancer SEER-Medicare, 2005-2014 (n=75671) 
 LVC No LVC   
 n=19071 n=56600   
 Mean (SD) Mean (SD) CI p-value 
Total healthcare expenditures 12589.57 (24028.45) 7647.83 (17988.73) 8752.17, 9034.37 <0.001 
Outpatient expenditures 6467.20 (8740.10) 4063.00 (6110.23) 4619.42, 4718.42 <0.001 
Inpatient expenditures 5276.75 (18032.29) 3114.84 (13664.18) 3553.42,3765.97 <0.001 
Other expenditures 845.69 (2996.22) 469.98 (2120.18) 547.74, 803.17 <0.001 
Note: Based on 75671 older (age >66 years) Fee-for-Service Medicare beneficiaries, with continuous enrollment 
in Medicare part A & Part B, diagnosed with incident localized prostate cancer between 2005 and 2014. 
Healthcare expenditures for patients completing curative treatment (i.e., “No CM”) do not include treatment 
costs. CI= Confidence interval, SEER= Surveillance, Epidemiology and End Results cancer Registry, CM= 











































Table 4.3. Healthcare Expenditures by Conservative Management Use among Elderly Fee-for-
Service Medicare Beneficiaries with Incident Localized Prostate Cancer SEER-Medicare, 2005-2014 
(n=75671) 
 CM No CM   
 n=13662 n=62009  
 Mean (SD) Mean (SD) p-value 
Total healthcare expenditures 7332.74 (18787.79) 9237.09 (20003.22) <0.001 
Outpatient expenditures 3681.65 (7334.92) 4886.44 (6840.01) <0.001 
Inpatient expenditures 3111.29 (13781.13) 3780.53 (15151.8) <0.001 
Other expenditures 539.8 (2438.32) 570.16 (2363.56)  
Note: Based on 75671 older (age >66 years) Fee-for-Service Medicare beneficiaries, with continuous enrollment 
in Medicare part A & Part B, diagnosed with incident localized prostate cancer between 2005 and 2014. 
Healthcare expenditures for patients completing curative treatment (i.e., “No CM”) do not include treatment 
costs. CI= Confidence interval, SEER= Surveillance, Epidemiology and End Results cancer Registry, CM= 






































Table 4.4 Parameter estimates of PCCI categories from unadjusted and adjusted generalized linear models 
on 12-24 months healthcare expenditures among elderly Medicare fee-for-service beneficiaries with incident 








 Unadjusted GLM Adjusted GLM 
Age     
66-74 8.949 (0.010) 7700.19 8.416 (0.055) $4518.79 





10 or more years  8.845 (0.009) 6939.60 8.416 (0.055) $4518.79 
Less than 5 years 1.120 (0.031) 14329.27 0.895 (0.033) $6540.21 
Between 5 and 10 years .599 (0.022) 5692.54 0.470 (0.023) $2711.25 
Conservative management     
No 9.131 (0.009) 7331.97 8.416 (0.055) $4518.79 
Yes -0.231 (0.021) -1905.28 -0.219 (0.022) $-932.05 
Low-value care1     
 8.956 (0.009) 7754.28 8.416 (0.055) $4518.79 
Total Low-value care 0.312 (0.013) 2839.27 0.174 (0.012) $858.82 
Low-risk prostate cancer     
No 9.141 (0.010) 9320.77 8.416 (0.055) $4518.79 
Yes -.140 (0.017) -1217.68 -0.023 (0.018) NS 
Care fragmentation     
 .010 (0.000) 52.87 .006 (0.00) $27.19 
Note: Based on 75671 older (age >66 years) Fee-for-Service Medicare beneficiaries, with continuous enrollment 
in Medicare part A & Part B, diagnosed with incident localized prostate cancer between 2005 and 2014. 
Healthcare expenditures for patients completing curative treatment (i.e., “No CM”) do not include treatment 
costs. Total healthcare expenditures include inpatient, outpatient, durable medical equipment, and home 
health agency costs with treatment-related cost subtracted. 
1. Sum of low-value care procedures in 12 months before prostate cancer diagnosis.   
Change # was calculated by difference between the 1) exponentiation of the model intercept term and 2) the 
sum of the intercept and the variable parameter estimate.  
Compare to omitted category 














Figure 4.1 SHAP Feature Importance and Summary Plot of Low-value Care and Conservative Management 
Use on Non-Treatment Related Total Healthcare Expenditures among Fee-for-Service Medicare Beneficiaries 





(A) Mean SHAP values and (B) SHAP summary plot in descending order of log-dollars. Based on 75671 older 
(age ≥ 66 years) Fee-for-Service Medicare beneficiaries, with continuous enrollment in Medicare Part A & Part 








Figure 4.2 SHAP Partial Density Plots of Selected Features on Non-Treatment Related Total Healthcare 
Expenditures among Fee-for-Service Medicare Beneficiaries with Incident Localized Prostate Cancer using 




SHAP Partial Dependence plots (PDP) of SHAP values (log-dollars) values by (A.) Multimorbidity (Physical 
conditions only), (B.) Care fragmentation, (C) Low value care total prior to incident prostate cancer diagnosis, 
and (D.) Conservative Management. Based on 75671 older (age ≥ 66 years) Fee-for-Service Medicare 
beneficiaries, with continuous enrollment in Medicare Part A & Part B, diagnosed with incident localized 
prostate cancer (Stage ≤T2a) between 2005 and 2014. 
Physical condition total = Total count of multimorbidity physical conditions. 
Care fragmentation = Bice-Boxerman continuity of care index to calculate care fragmentation during the 12 
month baseline period (See Methods). 
Low value care = Sum of low value care prior to incident prostate cancer diagnosis. 
Conservative Management = Yes (1)/No (0). 
SHAP = Shapley Additive ePlanations.   









5 Summary and Conclusion 
5.1 Summary of Findings and Discussion 
 The goal of this dissertation is to highlight healthcare practices that provide limited clinical benefit, 
potentially harmful effects, and a significant economic burden among older men with incident localized 
prostate cancer. This dissertation also highlights the role of patient experiences in receiving high value care for 
incident prostate cancer. Older men with localized prostate cancer represent a large, medically complex and 
growing population. Although prostate cancer is heterogeneous at the population level, high-level randomized 
evidence concluded a lack of significant survival benefit of treatment (surgery, radiation, chemotherapy, 
hormone therapy, cryotherapy) among men with intermediate grade disease and 15 year life expectancy.(104–
106) Conservative management (Active Surveillance and Watchful Waiting) within the context of cancer risk 
group, life expectancy estimates, and personal values has been promoted as high-value care as significant 
quality decrement and high costs of overtreatment can be avoided. Despite evidence-based guidelines 
recommending conservative management for a decade, many men with low-risk prostate cancer and limited 
life expectancy received treatment for prostate cancer. Higher rates of treatment use among fee-for-service 
(58%) versus integrated healthcare beneficiaries (20%) highlight disparities in evidenced-based healthcare 
delivery. 
 This dissertation focused on three related studies: 1) examine the leading predictors of low-value 
healthcare practice (i.e., prostate cancer treatment for low-risk prostate cancer) among older men; 2) assess the 
role of patient‐reported experience with care on high-value prostate cancer management; and 3) Estimate the 
association of high-value care on non-cancer related healthcare expenditures. In all of these studies an 
emphasis is placed on multimorbidity because of high prevalence and negative clinical, humanistic, and 
economic effects throughout cancer survivorship. We specifically examined the associations of patient‐reported 
experiences with evidence-based treatment selection and low-value care to reflect the standards of the Institute 
of Medicines (IOM) and The National Quality Task Force aim to promote patient-centered care and reductions 




 This dissertation filled a knowledge gap through a comprehensive analysis of clinical and non-clinical 
factors that drive low-value cancer treatment among incident low-risk prostate cancer. A novel feature of this 
dissertation is the use of machine learning algorithms and the application of model agnostic interpretable 
machine learning techniques. This dissertation also made a unique contribution and clarified the role of life 
expectancy on the complex decision making process of choosing from several treatments (surgery, radiation, 
cryotherapy, and or chemotherapy and hormone therapy) or conservative management. We distinguished 
between comorbidity and life expectancy to estimate the independent contribution of life expectancy on 
treatment choice. This dissertation is a series of firsts for its measurement of care fragmentation during cancer 
survivorship, use of machine learning algorithms and unlocking the “black box” prediction with interpretable 
machine learning techniques, and assessing the role of patient-reported experiences on high-value care among 
older men with incident prostate cancer.  
5.2 Implications and Suggestions for Future Research 
 A common theme that emerged from our studies is the negative effect of multimorbidity on outcomes 
(i.e., low-value cancer treatment, high-value conservative management, and non-cancer related healthcare 
expenditures). This finding is not surprising given the voluminous data and robust evidence on the negative 
health effects of multimorbidity on health outcomes in a variety of settings and populations. Adults with 
multimorbidity and incident cancer are at high-risk for poor quality of both cancer and non-cancer care 
(37,107) as  current non-cancer clinical guidelines are developed within a single-disease framework.(108) Men 
with multimorbidity and incident cancer may not opt for conservative management because of a preference for 
immediate cure (ie, “take care of it”)(87) and may have a preference to avoid one more condition that requires 
long‐term management. In addition, men are likely to experience fear of non-treatment regret,(88) emotional 
distress,(89) and anxiety.(90) The implementation of OCM which provides a bundled payment for all care 
during an episodic treatment will inherit the complex management requirements of men with multimorbidity 
and incident prostate cancer. Value-based payment mechanisms are needed to support the conservative 
management of incident localized prostate cancer with multimorbidity, especially among men with limited life 




other potential cascades of low-value care or increased care fragmentation without the benefit of reduced 
prostate cancer specific mortality.   
  Our results suggest focusing on reducing care fragmentation, such as broader system reforms to 
increase care continuity between primary care physicians and oncologists, could help reduce treatment 
selection among patients with low-risk prostate cancer. Considering our results, we speculate that care 
fragmentation is likely to contribute to differing treatment rates for low-risk prostate cancer between Medicare 
FFS and Veterans Administration beneficiaries (approximately 37%).(46) 
 For a subset of individuals older men with localized prostate cancer we observed that patient 
experiences with timely care was important in treatment choice.  Timely access to care for men with localized 
prostate cancer is not limited to initial diagnosis of prostate cancer, but the opportunity and ease by which a 
patient is able to access and utilize needed services along the continuum of care throughout survivorship.(93) 
Choices for elderly localized prostate cancer patients involve selecting curative and non-curative treatments 
with trade‐offs in efficacy, potential adverse quality of life effects, and competing risk mortality. Timeliness of 
care domains used in this dissertation, such as perceived barriers to appointment scheduling, are fundamental 
to shared decision‐making among multiple health‐care providers that significantly influence treatment choice 
for men with localized prostate cancer.(94–96) We speculate that adults with higher timely care ratings may 
choose CM if they have a favorable perception of health‐care system capacity to provide services once a need is 
detected. Our results suggest that addressing specific modifiable barriers to timely care along the cancer 
continuum for older adults with localized prostate cancer and limited life expectancy could reduce the adverse 
effects of overtreatment on health outcomes and costs.  
 A noteworthy finding is the superior performance of machine learning algorithms over traditional 
statistical models, specifically logistic regression. This dissertation confirmed flexibility, predictive accuracy, 
and ability of machine algorithms to handle multicollinear variables. With machine learning, model 
misspecification can be avoided through the use of cross-validation model tuning on “training” data before 
applying the algorithm to a “test” or new data set. Once validated, interpretable machine learning approaches, 
such as SHAP, can be applied to reveal the complexity and non-linearity of associations using feature 




revealed significant variation among individuals (i.e. patient-level) of estimated outcomes at specific feature 
values. Our results highlight the need to target individuals with non-linear, complex feature combinations 
pushing them toward low-value outcomes that are otherwise unobservable with “on average'' traditional 
statistical approaches.  
The application of machine learning algorithms to predict low- and high- value care are in alignment 
with the National Quality Forum created a Technology Evaluation Framework.(16) These organizations 
promote the use of advanced technologies, such as machine learning algorithms, to identify solutions to 
address high-value healthcare practices. The framework seeks to strengthen health literacy to complement 
shared decision making processes to facilitate evidence-based medicine while reducing propensity for low-
value services. Our study demonstrates that machine learning and interpretive approaches can be leveraged to 
proactively identify patients who may benefit from interventions, for both patients and physicians, to facilitate 
shared decision making regarding prostate cancer care and reduce the use of low-value care. 
Our results from the analysis on the association of low- and high- value care to non-cancer related 
healthcare expenditures suggest the development and implementation of targeted payment reforms could 
reduce the economic burden to the payers, specifically Medicare. Current Oncology Care Model (OCM) are 
voluntary five-year bundled payment programs developed by the Center for Medicare & Medicaid Innovation 
(CMMI) to facilitate high-value, lower-cost healthcare through improved care coordination and episodic or 
bundled reimbursement. OCM incentivizes providers to lower the total cost of care for patients throughout the 
treatment episodes.(109) Although multidisciplinary approaches have been proposed as a management 
strategy for prostate cancer survivors, it remains unclear how primary care and oncology specialist delivery 
coordinated care in a fragmented FFS environment. Our research highlights how the application of machine 
learning can be used to identify patients at risk of low-value care. Healthcare entities can leverage large patient 
data sets, claims registries, and electronic medical records to continuously re-train machine learning models to 
improve predictive accuracy and provide personalized medicine for many diseases. However, the 
implementation of such technologies will require a robust technical investment from healthcare entities to 




to support healthcare organizations in the development of predictive “precision” population health 
technologies.  
5.3 Strengths and Limitations 
Our dissertation was a series of many first. We used both multimorbidity and prostate cancer-specific of 
life expectancy measures to understand the independent contributions of comorbidity and prostate cancer 
specific mortality on treatment selection among men with localized prostate cancer. We used robust machine 
learning and statistical methods to explore novel predictive and statistical associations of low-value care, 
patient-reported experience measures, and care fragmentation on overtreatment and cost outcomes among 
older adults with multimorbidity. Our research supports nationally recognized strategic objectives for 
improving patient-centered care while identifying predictors to reduce inappropriate low-value care. We used 
cancer registry, claims, MCAHPS surveys, and other socio-demographic data linkages to incorporate measures 
of multimorbidity, care fragmentation, patient-reported experience measures, social determinants of health, 
and low-value care in machine learning and statistical models. Although educational attainment may not be 
modifiable among older adults, initiatives such as “health in all policies'' by the World Health Organization and 
the Centers for Disease and Prevention Control suggest the integration and consideration of community health 
policy(73) as social, economic, and physical environments have a significant impact on the health of an 
individual. With these considerations, we developed machine learning and statistical approaches using a 
competing demands framework in all of our study aims. 
Due to the retrospective nature of this work our findings are not causal. Generalizability to younger 
patients, health Maintenance Organization, and integrated healthcare networks may not be appropriate as our 
studies included only fee-for-service beneficiaries. Measurement of low-value care in claims data requires the 
estimation of clinical scenarios using inclusion and exclusion criteria that are diagnosis and/or procedure 
specific, and often include a temporal component. We could only select procedures meeting criteria for low-
value care that could be operationalized accurately in claims data, therefore, we are likely to underestimate the 




5.5 Conclusion  
 Our studies reveal that low-value cancer treatment is highly-prevalent as only 2 in 5 men received 
conservative management. In predictive models of low-value care (i.e., overtreatment) and high-value care 
(i.e., conservative management) we did not find a life expectancy of 10 or more years to be predictive. These 
results indicate that treatment choice among older adults, within the context of life expectancy, do not reflect 
evidence-based guidelines for prostate cancer treatment. Our findings suggest a need for broad 
























1.  Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer Statistics, 2021. CA Cancer J Clin. 2021 Jan 
12;71(1):7–33.  
2.  Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018 Jan 4;68(1):7–30.  
3.  Negoita S, Feuer EJ, Mariotto A, Cronin KA, Petkov VI, Hussey SK, et al. Annual Report to the Nation 
on the Status of Cancer, part II: Recent changes in prostate cancer trends and disease characteristics. 
Cancer. 2018 Jul 1;124(13):2801–2814.  
4.  Amin MB, Edge SB, Greene FL, Byrd DR, Brookland RK, Washington MK, et al., editors. AJCC cancer 
staging manual. Cham: Springer International Publishing; 2017.  
5.  Sanda MG, Cadeddu JA, Kirkby E, Chen RC, Crispino T, Fontanarosa J, et al. Clinically localized 
prostate cancer: AUA/ASTRO/SUO guideline. part I: risk stratification, shared decision making, and 
care options. J Urol. 2018;199(3):683–690.  
6.  National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN 
Guidelines) Prostate Cancer Version 2.2020 [Internet]. 2020 [cited 2020 May 25]. Available from: 
https://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf 
7.  Tosoian JJ, Mamawala M, Epstein JI, Landis P, Wolf S, Trock BJ, et al. Intermediate and Longer-Term 
Outcomes From a Prospective Active-Surveillance Program for Favorable-Risk Prostate Cancer. J Clin 
Oncol. 2015 Oct 20;33(30):3379–3385.  
8.  Klotz L, Vesprini D, Sethukavalan P, Jethava V, Zhang L, Jain S, et al. Long-term follow-up of a large 
active surveillance cohort of patients with prostate cancer. J Clin Oncol. 2015 Jan 20;33(3):272–277.  
9.  Donovan JL, Hamdy FC, Lane JA, Mason M, Metcalfe C, Walsh E, et al. Patient-Reported Outcomes 
after Monitoring, Surgery, or Radiotherapy for Prostate Cancer. N Engl J Med. 2016 Oct 
13;375(15):1425–1437.  
10.  Chen RC, Basak R, Meyer A-M, Kuo T-M, Carpenter WR, Agans RP, et al. Association Between Choice of 
Radical Prostatectomy, External Beam Radiotherapy, Brachytherapy, or Active Surveillance and 
Patient-Reported Quality of Life Among Men With Localized Prostate Cancer. JAMA. 2017 Mar 
21;317(11):1141–1150.  
11.  Barocas DA, Alvarez J, Resnick MJ, Koyama T, Hoffman KE, Tyson MD, et al. Association Between 
Radiation Therapy, Surgery, or Observation for Localized Prostate Cancer and Patient-Reported 
Outcomes After 3 Years. JAMA. 2017 Mar 21;317(11):1126–1140.  
12.  Chen RC, Rumble RB, Loblaw DA, Finelli A, Ehdaie B, Cooperberg MR, et al. Active surveillance for the 
management of localized prostate cancer (Cancer Care Ontario Guideline): American Society of Clinical 
Oncology clinical practice guideline endorsement. J Clin Oncol. 2016 Jun 20;34(18):2182–2190.  
13.  Mohler JL. The 2010 NCCN clinical practice guidelines in oncology on prostate cancer. J Natl Compr 
Canc Netw. 2010 Feb;8(2):145.  
14.  Sampurno F, Zheng J, Di Stefano L, Millar JL, Foster C, Fuedea F, et al. Quality indicators for global 
benchmarking of localized prostate cancer management. J Urol. 2018 Mar 1;200(2):319–326.  
15.  Institute of Medicine (US) Committee on Quality of Health Care in America. Executive Summary - 
Crossing the Quality Chasm - NCBI Bookshelf. 2001;  
16.  Agrawal S, Kizer K. The Care We Need – Driving Better Outcomes For People And Communities. The 
National Quality Forum; 2020.  
17.  Emanuel EJ, Fuchs VR. The perfect storm of overutilization. JAMA. 2008 Jun 18;299(23):2789–2791.  
18.  Schwartz AL, Landon BE, Elshaug AG, Chernew ME, McWilliams JM. Measuring low-value care in 
Medicare. JAMA Intern Med. 2014 Jul;174(7):1067–1076.  
19.  Shrank WH, Rogstad TL, Parekh N. Waste in the US health care system: estimated costs and potential 




20.  Colla CH, Morden NE, Sequist TD, Schpero WL, Rosenthal MB. Choosing wisely: prevalence and 
correlates of low-value health care services in the United States. J Gen Intern Med. 2015 Feb;30(2):221–
228.  
21.  Ganguli I, Lupo C, Mainor AJ, Raymond S, Wang Q, Orav EJ, et al. Prevalence and Cost of Care 
Cascades After Low-Value Preoperative Electrocardiogram for Cataract Surgery in Fee-for-Service 
Medicare Beneficiaries. JAMA Intern Med. 2019 Jun 3;  
22.  American Board of Internal Medicine. Choosing Wisely. An initiative of the ABIM foundation. 
[Internet]. ABIM Foundation. 2020 [cited 2020 Nov 9]. Available from: 
https://www.choosingwisely.org/ 
23.  Baxi SS, Kale M, Keyhani S, Roman BR, Yang A, Derosa AP, et al. Overuse of health care services in the 
management of cancer: A systematic review. Med Care. 2017;55(7):723–733.  
24.  Skolarus TA, Zhang Y, Hollenbeck BK. Understanding fragmentation of prostate cancer survivorship 
care: implications for cost and quality. Cancer. 2012 Jun 1;118(11):2837–2845.  
25.  Garg T, Young AJ, Kost KA, Danella JF, Larson S, Nielsen ME, et al. Burden of Multiple Chronic 
Conditions among Patients with Urological Cancer. J Urol. 2018;199(2):543–550.  
26.  Frandsen BR, Joynt KE, Rebitzer JB, Jha AK. Care fragmentation, quality, and costs among chronically 
ill patients. Am J Manag Care. 2015 May;21(5):355–362.  
27.  Kinsella N, Stattin P, Cahill D, Brown C, Bill-Axelson A, Bratt O, et al. Factors Influencing Men’s Choice 
of and Adherence to Active Surveillance for Low-risk Prostate Cancer: A Mixed-method Systematic 
Review. Eur Urol. 2018 Mar 26;74(3):261–280.  
28.  Schmidt T, Valuck T, Perkins B, Riposo J, Patel P, Westrich K, et al. Improving patient-reported 
measures in oncology: a payer call to action. J Manag Care Spec Pharm. 2021 Jan;27(1):118–126.  
29.  Doyle C, Lennox L, Bell D. A systematic review of evidence on the links between patient experience and 
clinical safety and effectiveness. BMJ Open. 2013 Jan 3;3(1).  
30.  Levit L, Balogh E, Nass S, Ganz PA, Committee on Improving the Quality of Cancer Care: Addressing 
the Challenges of an Aging Population, Board on Health Care Services, et al. Patient-Centered 
Communication and Shared Decision Making - Delivering High-Quality Cancer Care - NCBI Bookshelf. 
2013 Dec 27;  
31.  Mollica MA, Enewold LR, Lines LM, Halpern MT, Schumacher JR, Hays RD, et al. Examining colorectal 
cancer survivors’ surveillance patterns and experiences of care: a SEER-CAHPS study. Cancer Causes 
Control. 2017 Oct;28(10):1133–1141.  
32.  Trogdon JG, Falchook AD, Basak R, Carpenter WR, Chen RC. Total medicare costs associated with 
diagnosis and treatment of prostate cancer in elderly men. JAMA Oncol. 2019 Jan 1;5(1):60–66.  
33.  Kinsella N, Helleman J, Bruinsma S, Carlsson S, Cahill D, Brown C, et al. Active surveillance for prostate 
cancer: a systematic review of contemporary worldwide practices. Transl Androl Urol. 2018 
Feb;7(1):83–97.  
34.  Kent M, Vickers AJ. A systematic literature review of life expectancy prediction tools for patients with 
localized prostate cancer. J Urol. 2015 Jun;193(6):1938–1942.  
35.  Thurtle D, Rossi SH, Berry B, Pharoah P, Gnanapragasam VJ. Models predicting survival to guide 
treatment decision-making in newly diagnosed primary non-metastatic prostate cancer: a systematic 
review. BMJ Open. 2019 Jun 22;9(6):e029149.  
36.  Jayadevappa R, Chhatre S, Wong Y-N, Wittink MN, Cook R, Morales KH, et al. Comparative 
effectiveness of prostate cancer treatments for patient-centered outcomes: A systematic review and 
meta-analysis (PRISMA Compliant). Medicine. 2017 May;96(18):e6790.  
37.  Ricci-Cabello I, Violán C, Foguet-Boreu Q, Mounce LTA, Valderas JM. Impact of multi-morbidity on 
quality of healthcare and its implications for health policy, research and clinical practice. A scoping 




38.  Loeb S, Walter D, Curnyn C, Gold HT, Lepor H, Makarov DV. How Active is Active Surveillance? 
Intensity of Followup during Active Surveillance for Prostate Cancer in the United States. J Urol. 2016 
Sep;196(3):721–726.  
39.  Butler SS, Loeb S, Cole AP, Zaslowe-Dude C, Muralidhar V, Kim DW, et al. United States trends in 
active surveillance or watchful waiting across patient socioeconomic status from 2010 to 2015. Prostate 
Cancer Prostatic Dis. 2020;23(1):179–183.  
40.  Chawla N, Urato M, Ambs A, Schussler N, Hays RD, Clauser SB, et al. Unveiling SEER-CAHPS®: a new 
data resource for quality of care research. J Gen Intern Med. 2015 May;30(5):641–650.  
41.  Zaslavsky AM, Ayanian JZ, Zaborski LB. The validity of race and ethnicity in enrollment data for 
Medicare beneficiaries. Health Serv Res. 2012 Jun;47(3 Pt 2):1300–1321.  
42.  Health Resource & Service Administration. Area Health Resources Files [Internet]. Area Health 
Resources Files. 2019 [cited 2020 Feb 12]. Available from: https://data.hrsa.gov/topics/health-
workforce/ahrf 
43.  Introduction to Boosted Trees — xgboost 1.3.0-SNAPSHOT documentation [Internet]. [cited 2020 Oct 
29]. Available from: https://xgboost.readthedocs.io/en/latest/tutorials/model.html 
44.  Breiman L. Statistical Modeling: The Two Cultures. Stat Sci. 2001;16(3):199–231.  
45.  Lundberg SM, Lee S-I. A Unified Approach to Interpreting Model Predictions. 2017 Jan 1;  
46.  Loeb S, Byrne N, Makarov DV, Lepor H, Walter D. Use of Conservative Management for Low-Risk 
Prostate Cancer in the Veterans Affairs Integrated Health Care System From 2005-2015. JAMA. 2018 
Jun 5;319(21):2231–2233.  
47.  DuGoff EH, Canudas-Romo V, Buttorff C, Leff B, Anderson GF. Multiple chronic conditions and life 
expectancy: a life table analysis. Med Care. 2014 Aug;52(8):688–694.  
48.  National Cancer Institute. U.S. Population Data 1969-2017 - SEER Population Data [Internet]. 
Surveillance, Epidemiology, and End Results (SEER) Program Populations (1969-2017) 
(www.seer.cancer.gov/popdata), National Cancer Institute, DCCPS, Surveillance Research Program. 
2018 [cited 2019 Sep 21]. Available from: https://seer.cancer.gov/popdata/ 
49.  Fiano RM, Merrick GS, Innes KE, Mattes MD, LeMasters TJ, Shen C, et al. Associations of 
multimorbidity and patient-reported experiences of care with conservative management among elderly 
patients with localized prostate cancer. Cancer Med. 2020 Aug;9(16):6051–6061.  
50.  Anderson G, Robert Wood Johnson Foundation. Chronic Care: Making the Case for Ongoing Care 
[Internet]. Chronic Care: Making the Case for Ongoing Care. 2010 [cited 2020 Jan 27]. Available from: 
https://www.rwjf.org/en/library/research/2010/01/chronic-care.html 
51.  Sypes EE, de Grood C, Clement FM, Parsons Leigh J, Whalen-Browne L, Stelfox HT, et al. 
Understanding the public’s role in reducing low-value care: a scoping review. Implement Sci. 2020 Apr 
7;15(1):20.  
52.  Doupe P, Faghmous J, Basu S. Machine learning for health services researchers. Value Health. 
2019;22(7):808–815.  
53.  Modi PK, Kaufman SR, Qi J, Lane BR, Cher ML, Miller DC, et al. National Trends in Active Surveillance 
for Prostate Cancer: Validation of Medicare Claims-based Algorithms. Urology. 2018 Oct;120:96–102.  
54.  Daskivich TJ, Thomas I-C, Luu M, Shelton JB, Makarov DV, Skolarus TA, et al. External Validation of 
the Prostate Cancer Specific Comorbidity Index: A Claims Based Tool for the Prediction of Life 
Expectancy in Men with Prostate Cancer. J Urol. 2019 Aug 8;202(3):518–524.  
55.  Goodman RA, Posner SF, Huang ES, Parekh AK, Koh HK. Defining and measuring chronic conditions: 
imperatives for research, policy, program, and practice. Prev Chronic Dis. 2013 Apr 25;10:E66.  





57.  Pinheiro LC, Reshetnyak E, Safford MM, Nanus D, Kern LM. Differences in ambulatory care 
fragmentation between cancer survivors and noncancer controls. Cancer. 2020 Jul 1;126(13):3094–
3101.  
58.  Pollack CE, Hussey PS, Rudin RS, Fox DS, Lai J, Schneider EC. Measuring Care Continuity: A 
Comparison of Claims-based Methods. Med Care. 2016 May;54(5):e30–4.  
59.  Liu CW, Einstadter D, Cebul RD. Care fragmentation and emergency department use among complex 
patients with diabetes. Am J Manag Care. 2010 Jun;16(6):413–420.  
60.  Schwartz AL, Zaslavsky AM, Landon BE, Chernew ME, McWilliams JM. Low-Value Service Use in 
Provider Organizations. Health Serv Res. 2018;53(1):87–119.  
61.  Segal JB, Bridges JFP, Chang H-Y, Chang E, Nassery N, Weiner J, et al. Identifying possible indicators 
of systematic overuse of health care procedures with claims data. Med Care. 2014 Feb;52(2):157–163.  
62.  Reid RO, Rabideau B, Sood N. Impact of consumer-directed health plans on low-value healthcare. Am J 
Manag Care. 2017 Dec;23(12):741–748.  
63.  Mahal BA, Butler S, Franco I, Spratt DE, Rebbeck TR, D’Amico AV, et al. Use of Active Surveillance or 
Watchful Waiting for Low-Risk Prostate Cancer and Management Trends Across Risk Groups in the 
United States, 2010-2015. JAMA. 2019 Feb 19;321(7):704–706.  
64.  Aizer AA, Gu X, Chen M-H, Choueiri TK, Martin NE, Efstathiou JA, et al. Cost implications and 
complications of overtreatment of low-risk prostate cancer in the United States. J Natl Compr Canc 
Netw. 2015 Jan;13(1):61–68.  
65.  Raval AD, Madhavan S, Mattes MD, Sambamoorthi U. Types of chronic conditions combinations and 
initial cancer treatment among elderly Medicare beneficiaries with localised prostate cancer. Int J Clin 
Pract. 2016 Jul;70(7):606–618.  
66.  Schwartz AL, Jena AB, Zaslavsky AM, McWilliams JM. Analysis of Physician Variation in Provision of 
Low-Value Services. JAMA Intern Med. 2019 Jan 1;179(1):16–25.  
67.  Womble PR, Montie JE, Ye Z, Linsell SM, Lane BR, Miller DC, et al. Contemporary use of initial active 
surveillance among men in Michigan with low-risk prostate cancer. Eur Urol. 2015 Jan;67(1):44–50.  
68.  Löppenberg B, Friedlander DF, Krasnova A, Tam A, Leow JJ, Nguyen PL, et al. Variation in the use of 
active surveillance for low-risk prostate cancer. Cancer. 2018 Jan 1;124(1):55–64.  
69.  Boehm K, Dell’Oglio P, Tian Z, Capitanio U, Chun FKH, Tilki D, et al. Comorbidity and age cannot 
explain variation in life expectancy associated with treatment of non-metastatic prostate cancer. World 
J Urol. 2017 Jul;35(7):1031–1036.  
70.  Chen S, Bergman D, Miller K, Kavanagh A, Frownfelter J, Showalter J. Using applied machine learning 
to predict healthcare utilization based on socioeconomic determinants of care. Am J Manag Care. 
2020;26(1):26–31.  
71.  Al Hussein Al Awamlh B, Ma X, Christos P, Hu JC, Shoag JE. Active Surveillance for Black Men with 
Low-Risk Prostate Cancer in the United States. N Engl J Med. 2019 Dec 26;381(26):2581–2582.  
72.  Parikh RB, Robinson KW, Chhatre S, Medvedeva E, Cashy JP, Veera S, et al. Comparison by Race of 
Conservative Management for Low-Risk and Intermediate-Risk Prostate Cancers in Veterans From 
2004 to 2018. JAMA Netw Open. 2020 Sep 1;3(9):e2018318.  
73.  Center for Disease Control and Prevention. Health in All Policies | AD for Policy and Strategy | CDC 
[Internet]. 2015 [cited 2020 Jun 8]. Available from: https://www.cdc.gov/policy/hiap/index.html 
74.  Sequist TD, Schneider EC, Anastario M, Odigie EG, Marshall R, Rogers WH, et al. Quality monitoring of 
physicians: linking patients’ experiences of care to clinical quality and outcomes. J Gen Intern Med. 
2008 Nov;23(11):1784–1790.  
75.  Garg R, Shen C, Sambamoorthi N, Kelly K, Sambamoorthi U. Type of Multimorbidity and Patient-





76.  Johnston MC, Crilly M, Black C, Prescott GJ, Mercer SW. Defining and measuring multimorbidity: a 
systematic review of systematic reviews. Eur J Public Health. 2019 Feb 1;29(1):182–189.  
77.  Daskivich TJ, Fan K-H, Koyama T, Albertsen PC, Goodman M, Hamilton AS, et al. Effect of age, tumor 
risk, and comorbidity on competing risks for survival in a U.S. population-based cohort of men with 
prostate cancer. Ann Intern Med. 2013 May 21;158(10):709–717.  
78.  Klabunde CN, Potosky AL, Legler JM, Warren JL. Development of a comorbidity index using physician 
claims data. J Clin Epidemiol. 2000 Dec;53(12):1258–1267.  
79.  Klinkman MS. Competing demands in psychosocial care. A model for the identification and treatment of 
depressive disorders in primary care. Gen Hosp Psychiatry. 1997 Mar;19(2):98–111.  
80.  National Cancer Institute. Case-Mix Adjustment Guidance [Internet]. Guidance on Standard Covariate 
Adjustment for SEER-CAHPS Analyses. 2019 [cited 2020 Feb 13]. Available from: 
https://healthcaredelivery.cancer.gov/seer-cahps/researchers/adjustment_guidance.html 
81.  Li C. Little’s test of missing completely at random. The Stata Journal. 2013 Dec;13(4):795–809.  
82.  Auffenberg GB, Lane BR, Linsell S, Cher ML, Miller DC. Practice- vs Physician-Level Variation in Use of 
Active Surveillance for Men With Low-Risk Prostate Cancer: Implications for Collaborative Quality 
Improvement. JAMA Surg. 2017 Oct 1;152(10):978–980.  
83.  Lang MF, Tyson MD, Alvarez JR, Koyama T, Hoffman KE, Resnick MJ, et al. The Influence of 
Psychosocial Constructs on the Adherence to Active Surveillance for Localized Prostate Cancer in a 
Prospective, Population-based Cohort. Urology. 2017 Feb 9;103:173–178.  
84.  Tyson MD, Graves AJ, O’Neil B, Barocas DA, Chang SS, Penson DF, et al. Urologist-Level Correlation in 
the Use of Observation for Low- and High-Risk Prostate Cancer. JAMA Surg. 2017 Jan 1;152(1):27–34.  
85.  D’Amico TA, Bandini LAM, Balch A, Benson AB, Edge SB, Fitzgerald CL, et al. Quality Measurement in 
Cancer Care: A Review and Endorsement of High-Impact Measures and Concepts. J Natl Compr Canc 
Netw. 2020;18(3):250–259.  
86.  Bekelman JE, Rumble RB, Chen RC, Pisansky TM, Finelli A, Feifer A, et al. Clinically localized prostate 
cancer: ASCO clinical practice guideline endorsement of an american urological association/american 
society for radiation oncology/society of urologic oncology guideline. J Clin Oncol. 2018 Nov 
10;36(32):3251–3258.  
87.  Volk RJ, McFall SL, Cantor SB, Byrd TL, Le Y-CL, Kuban DA, et al. It“s not like you just had a heart 
attack”: decision-making about active surveillance by men with localized prostate cancer. 
Psychooncology. 2014 Apr;23(4):467–472.  
88.  Le Y-CL, McFall SL, Byrd TL, Volk RJ, Cantor SB, Kuban DA, et al. Is “Active Surveillance” an 
Acceptable Alternative?: A Qualitative Study of Couples’ Decision Making about Early-Stage, Localized 
Prostate Cancer. Narrat Inq Bioeth. 2016;6(1):51–61.  
89.  Latini DM, Hart SL, Knight SJ, Cowan JE, Ross PL, Duchane J, et al. The relationship between anxiety 
and time to treatment for patients with prostate cancer on surveillance. J Urol. 2007 Sep;178(3 Pt 
1):826–831.  
90.  Orom H, Nelson CJ, Underwood W, Homish DL, Kapoor DA. Factors associated with emotional distress 
in newly diagnosed prostate cancer patients. Psychooncology. 2015 Nov;24(11):1416–1422.  
91.  Goh AC, Kowalkowski MA, Bailey DE, Kazer MW, Knight SJ, Latini DM. Perception of cancer and 
inconsistency in medical information are associated with decisional conflict: a pilot study of men with 
prostate cancer who undergo active surveillance. BJU Int. 2012 Jul;110(2 Pt 2):E50–6.  
92.  Filson CP, Schroeck FR, Ye Z, Wei JT, Hollenbeck BK, Miller DC. Variation in use of active surveillance 
among men undergoing expectant treatment for early stage prostate cancer. J Urol. 2014 Jul;192(1):75–
80.  
93.  Daniels N. Equity of access to health care: some conceptual and ethical issues. Milbank Mem Fund Q 




94.  Kinsella N, Helleman J, Bruinsma S, Carlsson S, Cahill D, Brown C, et al. Active surveillance for prostate 
cancer: a systematic review of contemporary worldwide practices. Translational Andrology and Urology; 
Vol 7, No 1 (February 2018): Translational Andrology and Urology (Prostate Cancer Screening and 
Active Surveillance in the Western World). 2018;  
95.  Ehdaie B, Assel M, Benfante N, Malhotra D, Vickers A. A Systematic Approach to Discussing Active 
Surveillance with Patients with Low-risk Prostate Cancer. Eur Urol. 2017 Jan 24;71(6):866–871.  
96.  Xu J, Neale AV, Dailey RK, Eggly S, Schwartz KL. Patient perspective on watchful waiting/active 
surveillance for localized prostate cancer. J Am Board Fam Med. 2012 Dec;25(6):763–770.  
97.  Ennis RD, Parikh AB, Sanderson M, Liu M, Isola L. Interpreting Oncology Care Model Data to Drive 
Value-Based Care: A Prostate Cancer Analysis. J Oncol Pract. 2019 Mar;15(3):e238–e246.  
98.  Osawa I, Goto T, Yamamoto Y, Tsugawa Y. Machine-learning-based prediction models for high-need 
high-cost patients using nationwide clinical and claims data. npj Digital Med. 2020 Nov 11;3(1):148.  
99.  Hu L, Li L, Ji J, Sanderson M. Identifying and understanding determinants of high healthcare costs for 
breast cancer: a quantile regression machine learning approach. BMC Health Serv Res. 2020 Nov 
23;20(1):1066.  
100.  US Department of Labor. Bureau of Labor Statistics [Internet]. 2015 [cited 2020 Feb 28]. Available 
from: http://www.bls.gov/news.release/archives/cpi_06182015.pdf 
101.  Volpp KG, Loewenstein G, Asch DA. Choosing wisely: low-value services, utilization, and patient cost 
sharing. JAMA. 2012 Oct 24;308(16):1635–1636.  
102.  Modi PK, Kaufman SR, Herrel LA, Dupree JM, Luckenbaugh AN, Skolarus TA, et al. Practice-Level 
Adoption of Conservative Management for Prostate Cancer. J Oncol Pract. 2019 Sep 11;JOP1900088.  
103.  Xu J, Janisse J, Ruterbusch JJ, Ager J, Liu J, Holmes-Rovner M, et al. Patients’ survival expectations 
with and without their chosen treatment for prostate cancer. Ann Fam Med. 2016;14(3):208–214.  
104.  Bill-Axelson A, Holmberg L, Garmo H, Rider JR, Taari K, Busch C, et al. Radical prostatectomy or 
watchful waiting in early prostate cancer. N Engl J Med. 2014 Mar 6;370(10):932–942.  
105.  Wilt TJ, Brawer MK, Jones KM, Barry MJ, Aronson WJ, Fox S, et al. Radical prostatectomy versus 
observation for localized prostate cancer. N Engl J Med. 2012 Jul 19;367(3):203–213.  
106.  Hamdy FC, Donovan JL, Lane JA, Mason M, Metcalfe C, Holding P, et al. 10-Year Outcomes after 
Monitoring, Surgery, or Radiotherapy for Localized Prostate Cancer. N Engl J Med. 2016 Oct 
13;375(15):1415–1424.  
107.  Boyd CM, Darer J, Boult C, Fried LP, Boult L, Wu AW. Clinical practice guidelines and quality of care 
for older patients with multiple comorbid diseases: implications for pay for performance. JAMA. 2005 
Aug 10;294(6):716–724.  
108.  Dawes M. Co-morbidity: we need a guideline for each patient not a guideline for each disease. Fam 
Pract. 2010 Feb;27(1):1–2.  
109.  Centers for Medicare and Medicaid Services. Oncology Care Model | CMS Innovation Center [Internet]. 


































Supplemental Figure 7.1 Feature Importance of Treatment Prediction among Fee-for-Service 
Medicare Beneficiaries with Incident Low-risk Prostate Cancer using SEER Cancer Registry, 
2009-2014 (n=13870) 
 
Mean SHAP values in descending order of log-odds. Based on 13870 older (age ≥ 66 years) Fee-for-Service 
Medicare beneficiaries, with continuous enrollment in Medicare Part A & Part B, diagnosed with incident low-
risk prostate cancer (Gleason 6, PSA <10, Stage ≤T2a) between 2009 and 2014. 
Age group included 66-74 and 75 and over categories. 
Care fragmentation = Bice-Boxerman continuity of care index to calculate care fragmentation during the 12 
month baseline period (See Methods).  






Appendix 7.2 Unadjusted and Adjusted Odds Ratios and 95% Confidence Intervals (CI) of PCCI, Mental 
Health, Timeliness of Care, Low-risk Prostate Cancer, and Education on Conservative Management Use in 
among Fee-for-Service Medicare Beneficiaries with Incident Localized Prostate Cancer using Linked SEER 
Cancer Registry with MCAHPS, 2002-2013 (N = 496). 
 UOR [95% CI] p-value AOR [95% CI] p-value 
Prostate Cancer Comorbidity Index       
5 to 10 years life expectancy 0.58 [0.38 - 0.90] 0.014 0.48 [0.29 - 0.78] 0.003 
< 5 years life expectancy 0.58 [0.33 - 1.03] 0.062 0.42 [0.21 - 0.83] 0.012 
> 10 years life expectancy (Ref.)       
Getting Care Quickly 1.15 [1.05 - 1.27] 0.003 1.20 [1.09 - 1.34] 0.001 
Low-risk prostate cancer       
Yes 1.41 [0.95 - 2.08] 0.088 1.65 [1.07 - 2.58] 0.024 
No (Ref.)       
Mental Health       
Fair/Poor 2.97 [1.50 - 5.90] 0.002 5.54 [2.33 - 13.2] 0.001 
Excellent/Very Good (Ref.)       
Education       
College or more 2.49 [1.30 - 4.78] 0.006 3.28 [1.52 - 7.10] 0.002 
High-school graduate 2.41 [1.18 - 4.92] 0.015 3.57 [1.60 - 7.96] 0.002 


























Appendix 7.3 Unadjusted and Adjusted Odds Ratios and 95% Confidence Intervals of PCCI, 
Multimorbidity, Mental Health, Timeliness of Care, Low-risk Prostate Cancer, and Education on 
Conservative Management Use up to 24 Months after Incident Prostate Cancer among Fee-for-Service 
Medicare Beneficiaries using Linked SEER Cancer Registry with MCAHPS, 2002-2013 (N = 496). 




   
 Yes 0.52 [0.35 - 0.77] 0.001 0.42 [0.27 - 0.65] <0.001 
 No (Ref.) 
   
   
Getting Care Quickly 1.13 [1.02 - 1.24] 0.014 1.21 [1.09 - 1.35] <0.001 
Low-risk prostate cancer 
   
   
 Yes 1.46 [0.97 - 2.18] 0.068 1.76 [1.14 - 2.72] 0.01 
 No (Ref.) 
   
   
Mental Health 
   
   
 Fair/Poor 3.44 [1.73 - 6.81] <0.001 4.32 [1.86 - 10.1] <0.001 
 Excellent/Very Good (Ref.) 
   
   
Education 
   
   
 College or more  2.76 [1.35 – 5.65] 0.006 3.21 [1.50 – 6.89] 0.003 
 High-school graduate 3.06 [1.42 – 6.63] 0.004 3.53 [1.59-7.83] 0.002 
 No high-school graduation (Ref.)       
PCCI Model 
Prostate Cancer Comorbidity Index       
 5 to 10 years life expectancy 0.52 [0.33 – 0.82] 0.005 0.39 [0.30 - 0.70] <0.001 
 < 5 years life expectancy 0.56 [0.31 – 1.01] 0.056 0.34 [0.16 – 0.73] 0.005 
 >10 years life expectancy (Ref.)       
Getting Care Quickly    1.20 [1.08 - 1.34] 0.001 
Low-risk prostate cancer    1.76 [1.11 – 2.79] 0.017 
 Yes       
 No (Ref.)       
Mental Health       
 Fair/Poor    7.59 [3.07 – 18.8] <0.001 
 Excellent/Very Good (Ref.)       
Education       
 High-school graduate    0.26 [0.11 – 0.60] 0.002 
 No high-school grad. (Ref.)       
Note: Based on 496 older (age >66 years) Fee-for-Service Medicare beneficiaries, with continuous enrollment in Medicare 
part A & Part B, diagnosed with incident localized prostate cancer between 2003 and 2013. Adjusted for age, race, marital 
status, income, education, health status, urologist density, radiation oncologist density, SEER region, geography, 
diagnostic year, and low-risk prostate cancer.   
UOR= Unadjusted Odds Ratio, AOR= Adjusted Odds Ratio, N.S.= Not significant, CI= Confidence interval, Ref= 
Reference group, SEER= Surveillance, Epidemiology and End Results cancer Registry, MCAHPS= Medicare Consumer 
Assessment of Healthcare Providers and System surveys, CM= Conservative management, PCCI= Prostate Cancer 








Appendix 7.4 Prostate cancer treatment codes used within 12 months of prostate cancer diagnosis to Identify 
Conservative Management Use 
Radical prostatectomy 
55840, 55842, 55845, 55866, 55810, 55812, 55815 and 60.62, 17.42, 60.5, 60.4, and 
60.3 (40.3, 40.53, and 40.59 for lymph node dissection) 
Brachytherapy 
76873, 55859, 76965, 55860, 55875, 55876, 76873, 76965, 77326, 77327, 77328, 
77761, 77762, 77763, 77799, 77776, 77777, 77778, and 60.99, 92.27, 92.28, and 
92.29, 77781, 77782, 77783, 77784, 77785, 77786, 77787, 77789, 77790, Q3001, 
A9527, C1715, C1716, C1717, C1719, C1728, C2616, C2634, C2635, C2636, C2637, 
C2638, C2639, C2640, C2641, C2642, C2643, C2698, C2699, C9725 
External Beam 
Radiotherapy 
77305, 77310, 77315, 77321, 77371,77372, 77373, 77402, 77403, 77404, 77406, 
77407, 77408, 77409, 77411, 77412, 77413, 77414, 77416, 77422, 77423, 92.24, 92.26, 
77301, 77418, 0073T, 77380, 77381, 77520, 77522, 77523, and 77525, 77301,77338, 
77761, 77762, 77763, 77789, 77427 
Cryotherapy 50250, 50593, 55873, 55873, 60.62, C2618, G0160, G0161 
Androgen Deprivation 
Therapy 
J1050, J1051 (Progesterone),J1950 J9217 J9218 J9219, C9430 (Lupron), J9165 
(DES), J9202 (Zoladex), J3315 (Trelstar), J9225 CPT 11981(Vantas), all injections 
ICD-99.24, S0175 (Flutamide), J8999 (Bicalutamide/Flutamide/Nilutamide) 
S0165, J0128, C9216, (Abarelix), J9155 (Degarelix), S9560 (any hormone/adt), 
G0356 (any ADT ) 
Conservative 
management 




























Appendix 7.5 Patient Characteristics by Conservative Management among Fee-for-Service Medicare 
Beneficiaries with Incident Localized Prostate Cancer using Linked SEER Cancer Registry, 2005-2014 
(n=75671) 




N % N  % Χ2 p-value 
ALL  13662 18.1 62009 82.0 
  





  66-74 8424 17.0 41125 83.0 
  
  75+ 5238 20.1 20884 79.9 
  





  White 10741 17.4 50813 82.6 
  
  Black 1941 22.5 6671 77.5 
  
  Hispanic 188 14.7 1091 85.3 
  
 Other 750 18.6 3289 81.4   
Marital Status     813.3 <0.001 
  Married 8190 15.6 44303 84.4 
  
  Unmarried 997 19.4 4155 80.6 
  
 Separated/Divorced/Widowed 2204 23.2 7293 76.8   
  Unknown 2271 26.6 6258 73.4 
  
Income quintiles     35.5 <0.001 
  First 2772 18.9 11912 81.1 
  
  Second 2620 17.8 12133 82.2 
  
  Third 2696 18.3 12073 81.7 
  
  Four 2558 17.4 12160 82.6 
  
 Fifth 2642 17.5 12426 82.5   





  First 2604 17.7 12125 82.3 
  
  Second 2461 16.6 12349 83.4 
  
  Third 2496 16.8 12356 83.2 
  
 Four 2758 18.6 12055 81.4   
 Fifth 2984 20.1 11874 79.9   
Urologist density quintiles      
 
33.0 <0.001 
  First 2509 16.6 12562 83.4 
  
  Second 2820 18.3 12559 81.7 
  
 Third 2689 18.6 11762 81.4   
 Four 2817 18.1 12738 81.9   







Continued Appendix 7.5  
Radiation oncologist quintiles     58.18 <0.001 
 First 2631 17.1 12783 82.9   
 Second 2421 16.6 12183 83.4   
 Third 2756 18.6 12054 81.4   
 Four 2960 18.9 12667 81.1   
 Fifth 2865 19.0 12247 81.0   
Low-risk prostate cancer     2600 <0.001 
 GS >6 and/or PSA ≥10ng/mL 6245 12.8 42513 87.2   
 GS 6 and PSA <10ng/mL 7417 27.6 19496 72.4   





  0-2 Chronic conditions 7465 22.4 25901 77.6 
  
  >2 Chronic conditions 6197 14.6 36108 85.4 
  
Prostate Cancer Comorbidity Index     67.6 <0.001 
 10 or more years life expectancy 10780 18.6 47103 81.4   
 5-10 years life expectancy 1927 15.5 10503 84.5   
 5 or less years life expectancy  955 17.8 4403 82.2   
Low-value care     206.7 <0.001 
 Low-value care 3070 15.2 17140 84.8   
 No low-value care 10592 19.1 44869 80.9   
Preventative A1c test     38.8 <0.001 
 A1c test 1590 15.8 8456 84.2   
 No a1c test 12072 18.4 53553 81.6   
Preventative flu     422.4 <0.001 
 Influenza vaccination 4420 14.5 25966 85.5   
 No influenza vaccination 9242 20.4 36043 79.6   
Preventative lipid screen      <0.001 
 Lipid test 3161 15.2 17629 84.8   
 No lipid test 10501 19.1 44380 80.9   
Metro     14.2 <0.001 
 Metro county 11586 18.2 52052 81.8   
 Non-metro county 2047 17.2 9882 82.8   
SEER Region     458.1 <0.001 
 Northeast 2137 13.8 13382 86.2   
 South 3296 17.0 16067 83.0   
 North Central 1370 16.0 7193 84.0   
 West 6859 21.3 25367 78.7   
Year of diagnosis     198.4 <0.001 




 ≥2009 6925 16.3 35528 83.7   
 
Appendix 7.6 Low-value Care by Conservative Management Use among Fee-for-Service Medicare 







No CM (n=62009)  
 N LVC% N CM% N No CM % Χ2 p-value 
         
Preoperative chest radiography 2010 2.66  23.738 <0.001* 
 Yes   280 13.9 1730 86.1   
 No   13382 18.2 60279 81.8   
Preoperative echocardiography 1008 1.33%  11.982 <0.001* 
 Yes   140 13.9 868 86.1   
 No   13522 18.1 61141 81.9   
Arthroscopic surgery for knee 
osteoarthritis 
33 0.04 
 1.793 0.181 
 Yes   ** ** **    
 No   ** ** **    
Hypercoagulability testing for 
patients with DVT 
78 0.10 
 0.102 0.750 
 Yes   13 16.7 65 83.3   
 No   13649 18.1 61944 81.9   
Stress echocardiography for CAD or 
risk assessment 
1916 2.53 
 12.144 <0.001* 
 Yes   288 15.0 1628 85.0   
 No   13374 18.1 60381 81.9   
Laminectomy or spinal fusion 348 0.46  1.196 0.274 
 Yes   55 15.8 293 84.2   
 No   13607 18.1 61716 81.9   
Fiberoptic laryngoscopy for 
sinusitis 
636 0.84 
 4.649 0.031* 
 Yes   94 14.8 542 85.2   
 No   13568 18.1 61467 81.9   
Routine monitoring of digoxin in 
CHF patients 
613 0.81 
 2.731 0.098 
 Yes   95 15.5 518 84.5   
 No   13567 18.1 61491 81.9   
EEG or imaging monitoring in 
patients with syncope 
1388 1.83 
 0.064 0.800 
 Yes   247 17.8 1141 82.2   
 No   13415 18.1 60868 81.9   
Serological tests for helicobacter 
pylori 
732 0.97 
 5.442 0.020* 
 Yes   108 14.8 624 85.2   




MRI in individuals with traumatic 
brain injury 
16 0.02 
 0.005 0.942 
 Yes   ** ** ** **   
 No   ** ** ** **   
Traction for low back pain 5759 7.61     5.850 0.016* 
 Yes   510 16.4 2596 83.6   
 No   13152 18.1 59413 81.9   
Screening for asymptomatic carotid 
artery stenosis 
7367 9.74 
 65.614 <0.001* 
 Yes   1076 14.6 6291 85.4   
 No   12586 18.4 55718 81.6   
Immunoglobulin (IgG, IgE) tests 
for evaluation of allergy 
269 0.36 
 1.444 0.230 
 Yes   41 15.2 228 84.8   
 No   13621 18.1 61781 81.9   
MRI Lumbar Spine for Low Back 
Pain 
5759 7.61 
 25.889 <0.001* 
 Yes   897 15.6 4862 84.4   
 No   12765 18.3 57147 81.7   
IVC filters to prevent PE 41 0.05  0.059 0.808 
 Yes   ** ** ** **   
 No   ** ** ** **   
Renal angioplasty or stent 43 0.06  1.201 0.273 
 Yes   ** ** ** **   
 No   ** ** ** **   
Vitamin D screening 462 0.61  2.648 0.104 
 Yes   70 15.2 392 84.8   
 No   13592 18.1 61617 81.9   
Head imaging for uncomplicated 
headache 
332 0.44 
 0.018 0.893 
 Yes   59 17.8 273 82.2   
 No   13603 18.1 61736 81.9   
Imaging for plantar fasciitis 37 0.05  0.516 0.473 
 Yes   ** ** ** **   




































Appendix 7.8 Aim 1 python codes 
 
import pandas as pd 
import numpy as np 
feature_names for SHAP analyses below 
feature_names = [ "Married", "Age group 66-74", "Median income", "Care fragmentation", "Less than 
highschool education", "College education", "SEER Northeast", "Primary Care visit", "Urologist density", 
"Influenza vaccination", "SEER West", "Multimorbidity group", "A1c screening", "Lipid screening", "Bone 
density screening", "Psyhcology visit", "Life expectancy over 10 years", "Hispanic", "White race", "Black race", 
"Metro locality", "SEER South", "SEER Northcentral", "Separated/Divorced/Widowed","Unmarried", "Low 
value care (sum)", "Radiation Oncologist density", "Diagnostic year 2009", "Diagnostic year 2010", "Diagnostic 
year 2011", "Diagnostic year 2012", "Diagnostic year 2013", "Diagnostic year 2014" ] 
use the list to select a subset of the original DataFrame 
X = dataset[feature_names] 
print the first 5 rows 
X.head() 
#Instantiate Y with dependent/label var, X with indepdent/feature vars 
y = dataset['trmt'] 
#Split data into train and test data sets; 80/30  
from sklearn.model_selection import train_test_split 
X_train, X_test, y_train, y_test = train_test_split (X, y, test_size = 0.30, random_state=21) 
from collections import Counter 
 
# count # of examples in each class 
counter = Counter(y) 
# estimate scale_pos_weight value, assuming the class labels are 0 and 1. Modify according to your 
use-case 
weight = counter[0] / counter[1] 
Calibration before tune 
from sklearn.calibration import CalibratedClassifierCV 
import seaborn as sns 
 
fig, ax = plt.subplots(1, figsize=(12, 6)) 
 
# Create an uncorrected classifier. 
clf = xgc 
clf.fit(X_train, y_train) 
y_test_predict_proba = clf.predict_proba(X_test)[:, 1] 
fraction_of_positives, mean_predicted_value = calibration_curve(y_test, y_test_predict_proba, n_b
ins=10) 
 
plt.plot(mean_predicted_value, fraction_of_positives, 's-', color='red', label='Uncalibrated') 
 
# Create a corrected classifier. 





y_test_predict_proba = clf_sigmoid.predict_proba(X_test)[:, 1] 
fraction_of_positives, mean_predicted_value = calibration_curve(y_test, y_test_predict_proba, n_b
ins=10) 
 
plt.plot(mean_predicted_value, fraction_of_positives, 's-', label='Calibrated (Platt)') 






plt.title("$XGClassifier$ Sample Calibration Curve", fontsize=20); pass 
png 
png 
from sklearn.metrics import roc_auc_score, accuracy_score, recall_score, precision_score, f1_score, 
cohen_kappa_score 
# Performance for train 
train_y_pred = clf_sigmoid.predict(X_train) 
auc = roc_auc_score(y_train, train_y_pred) 
print("AUC performance for train : ", auc) 
 
# Calc bal_accuracy, recall, and average positive prediction score 
recall = recall_score(y_train, train_y_pred) 
print("Recall performance for train : ", recall) 
f1 = f1_score(y_train, train_y_pred) 
print("F1 performance for train : ", f1) 
prcsn = precision_score(y_train, train_y_pred,labels=np.unique(train_y_pred)) 
print("Precision performance for train : ", prcsn) 
 
# Performance for train 
y_pred = clf_sigmoid.predict(X_test) 
auc_t = roc_auc_score(y_test, y_pred) 
print("AUC performance for test : ", auc_t) 
 
# Calc bal_accuracy, recall, and average positive prediction score 
recall_t = recall_score(y_test, y_pred) 
print("Recall performance for test : ", recall_t) 
 
f1_t = f1_score(y_test, y_pred) 
print("F1 performance for test : ", f1_t) 
prcsn_t = precision_score(y_test, y_pred,labels=np.unique(y_pred)) 
print("Precision performance for test : ", prcsn_t) 
AUC performance for train :  0.6787989250338197 
Recall performance for train :  0.9956783454236765 
F1 performance for train :  0.8606497231672336 
Precision performance for train :  0.7578712406015038 




Recall performance for test :  0.958139534883721 
F1 performance for test :  0.8089412475456879 
Precision performance for test :  0.6999477260846837 
import xgboost as xgb # XGBoost  
# Preliminary model w/o tuning or cross-validation 
clf_xgb = xgb.XGBClassifier(objective='binary:logistic',scale_pos_weight=weight, 
                            seed=42) 
clf_xgb.fit(X_train,  
            y_train, 
            verbose=True, 
            ## the next three arguments set up early stopping. 
            early_stopping_rounds=10, 
            eval_metric=['auc'], 





XGBClassifier(base_score=0.5, booster='gbtree', colsample_bylevel=1, 
              colsample_bynode=1, colsample_bytree=1, gamma=0, gpu_id=-1, 
              importance_type='gain', interaction_constraints='', 
              learning_rate=0.300000012, max_delta_step=0, max_depth=6, 
              min_child_weight=1, missing=nan, monotone_constraints='()', 
              n_estimators=100, n_jobs=0, num_parallel_tree=1, random_state=42, 
              reg_alpha=0, reg_lambda=1, scale_pos_weight=0.4955790381712314, 
              seed=42, subsample=1, tree_method='exact', validate_parameters=1, 
              verbosity=None) 
# predict probabilities 
xgb_probs = clf_xgb.predict_proba(X_test) 
# keep probabilities for the positive outcome only 
xgb_probs = xgb_probs[:, 1] 




plt.hist(prediction[y_test==0], bins=50, label='Negatives') 
plt.hist(prediction[y_test==1], bins=50, label='Positives', alpha=0.7, color='r') 
plt.xlabel('Probability of being Positive Class', fontsize=25) 
plt.ylabel('Number of records in each bucket', fontsize=25) 
plt.legend(fontsize=15) 




# Performance for train 




auc = roc_auc_score(y_train, train_y_pred) 
print("AUC performance for train : ", auc) 
 
# Calc bal_accuracy, recall, and average positive prediction score 
recall = recall_score(y_train, train_y_pred) 
print("Recall performance for train : ", recall) 
f1 = f1_score(y_train, train_y_pred) 
print("F1 performance for train : ", f1) 
prcsn = precision_score(y_train, train_y_pred,labels=np.unique(train_y_pred)) 
print("Precision performance for train : ", prcsn) 
 
# Performance for train 
y_pred = clf_xgb.predict(X_test) 
auc_t = roc_auc_score(y_test, y_pred) 
print("AUC performance for test : ", auc_t) 
 
# Calc bal_accuracy, recall, and average positive prediction score 
recall_t = recall_score(y_test, y_pred) 
print("Recall performance for test : ", recall_t) 
 
f1_t = f1_score(y_test, y_pred) 
print("F1 performance for test : ", f1_t) 
prcsn_t = precision_score(y_test, y_pred,labels=np.unique(y_pred)) 
print("Precision performance for test : ", prcsn_t) 
 
kp_t = cohen_kappa_score(y_test, y_pred) 
print("Cohen Kappa for test : ", kp_t) 
AUC performance for train :  0.7268423776363454 
Recall performance for train :  0.7471832072850748 
F1 performance for train :  0.7892076948157809 
Precision performance for train :  0.8362411470029366 
AUC performance for test :  0.6110343978606433 
Recall performance for test :  0.6715563506261181 
F1 performance for test :  0.7101778282255014 
Precision performance for test :  0.753512645523886 
Cohen Kappa for test :  0.21011514238033613 
from sklearn.model_selection import GridSearchCV # cross validation and tuning 
from sklearn.model_selection import RepeatedStratifiedKFold 
 
cv = RepeatedStratifiedKFold(n_splits=10, n_repeats=3, random_state=1) 
 
## ROUND 0 
param_grid = { 
     'scale_pos_weight': [weight] 
} 
 
## NOTE: To speed up cross validiation, and to further prevent overfitting 
## we are only using a random subset of the data (90%) and are only 




optimal_params_0 = GridSearchCV( 
     estimator=xgb.XGBClassifier(objective='binary:logistic',  
                                 seed=42, 
                                 subsample=0.9, 
                                 colsample_bytree=0.5), 
     param_grid=param_grid, 
     scoring='roc_auc', ## see https://scikit-learn.org/stable/modules/model_evaluation.html#scori
ng-parameter 
     verbose=0, # NOTE: If you want to see what Grid Search is doing, set verbose=2 
     n_jobs = -1, 




                   y_train,  
                   early_stopping_rounds=10,                 
                   eval_metric=['auc'], 
                   eval_set=[(X_test, y_test)], 




# Performance for train 
train_y_pred = optimal_params_0.predict(X_train) 
auc = roc_auc_score(y_train, train_y_pred) 
recall = recall_score(y_train, train_y_pred) 
print("AUC for train : ", auc) 
print("Recall for train : ", recall) 
AUC for train :  0.6834020319039793 
Recall for train :  0.7076709368729742 
plot_confusion_matrix(optimal_params_0,  
                      X_test,  
                      y_test, 
                      values_format='d', 
                      display_labels=["No Treatment", "Treatment"]) 
<sklearn.metrics._plot.confusion_matrix.ConfusionMatrixDisplay at 0x1799dd47fa0> 
png 
png 
# Performance for train 
train_y_pred = optimal_params_0.predict(X_train) 
auc = roc_auc_score(y_train, train_y_pred) 
print("AUC performance for train : ", auc) 
 
# Calc bal_accuracy, recall, and average positive prediction score 




print("Recall performance for train : ", recall) 
f1 = f1_score(y_train, train_y_pred) 
print("F1 performance for train : ", f1) 
prcsn = precision_score(y_train, train_y_pred,labels=np.unique(train_y_pred)) 
print("Precision performance for train : ", prcsn) 
 
# Performance for train 
y_pred = optimal_params_0.predict(X_test) 
auc_t = roc_auc_score(y_test, y_pred) 
print("AUC performance for test : ", auc_t) 
 
# Calc bal_accuracy, recall, and average positive prediction score 
recall_t = recall_score(y_test, y_pred) 
print("Recall performance for test : ", recall_t) 
 
f1_t = f1_score(y_test, y_pred) 
print("F1 performance for test : ", f1_t) 
prcsn_t = precision_score(y_test, y_pred,labels=np.unique(y_pred)) 
print("Precision performance for test : ", prcsn_t) 
AUC performance for train :  0.6834020319039793 
Recall performance for train :  0.7076709368729742 
F1 performance for train :  0.7538018906699548 
Precision performance for train :  0.8063665142455153 
AUC performance for test :  0.5978129739102193 
Recall performance for test :  0.643649373881932 
F1 performance for test :  0.6911256242796773 
Precision performance for test :  0.7461634176690171 
# Use recommended XGboost approach or tune for best performance metric. 
weight = optimal_params_0.best_params_['scale_pos_weight'] 
## ROUND 1  
 
n_estimators = [20,50,100, 200,300,400,500, 600, 700, 800, 900] 
learning_rate = [0.0001, 0.001, 0.01, 0.1, 0.2]   
scale_pos_weight = [weight] 
param_grid_1 = dict(scale_pos_weight=scale_pos_weight,  
                  learning_rate=learning_rate,  
                  n_estimators=n_estimators) 
 
cv = RepeatedStratifiedKFold(n_splits=10, n_repeats=3, random_state=1) 
 
optimal_params_1 = GridSearchCV( 
     estimator=xgb.XGBClassifier(objective='binary:logistic',  
                                 seed=42, 
                                 subsample=0.9, 
                                 colsample_bytree=0.5), 
     param_grid=param_grid_1, 





     verbose=0, # NOTE: If you want to see what Grid Search is doing, set verbose=2 
     n_jobs = -1, 




                   y_train,  
                   early_stopping_rounds=10,                 
                   eval_metric=['auc'], 
                   eval_set=[(X_test, y_test)], 
                   verbose=False) 
 
print(optimal_params_1.best_params_) 
{'learning_rate': 0.01, 'n_estimators': 200, 'scale_pos_weight': 0.4955790381712314} 
# summarize results   
print("Best: %f using %s" % (optimal_params_1.best_score_, optimal_params_1.best_params_))   
means = optimal_params_1.cv_results_['mean_test_score']   
stds = optimal_params_1.cv_results_['std_test_score']   
params = optimal_params_1.cv_results_['params']   
for mean, stdev, param in zip(means, stds, params):   
    print("%f (%f) with: %r" % (mean, stdev, param))   
# Performance for train 
train_y_pred = optimal_params_1.predict(X_train) 
auc = roc_auc_score(y_train, train_y_pred) 
print("Performance for train : ", auc) 
 
# Performance for test 
y_pred_rd1 = optimal_params_1.predict(X_test) 
auc_t_rd1 = roc_auc_score(y_test, y_pred_rd1) 
print("AUC performance for test : ", auc_t_rd1) 
 
# Calc bal_accuracy, recall, and average positive prediction score 
recall_t_rd1 = recall_score(y_test, y_pred_rd1) 
print("Recall performance for test : ", recall_t_rd1) 
 
aps_t_rd1 = average_precision_score(y_test, y_pred) 
print("APS performance for test: ", aps_t_rd1) 
 
f1_t_rd1 = f1_score(y_test, y_pred_rd1) 
print("F1 performance for test : ", f1_t_rd1) 
prcsn_t_rd1 = precision_score(y_test, y_pred_rd1,labels=np.unique(y_pred_rd1)) 
print("Precision performance for test : ", prcsn_t_rd1) 
accry_t = accuracy_score(y_test, y_pred_rd1) 
print("Accuracy performance for test : ", accry_t) 
Performance for train :  0.6850635083482383 
AUC performance for test :  0.6114555640824836 




APS performance for test:  0.7196331537267628 
F1 performance for test :  0.7158131682611143 
Precision performance for test :  0.7523659305993691 
Accuracy performance for test :  0.6359048305695746 
learning_rate = optimal_params_1.best_params_['learning_rate'] 
n_estimators = optimal_params_1.best_params_['n_estimators'] 
## ROUND 2  
from sklearn.model_selection import RepeatedStratifiedKFold 
 
param_grid_2 = { 
     'max_depth': [1,2,3,4,5,6,7,8,9,10,11,12,13,14], 
     'min_child_weight': [1,2,3,4,5,6,7,8,9,10,11,12,13,14], 
     'scale_pos_weight': [weight], 
     'learning_rate':[learning_rate], 
     'n_estimators':[n_estimators] 
} 
 
cv = RepeatedStratifiedKFold(n_splits=10, n_repeats=3, random_state=1) 
 
optimal_params_2 = GridSearchCV( 
     estimator=xgb.XGBClassifier(objective='binary:logistic',  
                                 seed=42, 
                                 subsample=0.9, 
                                 colsample_bytree=0.5), 
     param_grid=param_grid_2, 
     scoring='roc_auc', ## see https://scikit-learn.org/stable/modules/model_evaluation.html#scori
ng-parameter 
     verbose=3, # NOTE: If you want to see what Grid Search is doing, set verbose=2 
     n_jobs = -1, 




                   y_train,  
                   early_stopping_rounds=10,                 
                   eval_metric=['auc'], 
                   eval_set=[(X_test, y_test)], 





{'learning_rate': 0.01, 'max_depth': 12, 'min_child_weight': 10, 'n_estimators': 200, 'scale_pos_weig
ht': 0.4955790381712314} 
# Performance for train 
train_y_pred = optimal_params_2.predict(X_train) 
auc = roc_auc_score(y_train, train_y_pred) 





# Performance for test 
y_pred_rd2 = optimal_params_2.predict(X_test) 
auc_t_rd2 = roc_auc_score(y_test, y_pred_rd2) 
print("AUC performance for test : ", auc_t_rd2) 
 
aps_t_rd2 = average_precision_score(y_test, y_pred_rd2) 
print("APS performance for test: ", aps_t_rd2) 
 
# Calc bal_accuracy, recall, and average positive prediction score 
recall_t_rd2 = recall_score(y_test, y_pred_rd2) 
print("Recall performance for test : ", recall_t_rd2) 
 
f1_t_rd2 = f1_score(y_test, y_pred_rd2) 
print("F1 performance for test : ", f1_t_rd2) 
prcsn_t_rd2 = precision_score(y_test, y_pred_rd2,labels=np.unique(y_pred_rd2)) 
print("Precision performance for test : ", prcsn_t_rd2) 
accry_t = accuracy_score(y_test, y_pred_rd2) 
print("Accuracy performance for test : ", accry_t) 
Performance for train :  0.7176366178513388 
AUC performance for test :  0.618159650285361 
APS performance for test:  0.7306195103281976 
Recall performance for test :  0.6726296958855098 
F1 performance for test :  0.7133371276797571 
Precision performance for test :  0.7592891760904685 
Accuracy performance for test :  0.6368661379476087 
min_child_weight = optimal_params_2.best_params_['min_child_weight'] 
max_depth = optimal_params_2.best_params_['max_depth'] 
## ROUND 3  
     
param_grid_3 = { 
     'max_depth': [max_depth], 
     'min_child_weight': [min_child_weight], 
     'scale_pos_weight': [weight], 
     'learning_rate':[learning_rate], 
     'n_estimators':[n_estimators], 
     'gamma': [0,0.001,0.002,0.01,0.1,0.2,0.3,0.4,0.5] 
} 
 
cv = RepeatedStratifiedKFold(n_splits=10, n_repeats=3, random_state=1) 
 
optimal_params_3 = GridSearchCV( 
     estimator=xgb.XGBClassifier(objective='binary:logistic',  
                                 seed=42, 
                                 subsample=0.9, 
                                 colsample_bytree=0.5), 
     param_grid=param_grid_3, 





     verbose=0, # NOTE: If you want to see what Grid Search is doing, set verbose=2 
     n_jobs = -1, 




                   y_train,  
                   early_stopping_rounds=10,                 
                   eval_metric=['auc'], 
                   eval_set=[(X_test, y_test)], 
                   verbose=False) 
 
print(optimal_params_3.best_params_) 
{'gamma': 0.01, 'learning_rate': 0.01, 'max_depth': 12, 'min_child_weight': 10, 'n_estimators': 200, 's
cale_pos_weight': 0.4955790381712314} 
# Performance for train 
train_y_pred = optimal_params_3.predict(X_train) 
auc = roc_auc_score(y_train, train_y_pred) 
print("Performance for train : ", auc) 
 
# Performance for test 
y_pred_rd3 = optimal_params_3.predict(X_test) 
auc_t_rd3 = roc_auc_score(y_test, y_pred_rd3) 
print("AUC performance for test : ", auc_t_rd3) 
 
# average precision score 
aps_t_rd3 = average_precision_score(y_test, y_pred_rd3) 
print("APS performance for test: ", aps_t_rd3) 
 
# Calc bal_accuracy, recall, and average positive prediction score 
recall_t_rd3 = recall_score(y_test, y_pred_rd3) 
print("Recall performance for test : ", recall_t_rd3) 
 
f1_t_rd3 = f1_score(y_test, y_pred_rd3) 
print("F1 performance for test : ", f1_t_rd3) 
prcsn_t_rd3 = precision_score(y_test, y_pred_rd3,labels=np.unique(y_pred_rd3)) 
print("Precision performance for test : ", prcsn_t_rd3) 
accry_t = accuracy_score(y_test, y_pred_rd3) 
print("Accuracy performance for test : ", accry_t) 
Performance for train :  0.7176366178513388 
AUC performance for test :  0.6183385411619263 
APS performance for test:  0.7307162431227368 
Recall performance for test :  0.6729874776386404 
F1 performance for test :  0.7135811836115326 
Precision performance for test :  0.7593863544610416 




# set n_estimaters according to round 3 
gamma = optimal_params_3.best_params_['gamma'] 
## ROUND 4     
 
param_grid_4 = { 
     'max_depth': [max_depth], 
     'min_child_weight': [min_child_weight], 
     'scale_pos_weight': [weight], 
     'learning_rate':[learning_rate], 
     'n_estimators':[n_estimators], 
     'gamma': [gamma], 
     'reg_lambda':[1,2,3,4,5,10,50], 
     'reg_alpha':[1,2,3,4,5,10,50] 
} 
 
cv = RepeatedStratifiedKFold(n_splits=10, n_repeats=3, random_state=1) 
 
optimal_params_4 = GridSearchCV( 
     estimator=xgb.XGBClassifier(objective='binary:logistic',  
                                 seed=42, 
                                 subsample=0.9, 
                                 colsample_bytree=0.5), 
     param_grid=param_grid_4, 
     scoring='roc_auc', ## see https://scikit-learn.org/stable/modules/model_evaluation.html#scori
ng-parameter 
     verbose=0, # NOTE: If you want to see what Grid Search is doing, set verbose=2 
     n_jobs = -1, 




                   y_train,  
                   early_stopping_rounds=10,                 
                   eval_metric=['auc'], 
                   eval_set=[(X_test, y_test)], 
                   verbose=False) 
 
print(optimal_params_4.best_params_) 
{'gamma': 0.01, 'learning_rate': 0.01, 'max_depth': 12, 'min_child_weight': 10, 'n_estimators': 200, 'r
eg_alpha': 1, 'reg_lambda': 3, 'scale_pos_weight': 0.4955790381712314} 
# Performance for train 
train_y_pred = optimal_params_4.predict(X_train) 
auc = roc_auc_score(y_train, train_y_pred) 
print("Performance for train : ", auc) 
 
# Performance for test 
y_pred_rd4 = optimal_params_4.predict(X_test) 




print("AUC performance for test : ", auc_t_rd4) 
 
# Calc bal_accuracy, recall, and average positive prediction score 
recall_t_rd4 = recall_score(y_test, y_pred_rd4) 
print("Recall performance for test : ", recall_t_rd4) 
 
# average precision score 
aps_t_rd4 = average_precision_score(y_test, y_pred_rd4) 
print("APS performance for test: ", aps_t_rd4) 
 
f1_t_rd4 = f1_score(y_test, y_pred_rd4) 
print("F1 performance for test : ", f1_t_rd4) 
prcsn_t_rd4 = precision_score(y_test, y_pred_rd4,labels=np.unique(y_pred_rd4)) 
print("Precision performance for test : ", prcsn_t_rd4) 
accry_t = accuracy_score(y_test, y_pred_rd4) 
print("Accuracy performance for test : ", accry_t) 
Performance for train :  0.6860186303260307 
AUC performance for test :  0.6065291241156949 
Recall performance for test :  0.6654740608228981 
APS performance for test:  0.7242139745672891 
F1 performance for test :  0.7054807509956381 
Precision performance for test :  0.7506053268765133 
Accuracy performance for test :  0.6267724104782504 
reg_lambda = optimal_params_4.best_params_['reg_lambda'] 
reg_alpha = optimal_params_4.best_params_['reg_alpha'] 
## ROUND 5  
     
param_grid_5 = { 
     'max_depth': [max_depth], 
     'min_child_weight': [min_child_weight], 
     'scale_pos_weight': [weight], 
     'learning_rate':[learning_rate], 
     'n_estimators':[n_estimators], 
     'gamma': [gamma], 
     'reg_lambda':[reg_lambda], 
     'reg_alpha':[reg_alpha], 
     'subsample':[0.3,0.5,0.7,0.9], 
     'colsample_bytree':[0.3,0.5,0.7,0.9] 
} 
 
cv = RepeatedStratifiedKFold(n_splits=10, n_repeats=3, random_state=1) 
 
optimal_params_5 = GridSearchCV( 
     estimator=xgb.XGBClassifier(objective='binary:logistic',  
                                 seed=42 
                                 ), 
     param_grid=param_grid_5, 





     verbose=0, # NOTE: If you want to see what Grid Search is doing, set verbose=2 
     n_jobs = -1, 




                   y_train,  
                   early_stopping_rounds=10,                 
                   eval_metric=['auc'], 
                   eval_set=[(X_test, y_test)], 
                   verbose=False) 
 
print(optimal_params_5.best_params_) 
{'colsample_bytree': 0.5, 'gamma': 0.01, 'learning_rate': 0.01, 'max_depth': 12, 'min_child_weight': 1
0, 'n_estimators': 200, 'reg_alpha': 1, 'reg_lambda': 3, 'scale_pos_weight': 0.4955790381712314, 'sub
sample': 0.9} 
# Performance for train 
train_y_pred = optimal_params_5.predict(X_train) 
auc = roc_auc_score(y_train, train_y_pred) 
print("Performance for train : ", auc) 
 
# Performance for test 
y_pred_rd5 = optimal_params_5.predict(X_test) 
auc_t_rd5 = roc_auc_score(y_test, y_pred_rd5) 
print("AUC performance for test : ", auc_t_rd5) 
 
# average precision score 
aps_t_rd5 = average_precision_score(y_test, y_pred_rd5) 
print("APS performance for test: ", aps_t_rd5) 
 
# Calc bal_accuracy, recall, and average positive prediction score 
recall_t_rd5 = recall_score(y_test, y_pred_rd5) 
print("Recall performance for test : ", recall_t_rd5) 
 
f1_t_rd5 = f1_score(y_test, y_pred_rd5) 
print("F1 performance for test : ", f1_t_rd5) 
prcsn_t_rd5 = precision_score(y_test, y_pred_rd5,labels=np.unique(y_pred_rd5)) 
print("Precision performance for test : ", prcsn_t_rd5) 
accry_t = accuracy_score(y_test, y_pred_rd5) 
print("Accuracy performance for test : ", accry_t) 
Performance for train :  0.6860186303260307 
AUC performance for test :  0.6065291241156949 
APS performance for test:  0.7242139745672891 
Recall performance for test :  0.6654740608228981 
F1 performance for test :  0.7054807509956381 
Precision performance for test :  0.7506053268765133 




subsample = optimal_params_5.best_params_['subsample'] 
colsample_bytree = optimal_params_5.best_params_['colsample_bytree'] 
## ROUND 6  
     
param_grid_6 = { 
     'max_depth': [max_depth], 
     'min_child_weight': [min_child_weight], 
     'scale_pos_weight': [weight], 
     'learning_rate':[learning_rate], 
     'n_estimators':[n_estimators], 
     'gamma': [gamma], 
     'reg_lambda':[reg_lambda], 
     'reg_alpha':[reg_alpha], 
     'subsample':[subsample], 
     'colsample_bytree':[colsample_bytree] 
} 
 
cv = RepeatedStratifiedKFold(n_splits=10, n_repeats=3, random_state=1) 
 
optimal_params_6 = GridSearchCV( 
     estimator=xgb.XGBClassifier(objective='binary:logistic',  
                                 seed=42), 
     param_grid=param_grid_6, 
     scoring='roc_auc', ## see https://scikit-learn.org/stable/modules/model_evaluation.html#scori
ng-parameter 
     verbose=0, # NOTE: If you want to see what Grid Search is doing, set verbose=2 
     n_jobs = -1, 




                   y_train,  
                   early_stopping_rounds=10,                 
                   eval_metric=['auc'], 
                   eval_set=[(X_test, y_test)], 
                   verbose=False) 
 
print(optimal_params_6.best_params_) 
{'colsample_bytree': 0.5, 'gamma': 0.01, 'learning_rate': 0.01, 'max_depth': 12, 'min_child_weight': 1
0, 'n_estimators': 200, 'reg_alpha': 1, 'reg_lambda': 3, 'scale_pos_weight': 0.4955790381712314, 'sub
sample': 0.9} 
print(f'Best: {optimal_params_6.best_score_} using {optimal_params_6.best_params_}','\n') 
Best: 0.6860864943064999 using {'colsample_bytree': 0.5, 'gamma': 0.01, 'learning_rate': 0.01, 'max
_depth': 12, 'min_child_weight': 10, 'n_estimators': 200, 'reg_alpha': 1, 'reg_lambda': 3, 'scale_pos_
weight': 0.4955790381712314, 'subsample': 0.9}  





xgbcl = optimal_params_6.best_estimator_ 
 
kfold = RepeatedStratifiedKFold(n_splits=10, n_repeats=3, random_state=1) 
 
#refit the model on k-folds to get stable avg error metrics 
scores = cross_validate(estimator=xgbcl, X=X_train, y=y_train, cv=kfold, n_jobs=-1,  
                        scoring=['accuracy', 'roc_auc','average_precision','precision', 'recall', 'f1','neg_log_loss']) 
 
print('Training 5-fold Cross Validation Results:\n') 
print('AUC: ', scores['test_roc_auc'].mean()) 
print('Average precision: ', scores['test_average_precision'].mean()) 
print('Accuracy: ', scores['test_accuracy'].mean()) 
print('Precision: ', scores['test_precision'].mean()) 
print('Recall: ', scores['test_recall'].mean()) 
print('F1: ', scores['test_f1'].mean()) 
print('Neg.LogLoss: ', scores['test_neg_log_loss'].mean(), '\n') 
Training 5-fold Cross Validation Results: 
 
AUC:  0.6876457369330226 
Average precision:  0.7995369612229754 
Accuracy:  0.6535853497120976 
Precision:  0.763820977300308 
Recall:  0.6962997945567067 
F1:  0.7284155332975544 
Neg.LogLoss:  -0.6369035750460006  
AUC: 0.6921795663616259 Accuracy: 0.7015148941290553 Precision: 0.7124730885535536 Recall: 
0.926738078882592 F1: 0.8055823014055182 Neg.LogLoss: -0.579314435521734 
import sklearn.metrics as metrics 
#Fit the final model 
xgbcl.fit(X_train, y_train) 
 
#Generate predictions against our training and test data 
pred_train = xgbcl.predict(X_train) 
proba_train = xgbcl.predict_proba(X_train) 
pred_test = xgbcl.predict(X_test) 
proba_test = xgbcl.predict_proba(X_test) 
 
# Print model report 
print("Classification report (Test): \n") 
print(metrics.classification_report(y_test, pred_test)) 
print("Confusion matrix (Test): \n") 
print(metrics.confusion_matrix(y_test, pred_test)/len(y_test)) 
 
print ('\nTrain Accuracy:', metrics.accuracy_score(y_train, pred_train)) 
print ('Test Accuracy:', metrics.accuracy_score(y_test, pred_test)) 
 
print ('\nTrain AUC:', metrics.roc_auc_score(y_train, proba_train[:,1])) 





# calculate the fpr and tpr for all thresholds of the classification 
train_fpr, train_tpr, train_threshold = metrics.roc_curve(y_train, proba_train[:,1]) 
test_fpr, test_tpr, test_threshold = metrics.roc_curve(y_test, proba_test[:,1]) 
 
train_roc_auc = metrics.auc(train_fpr, train_tpr) 
test_roc_auc = metrics.auc(test_fpr, test_tpr) 
 
import matplotlib.pyplot as plt 
fig, ax = plt.subplots(figsize=[7,5]) 
plt.title('Receiver Operating Characteristic') 
plt.plot(train_fpr, train_tpr, 'b', label = 'Train AUC = %0.2f' % train_roc_auc) 
plt.plot(test_fpr, test_tpr, 'g', label = 'Test AUC = %0.2f' % test_roc_auc) 
plt.legend(loc = 'lower right') 
plt.plot([0, 1], [0, 1],'r--') 
plt.xlim([0, 1]) 
plt.ylim([0, 1]) 
plt.ylabel('True Positive Rate') 
plt.xlabel('False Positive Rate') 
plt.show() 
 
# plot feature importance 
xgb.plot_importance(xgbcl, importance_type='gain'); 
Classification report (Test):  
 
              precision    recall  f1-score   support 
 
         0.0       0.44      0.55      0.49      1366 
         1.0       0.75      0.67      0.71      2795 
 
    accuracy                           0.63      4161 
   macro avg       0.60      0.61      0.60      4161 
weighted avg       0.65      0.63      0.63      4161 
 
Confusion matrix (Test):  
 
[[0.17976448 0.14852199] 
 [0.2247056  0.44700793]] 
 
Train Accuracy: 0.6966731898238747 
Test Accuracy: 0.6267724104782504 
 
Train AUC: 0.755213509518965 








from sklearn.calibration import CalibratedClassifierCV 
 
fig, ax = plt.subplots(1, figsize=(12, 6)) 
 
# Create an uncorrected classifier. 
clf = xgc 
clf.fit(X_train, y_train) 
y_test_predict_proba = clf.predict_proba(X_test)[:, 1] 
fraction_of_positives, mean_predicted_value = calibration_curve(y_test, y_test_predict_proba, n_b
ins=10) 
 
plt.plot(mean_predicted_value, fraction_of_positives, 's-', color='red', label='Uncalibrated') 
 
# Create a corrected classifier. 
clf_sigmoid = CalibratedClassifierCV(clf, cv=3, method='sigmoid') 
clf_sigmoid.fit(X_train, y_train) 
y_test_predict_proba = clf_sigmoid.predict_proba(X_test)[:, 1] 
fraction_of_positives, mean_predicted_value = calibration_curve(y_test, y_test_predict_proba, n_b
ins=10) 
 
plt.plot(mean_predicted_value, fraction_of_positives, 's-', label='Calibrated (Platt)') 
plt.plot([0, 1], [0, 1], '--', color='gray') 
 
# Create a corrected classifier. 
clf_sigmoid_tune = CalibratedClassifierCV(xgbcl, cv=3, method='sigmoid') 
clf_sigmoid_tune.fit(X_train, y_train) 
y_test_predict_proba = clf_sigmoid_tune.predict_proba(X_test)[:, 1] 
fraction_of_positives, mean_predicted_value = calibration_curve(y_test, y_test_predict_proba, n_b
ins=10) 
 
plt.plot(mean_predicted_value, fraction_of_positives, 's-', label='Calibrated (Platt), After tune') 






plt.title("$XGClassifier$ Sample Calibration Curve", fontsize=20); pass 
png 
png 
import sklearn.metrics as metrics 
#Fit the final model 
clf_sigmoid_tune.fit(X_train, y_train) 
 
#Generate predictions against our training and test data 
pred_train = clf_sigmoid_tune.predict(X_train) 
proba_train = clf_sigmoid_tune.predict_proba(X_train) 
pred_test = clf_sigmoid_tune.predict(X_test) 





# Print model report 
print("Classification report (Test): \n") 
print(metrics.classification_report(y_test, pred_test)) 
print("Confusion matrix (Test): \n") 
print(metrics.confusion_matrix(y_test, pred_test)/len(y_test)) 
 
print ('\nTrain Accuracy:', metrics.accuracy_score(y_train, pred_train)) 
print ('Test Accuracy:', metrics.accuracy_score(y_test, pred_test)) 
 
print ('\nTrain AUC:', metrics.roc_auc_score(y_train, proba_train[:,1])) 
print ('Test AUC:', metrics.roc_auc_score(y_test, proba_test[:,1])) 
 
print ('\nTrain PR-AUC:', metrics.average_precision_score(y_train, proba_train[:,1])) 
print ('Test PR-AUC:', metrics.average_precision_score(y_test, proba_test[:,1])) 
 
 
# calculate the fpr and tpr for all thresholds of the classification 
train_fpr, train_tpr, train_threshold = metrics.roc_curve(y_train, proba_train[:,1]) 
test_fpr, test_tpr, test_threshold = metrics.roc_curve(y_test, proba_test[:,1]) 
 
train_roc_auc = metrics.auc(train_fpr, train_tpr) 
test_roc_auc = metrics.auc(test_fpr, test_tpr) 
 
import matplotlib.pyplot as plt 
fig, ax = plt.subplots(figsize=[7,5]) 
plt.title('Receiver Operating Characteristic') 
plt.plot(train_fpr, train_tpr, 'b', label = 'Train AUC = %0.2f' % train_roc_auc) 
plt.plot(test_fpr, test_tpr, 'g', label = 'Test AUC = %0.2f' % test_roc_auc) 
plt.legend(loc = 'lower right') 
plt.plot([0, 1], [0, 1],'r--') 
plt.xlim([0, 1]) 
plt.ylim([0, 1]) 
plt.ylabel('True Positive Rate') 
plt.xlabel('False Positive Rate') 
plt.show() 
 
# plot feature importance 
xgb.plot_importance(xgbcl, importance_type='gain'); 
Classification report (Test):  
 
              precision    recall  f1-score   support 
 
         0.0       0.60      0.23      0.33      1366 
         1.0       0.71      0.92      0.80      2795 
 
    accuracy                           0.70      4161 
   macro avg       0.65      0.58      0.57      4161 





Confusion matrix (Test):  
 
[[0.0752223  0.25306417] 
 [0.05118962 0.62052391]] 
 
Train Accuracy: 0.7289113193943764 
Test Accuracy: 0.695746214852199 
 
Train AUC: 0.7814297155324872 
Test AUC: 0.6598860127240391 
 
Train PR-AUC: 0.8725053236929292 
Test PR-AUC: 0.7798344142467664 
# predicted probabilities using tuning and calibration curve 
final_model = clf_sigmoid_tune.fit(X_train, np.ravel(y_train)) 
 
predictions = final_model.predict(X_test) 
preds = final_model.predict_proba(X_test) 
# Create a dataframe for the probabilities of treatment 
preds_df = pd.DataFrame(preds[:,1], columns = ['prob_treatment']) 
print("Accuracy Score Before and After Thresholding: {}, {}".format(accuracy_score(y_test, predictio
ns), accuracy_score(y_test, roc_predictions))) 
print("Precision Score Before and After Thresholding: {}, {}".format(precision_score(y_test, predictio
ns), precision_score(y_test, roc_predictions))) 
print("Recall Score Before and After Thresholding: {}, {}".format(recall_score(y_test, predictions), re
call_score(y_test, roc_predictions))) 
print("F1 Score Before and After Thresholding: {}, {}".format(f1_score(y_test, predictions), f1_score(
y_test, roc_predictions))) 
print("Roc Score Before and After Thresholding: {}, {}".format(roc_auc_score(y_test, predictions), ro
c_auc_score(y_test, roc_predictions))) 
Accuracy Score Before and After Thresholding: 0.695746214852199, 0.6534486902186974 
Precision Score Before and After Thresholding: 0.7103163686382393, 0.7420393559928443 
Recall Score Before and After Thresholding: 0.9237924865831842, 0.7420393559928443 
F1 Score Before and After Thresholding: 0.8031104199066873, 0.7420393559928443 
Roc Score Before and After Thresholding: 0.5764643252828073, 0.6071104539847092 
from sklearn.calibration import CalibratedClassifierCV 
 
fig, ax = plt.subplots(1, figsize=(12, 6)) 
 
# Create an uncorrected classifier. 
clf = xgbcl 
clf.fit(X_train, y_train) 
y_test_predict_proba = clf.predict_proba(X_test)[:, 1] 
fraction_of_positives, mean_predicted_value = calibration_curve(y_test, y_test_predict_proba, n_b
ins=10) 
 





# Create a corrected classifier. 
clf_sigmoid = CalibratedClassifierCV(clf, cv=3, method='sigmoid') 
clf_sigmoid.fit(X_train, y_train) 
y_test_predict_proba = clf_sigmoid.predict_proba(X_test)[:, 1] 
fraction_of_positives, mean_predicted_value = calibration_curve(y_test, y_test_predict_proba, n_b
ins=10) 
 
plt.plot(mean_predicted_value, fraction_of_positives, 's-', label='Calibrated (Platt)') 
plt.plot([0, 1], [0, 1], '--', color='gray') 
 
# Create a corrected classifier. 
clf_sigmoid_tune = CalibratedClassifierCV(optimal_params_6.best_estimator_, cv=3, method='sig
moid') 
clf_sigmoid_tune.fit(X_train, y_train) 
y_test_predict_proba = clf_sigmoid_tune.predict_proba(X_test)[:, 1] 
fraction_of_positives, mean_predicted_value = calibration_curve(y_test, y_test_predict_proba, n_b
ins=10) 
 
plt.plot(mean_predicted_value, fraction_of_positives, 's-', label='Calibrated (Platt), After tune') 
plt.plot([0, 1], [0, 1], '--', color='green') 
 
# Create a corrected classifier. 
fraction_of_positives, mean_predicted_value = calibration_curve(y_test, roc_predictions, n_bins=1
0) 
 
plt.plot(mean_predicted_value, fraction_of_positives, 's-', label='Calibrated (Platt), After tune & thre
shold') 










shap_values_list = [] 
shap_values_list_1000 = [] 
for calibrated_classifier in clf_sigmoid_tune.calibrated_classifiers_: 
    explainer = shap.TreeExplainer(calibrated_classifier.base_estimator) 
    shap_values = explainer.shap_values(X_train) 
    shap_values_1000 = explainer.shap_values(X_test[:1000]) 
    shap_values_list_1000.append(shap_values_1000) 
    shap_values_list.append(shap_values) 
 
shap_values = np.array(shap_values_list).sum(axis=0) / len(shap_values_list) 





# Shap values for positive class   
shap.summary_plot(shap_values, X_train, max_display=15, cmap=plt.get_cmap("cool")) 
 
# Shap values for positive class   
shap.summary_plot(shap_values, X_train, max_display=15, plot_type="bar", cmap=plt.get_cmap("
cool")) 
 
# Shap values for positive class   
shap.summary_plot(shap_values, X_train, max_display=50, plot_type="bar", cmap=plt.get_cmap("
cool")) 
shap.dependence_plot("Married", shap_values, X_train.values, feature_names=feature_names,inter
action_index=None, cmap=plt.get_cmap("cool")) 
shap.dependence_plot("Age group 66-74", shap_values, X_train.values, feature_names=feature_na
mes,interaction_index=None, cmap=plt.get_cmap("cool")) 
 
shap.dependence_plot("Care fragmentation", shap_values, X_train.values, feature_names=feature_
names,interaction_index=None, cmap=plt.get_cmap("cool")) 
shap.dependence_plot("Median income", shap_values, X_train.values, feature_names=feature_nam
es,interaction_index=None, cmap=plt.get_cmap("cool")) 
shap.dependence_plot("Life expectancy over 10 years", shap_values, X_train.values, feature_names=
feature_names,interaction_index=None, cmap=plt.get_cmap("cool")) 



























Appendix 7.8 Aim 3 python codes 
import pandas as pd 
import numpy as np 
from scipy.stats import stats, randint 
import random 
from sklearn.model_selection import GridSearchCV, cross_val_score, learning_curve 
from sklearn.model_selection import train_test_split 
import xgboost as xgb 
from collections import Counter 
import itertools 
import matplotlib.pyplot as plt 
import numpy as np 
import seaborn as sns 
X_vars = [ 
    "Age at diagnosis", 
    "Hispanic", 
    "Metro locality", 
    "Physical condition total","Mental health condition total", 
    "A1c screening","Influenza vaccination","Lipid screening", 
    "SEER Northcentral","SEER Northeast","SEER South","SEER West", 
    "White race","Black race","Other race", 
    "Psyhcology visit","Primary Care visit", 
    "Median income", 
    "Urologist density","Radiation Oncologist density", 
    "College education","Less than highschool education", 
    "PCCI", 
    "Married","Separated/Divorced/Widowed","Unmarried","Marital status unknown", 
    "Low-risk prostate cancer", 
    "Low value care (sum)",  
    "Conservative management", 
    "Care fragmentation", 
    "Diagnostic year 2005", 
    'Diagnostic year 2006', 
    'Diagnostic year 2007', 
    'Diagnostic year 2008', 
    'Diagnostic year 2009', 
    'Diagnostic year 2010', 
    'Diagnostic year 2011', 
    'Diagnostic year 2012', 
    'Diagnostic year 2013', 
    'Diagnostic year 2014' 
] 
 
# use the list to select a subset of the original DataFrame 






y = dataset['notx_12_24maft'] 
y.head() 
0     3404.767935 
1     1613.494700 
2    54756.131876 
3      143.520000 
4     3225.969687 
Name: notx_12_24maft, dtype: float64 
import matplotlib.pyplot as plt 
import seaborn as sns; sns.set() 
 
#Organize Data 
SR_y = pd.Series(y, name="y (Target Vector Distribution)") 
 
#Plot Data 
fig, ax = plt.subplots() 





XGB regressor with grid search 
import numpy as np 
import pandas as pd 
from sklearn import preprocessing 
import xgboost as xgb 
from xgboost.sklearn import XGBRegressor 
import datetime 
from sklearn.model_selection import GridSearchCV 
from sklearn.metrics import r2_score 
y_train_full = dataset['notx_12_24maft'] 
x_train_full = dataset.drop(["notx_12_24maft"], axis=1) 
y_train_full = np.log1p(y_train_full) 
Confirm y_ln distribution 
import matplotlib.pyplot as plt 
import seaborn as sns; sns.set() 
 
#Organize Data 
SR_y_ln = pd.Series(y_train_full, name="y (Target Vector Distribution)") 
 
#Plot Data 








# Split, check distribution of train/test features 
from sklearn.model_selection import train_test_split 










import xgboost as xgb 
from sklearn.metrics import r2_score, mean_squared_error, mean_absolute_error 




n_estimators = [500,670,675]   
learning_rate = [0.008,0.009,0.01] 
 
param_grid_1 = dict(learning_rate=learning_rate, 
                    n_estimators=n_estimators) 
 
xgb_model = XGBRegressor(objective = 'reg:squarederror', 
                        seed=seed) 
 
optimal_params_1 = GridSearchCV( 
        estimator = xgb_model, 
        param_grid = param_grid_1, 
        scoring = 'r2', #R2 tune 
        #scoring = 'neg_mean_squared_error',  #MSE 
        cv = cv, 
        n_jobs = -1, 
        verbose = 1 
    ) 
 
optimal_params_1.fit(X_train, 
                     y_train, 
                     early_stopping_rounds=10, 




                     verbose=False) 
 
print("Learning rate: ", optimal_params_1.best_params_['learning_rate']) 
print("n_estimators: ",optimal_params_1.best_params_['n_estimators']) 
Fitting 10 folds for each of 9 candidates, totalling 90 fits 
 
 
[Parallel(n_jobs=-1)]: Using backend LokyBackend with 12 concurrent workers. 
[Parallel(n_jobs=-1)]: Done  26 tasks      | elapsed:  3.8min 
[Parallel(n_jobs=-1)]: Done  90 out of  90 | elapsed: 10.1min finished 
 
 
Learning rate:  0.009 
n_estimators:  670 
# summarize results   
print("Best: %f using %s" % (optimal_params_1.best_score_, optimal_params_1.best_params_))   
means = optimal_params_1.cv_results_['mean_test_score']   
stds = optimal_params_1.cv_results_['std_test_score']   
params = optimal_params_1.cv_results_['params']   
for mean, stdev, param in zip(means, stds, params):   
    print("%f (%f) with: %r" % (mean, stdev, param))  
Best: 0.344432 using {'learning_rate': 0.009, 'n_estimators': 670} 
0.339254 (0.025079) with: {'learning_rate': 0.008, 'n_estimators': 500} 
0.344367 (0.024457) with: {'learning_rate': 0.008, 'n_estimators': 670} 
0.344394 (0.024453) with: {'learning_rate': 0.008, 'n_estimators': 675} 
0.342533 (0.024821) with: {'learning_rate': 0.009, 'n_estimators': 500} 
0.344432 (0.024475) with: {'learning_rate': 0.009, 'n_estimators': 670} 
0.344430 (0.024477) with: {'learning_rate': 0.009, 'n_estimators': 675} 
0.343783 (0.024534) with: {'learning_rate': 0.01, 'n_estimators': 500} 
0.344329 (0.024393) with: {'learning_rate': 0.01, 'n_estimators': 670} 
0.344329 (0.024393) with: {'learning_rate': 0.01, 'n_estimators': 675} 
y_train_pred = optimal_params_1.best_estimator_.predict(X_train) 
y_test_pred = optimal_params_1.best_estimator_.predict(X_test) 
print('XGBregressor evaluating result:') 
print("Train MAE: ", sklearn.metrics.mean_absolute_error(y_train, y_train_pred)) 
print("Train RMSE: ", np.sqrt(sklearn.metrics.mean_squared_error(y_train, y_train_pred))) 
print("Train R2: ", np.sqrt(sklearn.metrics.r2_score(y_train, y_train_pred))) 
print("Test MAE: ", sklearn.metrics.mean_absolute_error(y_test, y_test_pred)) 
print("Test RMSE: ", np.sqrt(sklearn.metrics.mean_squared_error(y_test, y_test_pred))) 
print("Test R2: ", np.sqrt(sklearn.metrics.r2_score(y_test, y_test_pred))) 
XGBregressor evaluating result: 
Train MAE:  1.1343200343381408 
Train RMSE:  1.5691095294270383 
Train R2:  0.6387264523125636 




Test RMSE:  1.627370752580571 
Test R2:  0.5810544023298005 
learning_rate = optimal_params_1.best_params_['learning_rate'] 
n_estimators = optimal_params_1.best_params_['n_estimators'] 
 
param_grid_2 = {'learning_rate':[learning_rate], 
                'n_estimators':[n_estimators], 
                'max_depth':[4,5,6], 
                'min_child_weight':[11,12,13] 
               } 
 
xgb_model = XGBRegressor(objective = 'reg:squarederror', 
                        seed=seed) 
 
optimal_params_2 = GridSearchCV( 
        estimator = xgb_model, 
        param_grid = param_grid_2, 
        scoring = 'r2', 
        #scoring = 'neg_mean_absolute_error', #MAE 
        #scoring = 'neg_mean_squared_error',  #MSE 
        cv = cv, 
        n_jobs = -1, 
        verbose = 1 
    ) 
 
optimal_params_2.fit(X_train, 
                     y_train, 
                     early_stopping_rounds=10, 
                     eval_set=[(X_test, y_test)], 
                     verbose=False) 
     
print("max_depth: ", optimal_params_2.best_params_['max_depth']) 
print("min_child_weight: ",optimal_params_2.best_params_['min_child_weight']) 
Fitting 10 folds for each of 9 candidates, totalling 90 fits 
 
 
[Parallel(n_jobs=-1)]: Using backend LokyBackend with 12 concurrent workers. 
[Parallel(n_jobs=-1)]: Done  26 tasks      | elapsed:  2.9min 
[Parallel(n_jobs=-1)]: Done  90 out of  90 | elapsed:  9.2min finished 
 
 
max_depth:  5 
min_child_weight:  12 
max_depth = optimal_params_2.best_params_['max_depth'] 
min_child_weight = optimal_params_2.best_params_['min_child_weight'] 
y_train_pred = optimal_params_2.best_estimator_.predict(X_train) 




print('XGBregressor evaluating result:') 
print("Train MAE: ", sklearn.metrics.mean_absolute_error(y_train, y_train_pred)) 
print("Train RMSE: ", np.sqrt(sklearn.metrics.mean_squared_error(y_train, y_train_pred))) 
print("Train R2: ", np.sqrt(sklearn.metrics.r2_score(y_train, y_train_pred))) 
print("Test MAE: ", sklearn.metrics.mean_absolute_error(y_test, y_test_pred)) 
print("Test RMSE: ", np.sqrt(sklearn.metrics.mean_squared_error(y_test, y_test_pred))) 
print("Test R2: ", np.sqrt(sklearn.metrics.r2_score(y_test, y_test_pred))) 
XGBregressor evaluating result: 
Train MAE:  1.1557842730348065 
Train RMSE:  1.6082375631598405 
Train R2:  0.6148797875288853 
Test MAE:  1.1723220292261036 
Test RMSE:  1.6260654683448836 
Test R2:  0.5819676548322498 
# gamma tune 
 
param_grid_3 = {'learning_rate':[learning_rate], 
                'n_estimators':[n_estimators], 
                'max_depth':[max_depth], 
                'min_child_weight':[min_child_weight], 
                'gamma':[0.003,0.004,0.005,0.006,0.007] 
               } 
 
xgb_model = XGBRegressor(objective = 'reg:squarederror', 
                        seed=seed) 
 
optimal_params_3 = GridSearchCV( 
        estimator = xgb_model, 
        param_grid = param_grid_3, 
        scoring = 'r2', #MAE 
        #scoring = 'neg_mean_squared_error',  #MSE 
        cv = cv, 
        n_jobs = -1, 
        verbose = 1 
    ) 
 
optimal_params_3.fit(X_train, 
                     y_train, 
                     early_stopping_rounds=10, 
                     eval_set=[(X_test, y_test)], 
                     verbose=False) 
     
print("Gamma: ", optimal_params_3.best_params_['gamma']) 
Fitting 10 folds for each of 5 candidates, totalling 50 fits 
 
 
[Parallel(n_jobs=-1)]: Using backend LokyBackend with 12 concurrent workers. 




[Parallel(n_jobs=-1)]: Done  50 out of  50 | elapsed:  5.3min finished 
 
 
Gamma:  0.003 
gamma = optimal_params_3.best_params_['gamma'] 
y_train_pred = optimal_params_3.best_estimator_.predict(X_train) 
y_test_pred = optimal_params_3.best_estimator_.predict(X_test) 
print('XGBregressor evaluating result:') 
print("Train MAE: ", sklearn.metrics.mean_absolute_error(y_train, y_train_pred)) 
print("Train RMSE: ", np.sqrt(sklearn.metrics.mean_squared_error(y_train, y_train_pred))) 
print("Train R2: ", np.sqrt(sklearn.metrics.r2_score(y_train, y_train_pred))) 
print("Test MAE: ", sklearn.metrics.mean_absolute_error(y_test, y_test_pred)) 
print("Test RMSE: ", np.sqrt(sklearn.metrics.mean_squared_error(y_test, y_test_pred))) 
print("Test R2: ", np.sqrt(sklearn.metrics.r2_score(y_test, y_test_pred))) 
XGBregressor evaluating result: 
Train MAE:  1.1557842730348065 
Train RMSE:  1.6082375631598405 
Train R2:  0.6148797875288853 
Test MAE:  1.1723220292261036 
Test RMSE:  1.6260654683448836 
Test R2:  0.5819676548322498 
# max_delta_step 
 
param_grid_4 = {'learning_rate':[learning_rate], 
                'n_estimators':[n_estimators], 
                'max_depth':[max_depth], 
                'min_child_weight':[min_child_weight], 
                'gamma':[gamma], 
                'max_delta_step':[10,11,12], 
               } 
 
xgb_model = XGBRegressor(objective = 'reg:squarederror', 
                        seed=seed) 
 
optimal_params_4 = GridSearchCV( 
        estimator = xgb_model, 
        param_grid = param_grid_4, 
        scoring = 'r2', #MAE 
        #scoring = 'neg_mean_squared_error',  #MSE 
        cv = cv, 
        n_jobs = -1, 
        verbose = 1 
    ) 
 
optimal_params_4.fit(X_train, 
                     y_train, 




                     eval_set=[(X_test, y_test)], 
                     verbose=False) 
     
print("max_delta_step: ", optimal_params_4.best_params_['max_delta_step']) 
Fitting 10 folds for each of 5 candidates, totalling 50 fits 
 
 
[Parallel(n_jobs=-1)]: Using backend LokyBackend with 12 concurrent workers. 
[Parallel(n_jobs=-1)]: Done  26 tasks      | elapsed:  3.6min 
[Parallel(n_jobs=-1)]: Done  50 out of  50 | elapsed:  5.5min finished 
 
 
max_delta_step:  11 
max_delta_step = optimal_params_4.best_params_['max_delta_step'] 
y_train_pred = optimal_params_4.best_estimator_.predict(X_train) 
y_test_pred = optimal_params_4.best_estimator_.predict(X_test) 
print('XGBregressor evaluating result:') 
print("Train MAE: ", sklearn.metrics.mean_absolute_error(y_train, y_train_pred)) 
print("Train RMSE: ", np.sqrt(sklearn.metrics.mean_squared_error(y_train, y_train_pred))) 
print("Train R2: ", np.sqrt(sklearn.metrics.r2_score(y_train, y_train_pred))) 
print("Test MAE: ", sklearn.metrics.mean_absolute_error(y_test, y_test_pred)) 
print("Test RMSE: ", np.sqrt(sklearn.metrics.mean_squared_error(y_test, y_test_pred))) 
print("Test R2: ", np.sqrt(sklearn.metrics.r2_score(y_test, y_test_pred))) 
XGBregressor evaluating result: 
Train MAE:  1.1557842730348065 
Train RMSE:  1.6082375631598405 
Train R2:  0.6148797875288853 
Test MAE:  1.1723220292261036 
Test RMSE:  1.6260654683448836 
Test R2:  0.5819676548322498 
# reg_lambda, alpha 
 
param_grid_5 = {'learning_rate':[learning_rate], 
                'n_estimators':[n_estimators], 
                'max_depth':[max_depth], 
                'min_child_weight':[min_child_weight], 
                'gamma':[gamma], 
                'max_delta_step':[max_delta_step], 
                'reg_lambda':[1,2,3,4,5], 
                'reg_alpha':[1,2,3,4,5] 
               } 
 
xgb_model = XGBRegressor(objective = 'reg:squarederror', 
                        seed=seed) 
 




        estimator = xgb_model, 
        param_grid = param_grid_5, 
        scoring = 'r2', 
        #scoring = 'neg_mean_absolute_error', #MAE 
        #scoring = 'neg_mean_squared_error',  #MSE 
        cv = cv, 
        n_jobs = -1, 
        verbose = 1 
    ) 
 
optimal_params_5.fit(X_train, 
                     y_train, 
                     early_stopping_rounds=10, 
                     eval_set=[(X_test, y_test)], 
                     verbose=False) 
     
print("Reg_lambda: ", optimal_params_5.best_params_['reg_lambda']) 
print("Reg_alpha: ", optimal_params_5.best_params_['reg_alpha']) 
Fitting 10 folds for each of 25 candidates, totalling 250 fits 
 
 
[Parallel(n_jobs=-1)]: Using backend LokyBackend with 12 concurrent workers. 
[Parallel(n_jobs=-1)]: Done  26 tasks      | elapsed:  3.8min 
[Parallel(n_jobs=-1)]: Done 176 tasks      | elapsed: 18.5min 
[Parallel(n_jobs=-1)]: Done 250 out of 250 | elapsed: 25.6min finished 
 
 
Reg_lambda:  2 
Reg_alpha:  1 
reg_lambda = optimal_params_5.best_params_['reg_lambda'] 
reg_alpha = optimal_params_5.best_params_['reg_alpha'] 
y_train_pred = optimal_params_5.best_estimator_.predict(X_train) 
y_test_pred = optimal_params_5.best_estimator_.predict(X_test) 
print('XGBregressor evaluating result:') 
print("Train MAE: ", sklearn.metrics.mean_absolute_error(y_train, y_train_pred)) 
print("Train RMSE: ", np.sqrt(sklearn.metrics.mean_squared_error(y_train, y_train_pred))) 
print("Train R2: ", np.sqrt(sklearn.metrics.r2_score(y_train, y_train_pred))) 
print("Test MAE: ", sklearn.metrics.mean_absolute_error(y_test, y_test_pred)) 
print("Test RMSE: ", np.sqrt(sklearn.metrics.mean_squared_error(y_test, y_test_pred))) 
print("Test R2: ", np.sqrt(sklearn.metrics.r2_score(y_test, y_test_pred))) 
XGBregressor evaluating result: 
Train MAE:  1.1564939892972832 
Train RMSE:  1.6098665862703325 
Train R2:  0.613853885972447 
Test MAE:  1.1725238251572232 
Test RMSE:  1.6260069515321633 




# subsample, colsample_bytree 
 
param_grid_6 = {'learning_rate':[learning_rate], 
                'n_estimators':[n_estimators], 
                'max_depth':[max_depth], 
                'min_child_weight':[min_child_weight], 
                'gamma':[gamma], 
                'max_delta_step':[max_delta_step], 
                'reg_lambda':[reg_lambda], 
                'reg_alpha':[reg_alpha], 
                'colsample_bytree':[0.5,0.7,0.9], 
                'subsample':[0.5,0.7,0.9] 
               } 
 
xgb_model = XGBRegressor(objective = 'reg:squarederror', 
                        seed=seed) 
 
optimal_params_6 = GridSearchCV( 
        estimator = xgb_model, 
        param_grid = param_grid_6, 
        scoring = 'r2', 
        #scoring = 'neg_mean_absolute_error', #MAE 
        #scoring = 'neg_mean_squared_error',  #MSE 
        cv = cv, 
        n_jobs = -1, 
        verbose = 1 
    ) 
 
optimal_params_6.fit(X_train, 
                     y_train, 
                     early_stopping_rounds=10, 
                     eval_set=[(X_test, y_test)], 
                     verbose=False) 
     
print("colsample_bytree: ", optimal_params_6.best_params_['colsample_bytree']) 
print("subsample: ", optimal_params_6.best_params_['subsample']) 
Fitting 10 folds for each of 9 candidates, totalling 90 fits 
 
 
[Parallel(n_jobs=-1)]: Using backend LokyBackend with 12 concurrent workers. 
[Parallel(n_jobs=-1)]: Done  26 tasks      | elapsed:  2.6min 
[Parallel(n_jobs=-1)]: Done  90 out of  90 | elapsed:  8.2min finished 
 
 
colsample_bytree:  0.7 
subsample:  0.7 
colsample_bytree = optimal_params_6.best_params_['colsample_bytree'] 




y_train_pred = optimal_params_6.best_estimator_.predict(X_train) 
y_test_pred = optimal_params_6.best_estimator_.predict(X_test) 
print('XGBregressor evaluating result:') 
print("Train MAE: ", sklearn.metrics.mean_absolute_error(y_train, y_train_pred)) 
print("Train RMSE: ", np.sqrt(sklearn.metrics.mean_squared_error(y_train, y_train_pred))) 
print("Train R2: ", np.sqrt(sklearn.metrics.r2_score(y_train, y_train_pred))) 
print("Test MAE: ", sklearn.metrics.mean_absolute_error(y_test, y_test_pred)) 
print("Test RMSE: ", np.sqrt(sklearn.metrics.mean_squared_error(y_test, y_test_pred))) 
print("Test R2: ", np.sqrt(sklearn.metrics.r2_score(y_test, y_test_pred))) 
XGBregressor evaluating result: 
Train MAE:  1.1572504735959093 
Train RMSE:  1.608848084830042 
Train R2:  0.6144956247430783 
Test MAE:  1.1714188531336023 
Test RMSE:  1.6218698997451828 
Test R2:  0.5848885253562806 
model= XGBRegressor(booster='gbtree', 
                    learning_rate= learning_rate, 
                    reg_alpha=reg_alpha, 
                    colsample_bytree= colsample_bytree, 
                    gamma= gamma, 
                    reg_lambda= reg_lambda, 
                    max_delta_step= max_delta_step, 
                    max_depth= max_depth, 
                    min_child_weight= min_child_weight, 
                    n_estimators= n_estimators, 
                    sampling_method='uniform', 
                    subsample= subsample, 
                    seed=seed) 
 
model.fit(X_train, y_train) 
XGBRegressor(base_score=0.5, booster='gbtree', colsample_bylevel=1, 
             colsample_bynode=1, colsample_bytree=0.7, gamma=0.003, gpu_id=-1, 
             importance_type='gain', interaction_constraints='', 
             learning_rate=0.009, max_delta_step=11, max_depth=5, 
             min_child_weight=12, missing=nan, monotone_constraints='()', 
             n_estimators=670, n_jobs=0, num_parallel_tree=1, random_state=33, 
             reg_alpha=1, reg_lambda=2, sampling_method='uniform', 
             scale_pos_weight=1, seed=33, subsample=0.7, tree_method='exact', 
             validate_parameters=1, verbosity=None) 
variables = [ 
    "Age at diagnosis", 
    "Hispanic", 
    "Metro locality", 
    "Physical condition total","Mental health condition total", 




    "SEER Northcentral","SEER Northeast","SEER South","SEER West", 
    "White race","Black race","Other race", 
    "Psyhcology visit","Primary Care visit", 
    "Median income", 
    "Urologist density","Radiation Oncologist density", 
    "College education","Less than highschool education", 
    "PCCI", 
    "Married","Separated/Divorced/Widowed","Unmarried","Marital status unknown", 
    "Low-risk prostate cancer", 
    "Low value care (sum)",  
    "Conservative management", 
    "Care fragmentation" 
] 
import shap 
explainer = shap.TreeExplainer(model) 
 
shap_values = explainer.shap_values(X_train) 
 
# Shap values for positive class   
shap.summary_plot(shap_values, X_train, max_display=10) 
# Shap values for positive class   
shap.summary_plot(shap_values, X_train, max_display=10, plot_type="bar", cmap=plt.get_cmap("
cool")) 
shap.dependence_plot("Physical condition total", shap_values, X_train, interaction_index = None) 
shap.dependence_plot("Care fragmentation", shap_values, X_train, interaction_index = None) 
shap.dependence_plot("Low value care (sum)", shap_values, X_train, interaction_index = None) 
shap.dependence_plot("Conservative management", shap_values, X_train, interaction_index = None
) 
shap.dependence_plot("crfrg_10x", shap_values, X_train, interaction_index = "sum_lowval_12mbef
") 
shap.dependence_plot("mm_pcci", shap_values, X_train, interaction_index = "sum_lowval_12mbef
") 
shap.dependence_plot("mm_pcci", shap_values, X_train, interaction_index = "crfrg_10x") 
shap.dependence_plot("Low value care (sum)", shap_values, X_train, interaction_index = "Physical 
condition total") 
